UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 5, 2016 (March 30, 2016)

 

Citius Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Nevada

333-206903

27-3425913

(State or other jurisdiction

of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

 

63 Great Road

Maynard, MA 01754

01754

(Address of principal executive offices)

(Zip Code)

 

Registrant's telephone number, including area code: (978) 938-0338

 

_________________________________________________

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

Item 1.01 Entry into a Material Definitive Agreement.

 

On March 30, 2016, Citius Pharmaceuticals, Inc. (the "Company") entered into that certain Agreement and Plan of Merger (the "Agreement") by and among the Company, Citius LMB Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of the Company ("SubCo"), and Leonard-Meron Biosciences, Inc., a Delaware corporation ("LMB"). In accordance with the terms of the Agreement, on March 30, 2016 ("Effective Time"), LMB filed a certificate of merger ("Certificate of Merger") with the Secretary of State of the State of Delaware pursuant to which SubCo was merged with and into LMB ("Merger"), with LMB continuing as the surviving corporation ("Surviving Corporation"). The foregoing description of the Agreement is qualified in its entirety by reference to the Agreement and Plan of Merger by and among the Company, SubCo and LMB dated April 30, 2016, a copy of which attached hereto as Exhibit 2.1 and is hereby incorporated by reference into this Item 1.01.

 

Prior to the Merger, Leonard Mazur was the Chairman and a principal shareholder of LMB and Myron Holubiak was the President, Chief Executive Officer and a principal shareholder of LMB. Prior to the Merger, Leonard Mazur was Chief Executive Officer and Chairman of the Company and Myron Holubiak was a director of the Company. In addition, as required by the terms of the Agreement, Leonard Mazur made a direct investment in the Company as is further detailed in the "Financings" section below. The Company believes that the Merger and the transactions contemplated by the Agreement were as favorable to the Company as could have been obtained from a non-affiliated party.

 

Merger Consideration

 

Upon the Effective Time:

 

(i)

each share of LMB common stock ("LMB Common Stock") issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive 1.81 shares of common stock of the Company ("Citius Common Stock"), as calculated by dividing 33,940,878 shares of Citius Common Stock by the sum of all outstanding LMB Common Stock plus all shares of LMB Common Stock underlying outstanding LMB options, LMB convertible notes and LMB warrants;

(ii)

all of the outstanding convertible notes previously issued by LMB were converted into shares of LMB Common Stock immediately prior to the closing of the Merger ("LMB Note Shares") and each LMB Note Share was converted into the right to receive 1.81 shares of Citius Common Stock ;

(iii)

all of the vested and unvested outstanding LMB options were assumed by the Company, and each option was converted into an option to purchase the amount of Citius Common Stock equal to the product of the number of shares of LMB Common Stock subject to the LMB option multiplied by 1.81 shares of Citius Common Stock; and

(iv)

all of the warrants to purchase LMB Common Stock were converted into warrants to acquire Citius Common Stock, and each warrant is exercisable for the amount of Citius Common Stock equal to the product of the number of shares of LMB Common Stock subject to the LMB warrant multiplied by 1.81 shares of Citius Common Stock, subject the same terms and conditions as the LMB warrants.

 

As of the Effective Time, the stockholders of LMB became owners of 41% of the issued and outstanding shares of common stock of the Company.
 

 
2
 

 

Financings

 

As required by the terms of the Agreement, prior to the closing of the Merger, the Company entered into a Subscription Agreement with Leonard Mazur pursuant to which the Company issued to Leonard Mazur 5,000,000 shares of Citius Common Stock at a purchase price of $0.60 per share resulting in aggregate proceeds to the Company of $3,000,000. This was the same or a greater price per share as paid by certain non-affiliated investors who purchased an aggregate of 1,675,000 units at prices between $.54 per unit and $.60 per unit. Each unit consisted of one share of Citius Common Stock and one warrant to purchase one share of Citius Common Stock at a price of $0.60 per share.

 

The foregoing description is a summary only, does not purport to set forth the complete terms of the Subscription Agreement, and is qualified in its entirety by reference to the Subscription Agreement filed as an exhibit 10.2 to this Current Report and is hereby incorporated by reference into this Item 1.01.

 

Piggyback Registration Rights

 

In accordance with the terms of the Agreement, if at any time after the Effective Time, the Company proposes to file a registration statement under the Securities Act of 1933, as amended (the "Securities Act") with respect to an offering of its securities owned by officers, directors or 10% of the shareholders of the Company, excluding securities purchased in an offering, then the Company will give former LMB stockholders the opportunity to register the sale of such number of securities as such former LMB Stockholders may request in writing pursuant to the terms of the Agreement.

 

Employment Agreement

 

In accordance with the terms of the Agreement, on March 30, 2016, the Company entered into an employment agreement ("Employment Agreement") with Myron Holubiak pursuant to which Mr. Holubiak will serve as the Company's Chief Executive Officer for a term of 3 years, which term will automatically be extended for additional 1 year periods unless earlier terminated ("Term"). In consideration for Mr. Holubiak's services, the Company shall pay to Mr. Holubiak (i) an annual base salary equal to $450,000, (ii) a discretionary bonus on each anniversary of the effective date during the Term in an amount up to 50% of Mr. Holubiak's then current base salary based on the attainment of certain financial, clinical development and business milestones as established annually by the Company's Board of Directors and (iii) an incentive bonus based upon Market Capitalization (as defined in the Employment Agreement) of the Company. Upon termination of Mr. Holubiak's employment with the Company, under certain circumstances, Mr. Holubiak shall be entitled to receive certain severance as further described in the Employment Agreement.

 

The foregoing description is a summary only, does not purport to set forth the complete terms of the Employment Agreement, and is qualified in its entirety by reference to the Employment Agreement filed as exhibit 10.1 to this Current Report and is hereby incorporated into this Item 1.01.

 

Voting Agreement

 

In connection with the execution of the Agreement, on March 30, 2016, the Company entered into a Voting Agreement (the "Voting Agreement") with Leonard Mazur and certain other stockholders holding greater than a majority of shares of the Company (the "Stockholders"). Under the Voting Agreement, the Stockholders have agreed to vote their shares in whatever manner necessary to ensure that Mr. Mazur has the right to appoint a majority of the members of the Board of Directors.

 

The foregoing description is a summary only, does not purport to set forth the complete terms of the Voting Agreement, and is qualified in its entirety by reference to the Voting Agreement filed as an exhibit 10.3 to this Current Report and is hereby incorporated by reference into this Item 1.01. 
  

 
3
 

 

Post-Merger Officers and Directors of the Company and the Surviving Corporation

 

Pursuant to the terms of the Agreement, Leonard Mazur or his duly appointed representative had the right to appoint a majority of the members of the Board of Directors of the Company at the Effective Time, which directors will hold such positions until the earlier of their resignation or removal or until their respective successors are duly elected and qualified, as the case may be; provided, however, Leonard Mazur will only have the right to appoint a majority of the members of the Board of Directors of the Company until such time as the Company is listed on a national securities exchange. At the Effective Time on March 30, 2016, the following persons were appointed officers and directors of the Company:

 

Name

 

Age

 

Title

Myron Holubiak 

 

69

 

President, Chief Executive Officer and Director

Leonard Mazur 

 

71

 

Chairman and Secretary

Suren Dutia

 

72

 

Director

Carol Webb 

 

69

 

Director

Dr. William Kane

 

72

 

Director

Howard Safir 

 

74

 

Director

 

At the Effective Time on March 30, 2016, the following persons were appointed officers and directors of the Surviving Corporation:

 

Name

 

Age

 

Title

Jaime Bartushak 

 

48

 

Executive Vice President, Chief Financial Officer, Treasurer and Director

Gary F. Talarico

 

61

 

Executive Vice President, Operations

 

Representations, Warranties and Covenants

 

The parties to the Agreement made representations, warranties and covenants that are customary for transactions of this nature. The representations and warranties were qualified by information in confidential disclosure schedules exchanged by the parties together with the Agreement. While the Company does not believe that these schedules contain material information that the securities laws require it to publicly disclose, the disclosure schedules do contain information that modifies, qualifies and creates exceptions to the representations and warranties set forth in the Agreement. Accordingly, the representations and warranties should not be relied on as characterizations of the actual state of facts.

 

Indemnification

 

Following the Effective Time, LMB and the Surviving Corporation are required to indemnify, defend and hold harmless the Company and its officers, directors, stockholders and affiliates from and against damages or amounts paid in settlement arising out of or related to the breach of any representation, warranty or covenant made by LMB in the Agreement or in any document delivered pursuant to the Agreement. Similarly, the Company is required to indemnify, defend and hold harmless LMB and its officers, directors, stockholders and affiliates from and against damages or amounts paid in settlement arising out of or related to the breach of any representation, warranty or covenant made by the Company in the Agreement or in any document delivered pursuant to the Agreement.

 

Leonard Mazur and Myron Holubiak agreed personally, jointly and severally, to indemnify, defend and hold harmless the Company and its directors, officers, stockholders and affiliates from and against any liability based in whole or in part on or arising in whole or in part out of or related to any breach of the representations of LMB with respect to the capital structure of LMB and broker's fees in connection with the Agreement and the transactions contemplated by the Agreement. 
  

 
4
 

 

Other than with respect to fraud or other equitable remedies, the parties' rights to indemnification are the sole remedy with respect to any and all claims for, arising out of or relating to the transactions contemplated by the Agreement, including for breach, inaccuracy or default of any of the representations, warranties, covenants and agreements set forth in the Agreement or any other transaction document.

 

In addition to the foregoing indemnification, f rom the Effective Time through the sixth anniversary of the Effective Time, the Company and the Surviving Corporation are required to indemnify and hold harmless each person who was at the Effective Time, or has been at any time prior to the Effective Time, a director or officer of LMB against certain claims as further discussed in the Agreement.

 

LMB Business

 

Overview

 

The Company believes that the acquisition of LMB is a synergistic acquisition that will create certain economies of scale and provide the Company with a phase 3 ready drug product with significant market potential.

 

LMB is a late-stage specialty pharmaceutical company focused on the development and commercialization of critical care products with a concentration on anti-infectives. The Company is developing Mino-Lok TM , an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, or CRBSIs. These bloodstream infections are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs), and in hemodialysis patients where venous access presents a difficult challenge. Mino-Lok is considered an antibiotic lock therapy (ALT) and is intended to salvage the CVC obviating the need to remove and replace the catheter. This is a recognized unmet medical need since there are no alternatives other than the risky removal and reinsertion of the CVC. Studies show that removal and reinsertion of CVCs have a 15 to 20% complication rate, including pneumothorax, misplacement, and arterial puncture. Also, there are no alternative pharmacotherapies being developed for this condition. Mino-Lok is a patent-protected, novel solution containing minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, and provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter. Mino-Lok is used in 2-hour locking cycles allowing the CVC to be used for its intended purposes for the remaining 22 hours each day. Mino-Lok is a discovery of clinicians and technologists at the M.D. Anderson Cancer Center (MDACC).

 

LMB finalized a worldwide license to the patented technology (with the exception of South America) in May 2014 with the Investigational New Drug (IND) being transferred to LMB from MDACC in September 2014. The phase 2b study was completed in December 2014. There were 90 patients in the study with 30 patients in the active arm and 60 patients in a matched cohort for comparison. The match was retrospective, but within a contemporaneous timeframe to the active trial. Patients were matched for cancer type, infecting organism, and level of neutropenia. All patients were cancer patients and treated at the MDACC. The analysis showed outstanding comparative results. The efficacy of Mino-Lok therapy was 100% in salvaging CVCs, helping to cure all of the bacteremias, and having no significant adverse events, compared to an 18% serious adverse event rate in the matched cohort where patients had the infected CVCs removed and replaced with a new CVC.

 

Based on the Phase 2b results, LMB believes that Mino-Lok is highly effective in salvaging infected indwelling catheters and is well tolerated, making Mino-Lok an attractive alternative to removing and re-inserting a new CVC. The Company had an End-of-Phase 2 (EOP2) meeting with the FDA on May 23, 2015. The agency acknowledged the challenges in developing new treatments for CRBSI, provided feedback on the proposed phase 3 study. FDA agreed that the phase 2b study was sufficient to allow entry into a phase 3 study. Both FDA and LMB recognized that there is not a defined regulatory pathway and that developing one would require discussion between both parties. FDA offered to work closely with LMB and asked the company to submit a revised phase 3 protocol for review.

 

On October 2, 2015 LMB received a notification from FDA that Mino-Lok had received a Qualified Infectious Disease Product (QIDP) designation. QIDP provides 1) Fast Track Status (sponsors are granted early and frequent communications with the FDA; 2) Priority Review, which reduces the NDA review time from 12 to 8 months: and, 3) Market Exclusivity, NDAs for QIDPs are granted an additional 5 years of market exclusivity with Hatch-Waxman for a combined total of 10 years regardless of patent protection.

 

LMB submitted a revised phase 3 protocol based on the Agency's guidance on February 16 2016. The FDA agreed that the outline of the phase 3 trial design and LMB's responses to the Division's comments were acceptable. The Agency asked that LMB submit the detailed clinical protocol, statistical analysis plan, and sample informed consent form; and reinforced that two adequate and well-controlled clinical trials would be needed to support approval of Mino-Lok. LMB submitted the requested documents on March 17, 2016.

 

LMB plans to conduct a phase 3, multi-center, randomized, double blind, placebo- and active- controlled study in 700 patients. LMB believes that the Mino-Lok NDA can be approved within two and one half years based on the Company's current development plan. 
  

 
5
 

 

Market Opportunity

 

Professional market feedback suggests that there is an urgent need to develop an alternative to the standard of care (SOC) for CLABSI, as CVC manipulation is associated with a high degree of severe adverse effects, causing discomfort and an increased level of morbidity. Additionally, if successful, we expect that CVC salvage with Mino-Lok therapy will provide excellent economics and lead to a quick uptake of Mino-Lok in the marketplace.

 

The SOC in the management of CLABSI consists of removing the infected CVC and replacing it with a new catheter at a different vascular access site. However, in cancer and hemodialysis patients with long-term surgically implantable silicone catheters, removal of the CVC and reinsertion of a new one at a different site might be difficult, or even impossible, because of the unavailability of other accessible vascular sites and the need to maintain infusion therapy. Furthermore, critically ill patients with short term catheters often have underlying coagulopathy, where the blood's ability to clot is impaired. This condition would make reinsertion of a new CVC at a different site, in the setting of CLABSI, risky in terms of mechanical complications, such as hemopneumothorax, misplacement or arterial puncture.

 

Cost is also another important factor in determining whether to replace an infected CVC or salvage the CVC with a flush solution. In a study published in Hemodialysis International (Vol. 9, Issue 1, 2005), it was estimated that the cost of replacing a hemodialysis catheter could reach $2,000, which includes the cost of specialty personnel such as interventional radiologist, radiology technician, radiology nurse and all of the other costs involved with the replacement. The current cost for this procedure is estimated to be greater than $4,000. While direct cost minimization is significant, there has been no cost-effectiveness or cost-benefit analysis to estimate the cost savings in terms of improvements in morbidity, mortality and quality-of-life. LMB's own estimates of these economic analyses show significant economic benefit.

 

LMB estimates the potential market for Mino-Lok as a salvage lock solution in the United States at approximately 474 million locks or approximately $600 million per year. LMB estimates in its analysis that Mino-Lok will cost about $1,000 to $1,400 per course of therapy, which provides a wide margin of savings compared to replacing the catheter, and makes this approach highly cost-effective. Salvage in the long-term CVC market constitutes the bulk of the market potential. LMB estimates for the Mino-Lok market potential are as follows:

 

 

 

Short Term CVC

 

 

Long Term CVC

 

 

Combined

 

No. Catheters

 

3 million

 

 

4 million

 

 

7 million

 

Avg. Duration (days)

 

 

12

 

 

 

100

 

 

N/A

 

Catheter Days

 

36 million

 

 

400 million

 

 

436 million

 

Infection Rate

 

2/1,000 days

 

 

1/1,000 days

 

 

N/A

 

Catheters Infected

 

 

72,000

 

 

 

400,000

 

 

 

472,000

 

Flushes/Catheter

 

 

5

 

 

 

7

 

 

 

6.7

 

Total Salvage Locks

 

 

360,000

 

 

 

2,800,000

 

 

 

3,160,000

 

Market Value US Alone (Revenue)

 

$

50-100 million

 

 

$

420-840 million

 

 

$

470-950 million

 

 

Sources: Ann Intern Med 2000; 132:391–402, Clev Clin J Med 2011; 78(1):10-17, JAVA 2007; 12(1):17-27, J Inf Nurs 2004;27(4):245-250, http://www.jointcommission.org/assets/1/18/CLABSI_Monograph.pdf and internal estimates.

 

Commercialization Strategy

 

LMB intends to use the existing wholesale network for hospital distribution of Mino-Lok. LMB also intends to launch Mino-Lok with infectious disease specialists in major hospitals in the U.S. While there are a total of 4,012 short term acute care hospitals ("STACs") in the U.S., LMB intends to focus on approximately 1,000 STACs with over 300 beds in the U.S. which we consider the primary marketing target for Mino-Lok. These institutions have infection control committees and ICUs. There are 8,000 infectious disease specialists in the U.S. To reach these primary marketing targets, LMB intends to employ a national sales force and medical liaisons to represent LMB and promote Mino-Lok. The sales model will primarily be one of achieving formulary and infection control committee acceptance, and pulling through this formulary acceptance with promotion to infectious disease specialists, intensivists and ICU nursing staff. Key account managers will be required to address major group purchasing organizations ("GPOs") and healthcare systems. Education of infectious disease experts and ICU personnel will be critical success factors to change an SOC procedure to Mino-Lok treatment. LMB intends to conduct educational seminars at all major infectious disease and critical care meetings. 

 

LMB initially plans to develop Mino-Lok for the U.S. market. If LMB achieves regulatory approval and successfully launches Mino-Lok in the U.S., LMB plans to begin the process to commercialize Mino-Lok in foreign markets, primarily Europe and the Pacific Rim.

 

 
6
 

   

Intellectual Property

 

The U.S. Patent for Mino-Lok was filed on June 7, 2004 and issued on October 13, 2009. The expiration date is June 7, 2024. There are corresponding patents pending in Europe and Canada. The claimed subject matter of U.S. Patent No. 7,601,731 includes a solution that comprises ethanol; in a specific range, EDTA and an antibiotic or antifungal that is effective in eradicating Candida parapsilosis or MRSA in a biofilm. On April 15. 2014 an application was filed for the enhanced stability of the reconstituted solution. Below are the issued patents:

 

 

·

U.S. Patent 7,601,731; EP Ser. No.:04754538.9; CA Ser.No.:2,528,522; U.S. Ser. No.: 13/095,262; and, U.S. Ser. No.: 13/621,628. "Antimicrobials in Combination with Chelators and Ethanol for the Rapid Eradication of Microorganisms Embedded in Biofilm"; Issued October 13, 2009.

 

 

 

 

·

U.S. Ser. No.: 14/253,265. "Antimicrobial Lock/Flush Solutions with Enhance Stability".

 

LMB has a patent and technology license agreement with Novel Anti-Infective Technologies, LLC ("NAT") to develop and commercialize Mino-Lok on an exclusive, worldwide sublicensable basis, excluding for South America. Unless earlier terminated pursuant to the terms of the license agreement, the license agreement remains in effect until the date that all patents licensed under the agreement have expired and all patent applications within the licensed patent rights have been cancelled, withdrawn or expressly abandoned.

 

Competition

 

Currently, the only alternative to Mino-Lok in the treatment of infected CVCs in CLABSI patients, of which LMB is aware, is the SOC of removing the culprit CVC and replacing a new CVC at a different vascular site. LMB is not aware of any Investigational New Drug Applications ("INDs") for a salvage antibiotic lock solution and does not expect any to be forthcoming due to the difficulty of meeting the necessary criteria to be effective and practical.

 

At this time, there are no pharmacologic agents approved in the U.S. for the prevention or treatment of CLABSIs in central venous catheters. LMB is aware that there are several agents in development for prevention but none for salvage, the most prominent of these appear to be Neutrolin from CorMedix and B-Lock from Great Lakes Pharmaceuticals, Inc. ("GLP").

 

Neutrolin Ò (CorMedix)

 

Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination containing taurolidine, citrate and heparin that is active against common microbes. CorMedix Inc. sought to receive FDA approval of Neutrolin, but was informed that Neutrolin had been assigned to the Center for Drug Evaluation and Research ("CDER") for review as a drug. CorMedix opted to pursue a CE Mark in Europe for Neutrolin as a prevention and maintenance lock solution and received an approval as a Class III CE Mark approved (drug-device) in July 2013. CorMedix stated that they met with FDA in the fourth quarter 2013 and were informed that they would have to conduct at least one Phase III clinical trial in hemodialysis catheters and potentially one Phase III clinical trial in another indication. In August 2014, both the FDA and Cormedix have agreed to the Phase III protocol design for Neutrolin in hemodialysis patients with a central venous catheter. CorMedix states that it plans to proceed with a pivotal Phase 3 multi-center clinical trial in hemodialysis patients with central venous catheters. Additionally, the Company has submitted to the FDA for review a Phase 3 protocol to support the use of Neutrolin Ò to prevent catheter related bloodstream infections for oncology patients receiving total parenteral nutrition (TPN). Cormedix stated that they expected to launch two Phase 3 trials in 4Q2015. We are unaware if these have been initiated. 
  

 
7
 

 

B-Lock™ (Great Lakes Pharmaceuticals)

 

B-Lock is a triple combination of trimethoprim, EDTA and ethanol from GLP. On July 24, 2012, GLP announced the initiation of a clinical study of B-Lock. GLP has stated that it has developed B-Lock as a device/drug combination product capable of effective prevention of catheter related bloodstream infection ("CRBI"). The study that was announced is a prospective, randomized, active control clinical investigation to be conducted in 22 clinical sites in Hungary and Poland and involves up to 400 patients on renal dialysis who required a central venous catheter for vascular access. GLP has stated that the clinical data would be used for CE Mark approval in the European Union. LMB is unaware as to the progress or results of these studies. In addition, LMB not aware of any IND being filed in the US for B-Lock, nor is LMB aware of any clinical studies to support salvage of infected catheters in bacteremic patients.

 

Neither of these lock solutions have been shown to be effective in salvaging catheters in bacteremic patients, and LMB does not expect that either would be pursued for this indication.

 

United States Government Regulation

 

The research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing, among other things, of LMB's products are extensively regulated by governmental authorities in the United States and other countries. LMB's products may be classified by the FDA as a drug or a medical device depending upon the indications for use or claims. Because certain of LMB's product candidates are considered as medical devices and others are considered as drugs for regulatory purposes, LMB intends to submit applications to regulatory agencies for approval or clearance of both medical devices and pharmaceutical product candidates.

 

In the United States, the FDA regulates drugs and medical devices under the Federal Food, Drug, and Cosmetic Act and the agency's implementing regulations. If LMB fails to comply with the applicable United States requirements at any time during the product development process, clinical testing, and the approval process or after approval, LMB may become subject to administrative or judicial sanctions. These sanctions could include the FDA's refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, warning letters, adverse publicity, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. Any agency enforcement action could have a material adverse effect on LMB.

 

Foreign Regulatory Requirements

 

LMB and any collaborative partners may be subject to widely varying foreign regulations, which may be different from those of the FDA, governing clinical trials, manufacture, product registration and approval and pharmaceutical sales. Whether or not FDA approval has been obtained, LMB or their collaboration partners must obtain a separate approval for a product by the comparable regulatory authorities of foreign countries prior to the commencement of product marketing in such countries. In certain countries, regulatory authorities also establish pricing and reimbursement criteria. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. In addition, under current United States law, there are restrictions on the export of products not approved by the FDA, depending on the country involved and the status of the product in that country.

 

International sales of medical devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or are banned or deviate from lawful performance standards, are subject to FDA export requirements. Exported devices are subject to the regulatory requirements of each country to which the device is exported. Some countries do not have medical device regulations, but in most foreign countries, medical devices are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to application in the U.S. to take advantage of differing regulatory requirements. Most countries outside of the U.S. require that product approvals be recertified on a regular basis, generally every 5 years. The recertification process requires that LMB evaluate any device changes and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance. Where recertification applications are required, they must be approved in order to continue selling LMB's products in those countries.

 

In the European Union, in order for a product to be marketed and sold, it is required to comply with the Medical Devices Directive and obtain CE Mark certification. The CE Mark certification encompasses an extensive review of the applicant's quality management system which is inspected by a notified body's auditor as part of a stage 1 and 2 International Organization for Standardization ("ISO") 13485:2003 audit, in accordance with worldwide recognized ISO standards and applicable European Medical Devices Directives for quality management systems for medical device manufacturers. Once the quality management system and design dossier has been successfully audited by a notified body and reviewed and approved by a competent authority, a CE certificate for the medical device will be issued. Applicants are also required to comply with other foreign regulations such as the requirement to obtain Ministry of Health, Labor and Welfare approval before a new product can be launched in Japan. The time required to obtain these foreign approvals to market LMB's products may vary from U.S. approvals, and requirements for these approvals may differ from those required by the FDA.

 

 
8
 

  

Medical device laws and regulations are in effect in many of the countries in which LMB may do business outside the United States. These laws and regulations range from comprehensive device approval requirements for LMB's medical device product to requests for product data or certifications. The number and scope of these requirements are increasing. LMB may not be able to obtain regulatory approvals in such countries and may be required to incur significant costs in obtaining or maintaining its foreign regulatory approvals. In addition, the export of certain of LMB's products which have not yet been cleared for domestic commercial distribution may be subject to FDA export restrictions. Any failure to obtain product approvals in a timely fashion or to comply with state or foreign medical device laws and regulations may have a serious adverse effect on LMB's business, financial condition or results of operations.

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

The disclosure set forth above in Item 1.01 of this Current Report is incorporated by reference herein. The acquisition was closed on March 30, 2016.

 

Item 3.02 Unregistered Sales of Equity Securities.

 

The disclosure set forth above in Item 1.01 of this Current Report is incorporated by reference herein. The shares of Citius Common Stock issued in connection with the Agreement and the transactions contemplated thereby were not registered under the Securities Act, in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

The disclosure set forth above in Item 1.01 of this Current Report is incorporated by reference herein.

 

Effective as of March 30, 2016, the following persons were appointed officers and directors of the Company:

 

Name

 

Age

 

Title

Myron Holubiak 

 

69

 

President, Chief Executive Officer and Director

Leonard Mazur 

 

71

 

Chairman and Secretary

Suren Dutia

 

72

 

Director

Carol Webb 

 

69

 

Director

Dr. William Kane

 

72

 

Director

Howard Safir 

 

74

 

Director

 

Set forth below is biographical information on each of the new officers and directors.

 

Carol Webb

 

Since April 2014, Carol Webb has served as a director of LMB. From 2000 to 2005, she served as Company Group Chairman of Johnson & Johnson, and from 1987 to 2000 she served in capacities including President, Vice President, Executive Director, Product Management and Senior Product Director of Ortho Biotech. Ms. Webb has worked in various positions including Sales Representative, Sales Trainer, Product Manager and Manager of Public Policy at Roche Laboratories from 1972 to 1983. Ms. Webb received her B.S. in Biology from Bowling Green State University. We believe that Ms. Webb is qualified to serve as a member of our Board of Directors because she brings over forty years of pharmaceutical sales, marketing and business development experience to our Board of Directors.

 

There is no family relationship between Ms. Webb and any of our other officers and directors. There are no understandings or arrangements between Ms. Webb and any other person pursuant to which Ms. Webb was appointed as director.

 

 
9
 

 

Dr. William Kane

 

Since April 2014, Mr. William Kane has served as a director of LMB. He has served as a Clinical Professor at Duke University Medical Center since 2003. From 2006 to 2009, he served as the Chief Executive Officer of RadarFind Corporation, and from 2002 to 2003, he served as the Interim Chief Medical Officer of Mercy Fitzgerald Hospital. From 1996 until 2002, Dr. Kane served as the President and Chief Executive Officer of InteCardia, Inc., and from 1995 until 1996, he was with Health Care Consultant. From 1993 to 1995, Dr. Kane served in various capacities at Sharp Healthcare including Executive Vice President, Operations and Executive Vice President, Community Care. From 1992 to 1993, he was the Senior Vice President, Medical Affairs at Independence Blue Cross, and from 1990 to 1992, he served in various capacities at CentraState Medical Center including President, Chief Executive Officer, Executive Vice President and Chief Operating Officer. Medical Center. From 1989 to 1990, Dr. Kane was with Cain Brothers, Shattuck & Co., and from 1988 to 1989, he was the Senior Vice President, Health Services Division of American International Healthcare (formerly JBI). From 1986 to 1987, Dr. Kane was the Executive Vice President and Corporate Medical Director of CIGNA Healthplan, Inc., and from 1984 to 1986, he was at U.S. Healthcare, Inc. and served in various capacities including Senior Vice President Medical Delivery, President and Senior Medical Director. Dr. Kane is currently the chair of the board of directors of Research Triangle Park and was a past member of the board of directors of Pisacano Leadership Foundation and Make-A-Wish Foundation. In addition, he previously served on the Management Advisory Committee of Cornucopia House Cancer Support Center. Dr. Kane received his B.S. in Biology from the University of Scranton and his M.D. with Honors from the Temple University School of Medicine. We believe that Dr. Kane is qualified to serve as a member of our Board of Directors because of his extensive experience in the healthcare industry.

 

There is no family relationship between Dr. Kane and any of our other officers and directors. There are no understandings or arrangements between Dr. Kane and any other person pursuant to which Dr. Kane was appointed as director.

 

Howard Safir

 

Howard Safir has served as a director of LMB since April 2014. He has served as Chairman and Chief Executive Officer of VRI Technologies LLC, a security consulting and law enforcement integrator. From 2001 until 2010, Mr. Safir served as the Chairman and Chief Executive Officer of SafirRosetti, a provider of security and investigation services and a wholly-owned subsidiary of Global Options Group Inc. Mr. Safir served as the Vice Chairman of Global Options Group Inc. from its 2005 acquisition of SafirRosetti until 2010. He served as Chief Executive Officer of Bode Technology, also a wholly-owned subsidiary of Global Options Group Inc., from 2007 to 2010. Mr. Safir currently serves as a director of Implant Sciences Corporation, an explosives device detection company, and LexisNexis Special Services, Inc., a leading provider of information and technology solutions to governments, as well as Verint Systems Inc. During his career, Mr. Safir served as the 39 th Police Commissioner of the City of New York, as Associate Director for Operations, U.S. Marshals Service and as Assistant Director of the Drug Enforcement Administration. We believe that Mr. Safir is qualified to serve as a member of our Board of Directors because of his background of serving on public company boards and his business experience.

 

There is no family relationship between Dr. Safir and any of our other officers and directors. There are no understandings or arrangements between Dr. Safir and any other person pursuant to which Dr. Safir was appointed as director.

 

Item 5.03 Amendment to Bylaws .

 

In connection with the Merger, on March 30, 2016, the Company adopted amended and restated bylaws to make certain modifications to the manner in which directors may be appointed and to provide for indemnification of the Company's officers and directors, as well as certain changes that are necessitated by the increase in directors.

 

The foregoing description of the Amended and Restated Bylaws is qualified in its entirety by reference to the Amended and Restated Bylaws a copy of which is attached hereto as Exhibit 3.1 and is hereby incorporated by reference into this Item 5.03.
 

 
10
 

 

Item 7.01 Regulation FD Disclosure.

 

On April 4, 2016, the Company issued a press release announcing execution of the Agreement.

 

A copy of the press release that discusses this matter is filed as an exhibit to this Current Report, and incorporated by reference in this report. The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities, except as shall be expressly set forth by specific reference in any such filing.

 

Forward-Looking Statements

 

The SEC encourages registrants to disclose forward-looking information so that investors can better understand the future prospects of a registrant and make informed investment decisions. This Current Report and exhibits may contain these types of statements, which are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and which involve risks, uncertainties and reflect the Registrant's judgment as of the date of this Current Report. Forward-looking statements may relate to, among other things, operating results and are indicated by words or phrases such as "believes," "expects," "should," "will," "seeks," "intends" and similar words or phrases. These statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those anticipated at the date of this Current Report. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented within.

 

 
11
 

 

Item 9.01. Financial Statements and Exhibits.

 

(a) Financial Statements of Business Acquired

 

The Company will provide the financial statements that are required to be filed with this Current Report as an amendment no later than 71 calendar days after the date this Current Report on Form 8-K is required to be filed pursuant to Item 2.01.

 

(d) Exhibits.

 

Exhibit No.

 

Description of Exhibit

 

 

 

2.1

 

Agreement and Plan of Merger by and among the Company, SubCo and LMB dated March 30, 2016.*

 

 
3.1

 

Amended and Restated By-Laws of Citius Pharmaceuticals, Inc. dated March 30. 2016

 

 
10.1

 

Employment Agreement by and between the Company and Myron Holubiak dated March 30, 2016.

 

 
10.2

 

Subscription Agreement by and between the Company and Leonard Mazur dated March 21, 2016.

 

 
10.3

 

Voting Agreement by and among the Company, Leonard Mazur and certain other stockholders of the Company dated March 30, 2016.

 

 
99.1

 

Press Release dated April 4, 2016.

________________

*

Certain exhibits and schedules to the Agreement and Plan of Merger have been omitted in accordance with Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request.

 

 
12
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CITIUS PHARMACEUTICALS, INC.

Date: April 5, 2016

By:

/s/ Leonard Mazur

Leonard Mazur

President and Chief Executive Officer

 

 

13


EXHIBIT 2.1

 

 

 

 

 

AGREEMENT AND PLAN OF MERGER

BY AND AMONG

CITIUS PHARMACEUTICALS, INC.,

CITIUS LMB ACQUSITION CORP.

AND

LEONARD-MERON BIOSCIENCES, INC.

 

 

Dated as of March 30, 2016

 

 

 

 

 

 
1
 

 

AGREEMENT OF PLAN AND MERGER

 

TABLE OF CONTENTS

 

 

 

 

Page

 

 

 

 

 

 

ARTICLE I      THE MERGER

 

 

6

 

 

 

 

 

 

 

Section 1.1

The Merger

 

 

6

 

Section 1.2

Effective Time

 

 

7

 

Section 1.3

Effects of the Merger

 

 

7

 

Section 1.4

Certificate of Incorporation, Bylaws, Directors and Officers of the Surviving Corporation

 

 

7

 

Section 1.5

Directors and Officers of Citius

 

 

7

 

Section 1.6

Citius Financings

 

 

8

 

Section 1.7

Conversion of Securities

 

 

8

 

Section 1.8

Adjustment of Merger Consideration

 

 

9

 

Section 1.9

Exchange of Shares

 

 

10

 

Section 1.10

Restricted Citius Shares

 

 

11

 

Section 1.11

Treatment of LMB Options and LMB Warrants

 

 

13

 

Section 1.12

Further Assurances

 

 

14

 

Section 1.13

Closing

 

 

14

 

Section 1.14

Tax Consequences

 

 

14

 

 

 

 

 

 

 

ARTICLE II      REPRESENTATIONS AND WARRANTIES OF LMB

 

 

15

 

 

 

 

 

 

 

Section 2.1

Organization, Standing and Power

 

 

15

 

Section 2.2

Certificate of Incorporation and Bylaws

 

 

15

 

Section 2.3

Capital Structure

 

 

15

 

Section 2.4

Authority

 

 

16

 

Section 2.5

Consents and Approvals; No Violation

 

 

17

 

Section 2.6

Regulatory Compliance

 

 

17

 

Section 2.7

Undisclosed Liabilities

 

 

18

 

Section 2.8

Litigation

 

 

19

 

Section 2.9

Taxes

 

 

19

 

Section 2.10

Environmental Matters

 

 

20

 

Section 2.11

Intellectual Property

 

 

21

 

Section 2.12

Contracts

 

 

21

 

Section 2.13

Labor and Other Employment Matters

 

 

22

 

Section 2.14

Employee Benefits; ERISA

 

 

23

 

Section 2.15

Brokers

 

 

24

 

Section 2.16

Certain Business Practices; Compliance with Laws

 

 

24

 

Section 2.17

Reorganization

 

 

24

 

Section 2.18

Related Party Transactions

 

 

24

 

Section 2.19

Representations Complete

 

 

24

 

 

 
2
 

 

ARTICLE III      REPRESENTATIONS AND WARRANTIES OF CITIUS AND SUBCO

 

 

25

 

 

 

 

 

 

 

Section 3.1

Organization, Standing and Power

 

 

25

 

Section 3.2

Capital Structure

 

 

26

 

Section 3.3

Authority

 

 

26

 

Section 3.4

SEC Documents and Other Reports

 

 

27

 

Section 3.5

Financial Statements

 

 

29

 

Section 3.6

Litigation

 

 

29

 

Section 3.7

Consents and Approvals; No Violation

 

 

29

 

Section 3.8

Regulatory Compliance

 

 

30

 

Section 3.9

Intellectual Property

 

 

31

 

Section 3.10

Brokers

 

 

32

 

Section 3.11

Operations of SubCo

 

 

32

 

Section 3.12

Taxes

 

 

32

 

Section 3.13

Contracts

 

 

34

 

Section 3.14

Environmental Matters

 

 

35

 

Section 3.15

Insurance

 

 

35

 

Section 3.16

Labor and Other Employment Matters

 

 

35

 

Section 3.17

Employee Benefits; ERISA

 

 

36

 

Section 3.18

Absence of Certain Changes or Events

 

 

37

 

Section 3.19

Related Party Trnasactions

 

 

37

 

Section 3.20

Reorganization

 

 

37

 

Section 3.21

Representations Complete

 

 

37

 

 

 

 

 

 

 

ARTICLE IV      ADDITIONAL AGREEMENTS

 

 

37

 

 

 

 

 

 

 

Section 4.1

Reasonable Best Efforts

 

 

37

 

Section 4.2

Public Announcements

 

 

38

 

Section 4.3

Notification of Certain Matters

 

 

38

 

Section 4.4

Citius Financial Statements

 

 

38

 

Section 4.5

Reservation of Citius Common Stock

 

 

38

 

Section 4.6

Stockholder Litigation

 

 

38

 

Section 4.7

LMB Stockholder Approval

 

 

39

 

Section 4.8

Indemnification of Officers and Directors

 

 

39

 

Section 4.9

Tax Matters

 

 

40

 

 

 

 

 

 

 

ARTICLE V      CONDITIONS PRECEDENT TO THE MERGER

 

 

40

 

 

 

 

 

 

 

Section 5.1

Conditions to Each Party's Obligation to Effect the Merger

 

 

40

 

Section 5.2

Conditions to Obligation of Citius to Effect the Merger

 

 

41

 

Section 5.3

Conditions to Obligations of LMB to Effect the Merger

 

 

41

 

 

 

 

 

 

 

ARTICLE VI      TERMINATION 

 

 

42

 

 

 

 

 

 

 

Section 6.1

Termination

 

 

42

 

Section 6.2

Effect of Termination

 

 

44

 

 

 
3
 

 

ARTICLE VII      INDEMNIFICATION

 

 

44

 

 

 

 

 

 

 

Section 7.1

Survival of Representations and Warranties

 

 

44

 

Section 7.2

Indemnification

 

 

45

 

Section 7.3

Notice of Claim; Third Party Claims

 

 

45

 

Section 7.4

Limitation on Indemnification Obligations of Seller

 

 

46

 

Section 7.5

Adjustments to Indemnification Payments

 

 

47

 

Section 7.6

Exclusive Remedy

 

 

47

 

 

 

 

 

 

 

ARTICLE VIII      GENERAL PROVISIONS

 

 

48

 

 

 

 

 

 

 

Section 8.1

Notices

 

 

48

 

Section 8.2

Interpretation

 

 

49

 

Section 8.3

Counterparts

 

 

49

 

Section 8.4

Entire Agreement; No Third-Party Beneficiaries

 

 

49

 

Section 8.5

Governing Law

 

 

49

 

Section 8.6

Amendment

 

 

49

 

Section 8.7

Waiver

 

 

49

 

Section 8.8

Specific Performance; Submission to Jurisdiction

 

 

50

 

Section 8.9

Waiver of Jury Trial

 

 

50

 

Section 8.10

Assignment

 

 

51

 

Section 8.11

Expenses

 

 

51

 

Section 8.12

Severability

 

 

51

 

Section 8.13

Legal Representation

 

 

51

 

Section 8.14

Definitions

 

 

51

 

 

 

 

 

 

 

Exhibits

 

 

 

 

 

 

 

 

 

 

 

Exhibit A

Employment Agreement

 

 

 

 

Exhibit B

Written Consent of LMB Stockholders

 

 

 

 

 

 

 

 

 

 

Schedules

 

 

 

 

 

 

 

 

 

 

 

Schedule 1.4(b)

Directors and Officers of Surviving Corporation

 

 

 

 

Schedule 1.5(a)

Directors of Citius

 

 

 

 

Schedule 1.5(b)

Officers of Citius

 

 

 

 

Schedule 1.7(c)

Unconverted LMB Convertible Notes

 

 

 

 

Schedule 1.11(i)

Options Being Converted to Citius Equivalents

 

 

 

 

Schedule 2.1

LMB Subsidiaries

 

 

 

 

Schedule 3.1

Citius Operating Subs

 

 

 

 

 

 
4
 

 

AGREEMENT AND PLAN OF MERGER

 

This AGREEMENT AND PLAN OF MERGER, dated as of March 30, 2016 (this " Agreement "), is entered into by and among CITIUS PHARMACEUTICALS, INC., a Nevada corporation (" Citius "), CITIUS LMB ACQUISITION CORP., a Delaware corporation and a wholly owned subsidiary of Citius (" SubCo "), and LEONARD-MERON BIOSCIENCES, INC., a Delaware corporation (" LMB ").

 

W I T N E S S E T H:

 

WHEREAS, Citius is a Nevada corporation having authorized capital stock consisting of: (i) 90,000,000 shares of common stock, par value $0.001 per share (the " Citius Common Stock "), of which 35,326,220 shares are issued and outstanding as of the date hereof and (ii) 10,000,000 shares of preferred stock, par value $0.001 per share (the " Citius Preferred Stock "), of which no shares are issued and outstanding as of the date hereof. In addition, Citius has (i) warrants to purchase up to 9,838,797 shares of Citius Common Stock (" Citius Warrants ") and (ii) options to purchase up to 4,700,000 Citius Common Stock (" Citius Options ") outstanding as of the date hereof; and

 

WHEREAS, SubCo is a Delaware corporation having authorized capital stock consisting of 1,000 shares of Common Stock, par value $0.001 per share (the " SubCo Common Stock "), of which 1,000 shares are issued and outstanding as of the date hereof, all of which are owned of record and beneficially by Citius; and

 

WHEREAS, LMB is a Delaware corporation having authorized capital stock consisting of: (i) 30,000,000 shares of common stock, par value $0.001 per share (the " LMB Common Stock "), of which 11,607,500 shares are issued and outstanding as of the date hereof. LMB also has issued convertible promissory notes (" LMB Convertible Notes ") that will convert into approximately 4,485,180 shares of LMB Common Stock immediately prior to Closing (as hereinafter defined), but the final number of converted shares of LMB Common Stock will be calculated and set on the day prior to Closing based on the outstanding principal and interest due under the LMB Convertible Notes at such time. In addition, LMB has (i) warrants to purchase up to 2,013,349 shares of LMB Common Stock (" LMB Warrants "), which will be calculated and set on the day prior to Closing based on the outstanding principal and interest due under the LMB Convertible Notes at such time and any amendments to the LMB Warrants, and (ii) options to purchase up to 640,000 shares of LMB Common Stock (" LMB Options ") outstanding as of the date hereof; and

 

WHEREAS, upon the terms and subject to the conditions of this Agreement, SubCo will be merged with and into LMB (the " Merger "), with LMB continuing as the Surviving Corporation, in accordance with the applicable provisions of the Delaware General Corporation Law (the " DGCL "), whereby each issued and outstanding share of LMB Common Stock will be converted into such number of shares of Citius Common Stock determined as provided herein; and

 

 
5
 

 

WHEREAS, on or prior to the Closing, Citius shall enter into an employment agreement with Myron Holubiak in the form of Exhibit A attached hereto (the " Employment Agreement ") pursuant to which Myron Holubiak shall serve as the Chief Executive Officer of Citius; and

 

WHEREAS, the board of directors of LMB has, upon the terms and subject to the conditions set forth herein, (i) determined that the transactions contemplated by this Agreement, including the Merger, are fair to and in the best interests of LMB and its stockholders, (ii) approved, adopted and declared advisable this Agreement and the transactions contemplated hereby, including the Merger and (iii) recommended that LMB's stockholders approve this Agreement and the Merger; and

 

WHEREAS, the boards of directors of Citius and SubCo have, upon the terms and subject to the conditions set forth herein, (i) determined that the transactions contemplated by this Agreement, including the Merger, are fair to and in the best interests of Citius and SubCo and their respective stockholders and (ii) approved, adopted and declared advisable this Agreement and the transactions contemplated hereby, including the Merger; and

 

WHEREAS, the sole shareholder of SubCo has, upon the terms and subject to the conditions set forth herein, approved this Agreement and the transactions contemplated hereby, including the Merger; and

 

WHEREAS, promptly following the execution of this Agreement, all of the holders of LMB Common Stock shall approve by written consent or otherwise the Merger, the execution by LMB of this Agreement and the consummation of the transactions contemplated herein, in accordance with Sections 228 and 251 of the DGCL (the " LMB Stockholder Approval "), the LMB Charter and the LMB Bylaws (as hereinafter defined), in each case as in effect as of the date hereof;

 

WHEREAS, for federal income Tax purposes, it is intended that the Merger shall qualify as a "reorganization" within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as amended (the " Code "), and it is intended that this Agreement be and be adopted as a "plan of reorganization" for purposes of Sections 354 and 361 of the Code;

 

NOW, THEREFORE, in consideration of the premises, representations, warranties and agreements herein contained, the parties to this Agreement agree as follows:

 

ARTICLE I

 

THE MERGER

 

Section 1.1 The Merger . Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the DGCL, SubCo shall be merged with and into LMB at the Effective Time (as hereinafter defined). Following the Effective Time, the separate corporate existence of SubCo shall cease, and LMB shall continue as the surviving corporation of the Merger (the " Surviving Corporation ") and shall succeed to and assume all the rights and obligations of SubCo in accordance with the DGCL.

 

 
6
 

 

Section 1.2 Effective Time . On the Closing Date (as hereinafter defined), LMB and SubCo shall file a certificate of merger (the " Certificate of Merger ") executed in accordance with, and containing such information as is required by, the relevant provisions of the DGCL with the Secretary of State of the State of Delaware. The Merger shall become effective immediately when the Certificate of Merger is duly filed with the Secretary of State of the State of Delaware or, if agreed to by the parties, at such time thereafter as is provided in the Certificate of Merger in accordance with the relevant provisions of the DGCL (such date and time the Merger becomes effective being referred to herein as the " Effective Time ").

 

Section 1.3 Effects of the Merger . The Merger shall have the effects set forth in this Agreement, the Certificate of Merger and the applicable provisions of the DGCL. Without limiting the generality of the foregoing, and subject thereto, at the Effective Time, all of the property, rights, privileges, powers and franchises of LMB and SubCo shall vest in the Surviving Corporation, and all debts, liabilities and duties of LMB and SubCo shall become the debts, liabilities and duties of the Surviving Corporation, all as provided under the DGCL.

 

Section 1.4 Certificate of Incorporation, Bylaws, Directors and Officers of the Surviving Corporation .

 

(a) At the Effective Time, the Certificate of Incorporation of LMB, as in effect immediately prior to the Effective Time, shall become the Certificate of Incorporation of the Surviving Corporation until thereafter changed or amended as provided therein or by applicable laws. At the Effective Time, the Bylaws of LMB, as in effect immediately prior to the Effective Time, shall become the Bylaws of the Surviving Corporation until thereafter changed or amended as provided therein, in the Certificate of Incorporation of the Surviving Corporation or by applicable laws.

 

(b) The individuals listed on Schedule 1.4(b) attached hereto shall be the directors and officers of the Surviving Corporation at the Effective Time, as reflected therein, until the earlier of their resignation or removal or until their respective successors are duly elected and qualified, as the case may be.

 

Section 1.5 Directors and Officers of Citius . As of the Effective Time, Citius shall take the following actions:

 

(a) Pursuant to the Mazur Investment (defined below), Leonard Mazur or his duly appointed representative shall have the right to appoint a majority of the members of the board of directors of Citius (the " Citius Board ") at the Effective Time, which directors shall hold such positions until the earlier of their resignation or removal or until their respective successors are duly elected and qualified, as the case may be; provided , however , Leonard Mazur shall only have the right to appoint a majority of the members of the Citius Board until such time as Citius is listed on a national securities exchange. Immediately following the Effective Time, the Citius Board shall be comprised of the individuals listed on Schedule 1.5(a) attached hereto.

 

(b) As of the Effective Time, the individuals listed on Schedule 1.5(b) shall be appointed as the executive officers of Citius. Each existing executive officer of Citius who is not remaining in such capacity shall submit a written resignation from his or her position as an executive officer of Citius on or prior to the Closing Date, which shall be effective as of the Effective Time.

 

 
7
 

 

Section 1.6 Citius Financings .

 

(a) Prior to the Closing, Citius shall raise at least Three Million Dollars ($3,000,000) from the sale of equity securities to Leonard Mazur (the " Mazur Investment "). In consideration for the Mazur Investment, Leonard Mazur shall receive the right to appoint a majority of the members of the Citius Board. The proceeds from the Mazur Investment shall be used for the development of LMB's product candidate after the Closing.

 

(b) Prior to or simultaneously with the Closing, Citius shall engage in the sale of equity securities to unaffiliated investors for which it will receive a minimum of Nine Hundred Thousand Dollars ($900,000) in net proceeds to be used for post-merger operations (the " Citius Financing ").

 

The Mazur Investment and Citius Financing shall hereinafter be collectively referred to as the " Permitted Issuances ".

 

Section 1.7 Conversion of Securities . At the Effective Time, by virtue of the Merger and without any action on the part of SubCo, LMB or the holders of any securities of SubCo or LMB, other than as contemplated in this Agreement, the following shall occur:

 

(a) Conversion of SubCo Shares . Each share of SubCo Common Stock issued and outstanding immediately prior to the Effective Time shall be converted into and become one validly issued, fully paid and non-assessable share of common stock, par value $0.001 per share, of the Surviving Corporation and shall constitute the only outstanding shares of capital stock of the Surviving Corporation. From and after the Effective Time, all certificates representing the SubCo Common Stock shall be deemed for all purposes to represent the number of shares of common stock of the Surviving Entity into which they were converted in accordance with the immediately preceding sentence.

 

(b) Conversion of LMB Common Stock . Subject to Sections 1.7(e) and 1 .9(d) , each share of LMB Common Stock (each an " LMB Share ") issued and outstanding immediately prior to the Effective Time shall, at the Effective Time, automatically be converted into the right to receive a number of fully paid and nonassessable shares of Citius Common Stock (each a " Citius Share ") equal to the Exchange Ratio (the " Common Stock Consideration "). From and after the Effective Time, the holder(s) of certificates, if any, evidencing ownership of the LMB Shares outstanding immediately prior to the Effective Time shall cease to have any rights with respect to such LMB Shares, except as otherwise provided for herein or under applicable law.

 

(c) Treatment of LMB Convertible Notes . Unless otherwise set forth on Schedule 1.7(c) attached hereto, immediately prior to the Closing, all of the LMB Convertible Notes shall be converted into shares of LMB Common Stock (the " LMB Note Shares ") or debt of LMB without any conversion features. Subject to Sections 1.7(f) and 1.9(d) , each LMB Note Share shall be converted into the right to receive the Common Stock Consideration in accordance with Section 1.7(b) (the " LMB Note Stock Consideration " and together with the Common Stock Consideration, the " Merger Consideration "), subject to the procedures, terms and conditions applicable to LMB Shares under this Agreement.

 

 
8
 

 

(d) Reservation of Shares . At the Effective Time, Citius shall reserve (free from preemptive rights) out of the Merger Shares, for the purposes of effecting the conversion of any issued and outstanding LMB Convertible Notes that are not converted into LMB Common Stock immediately prior to the Effective Time, sufficient Merger Shares to provide for the conversion of such LMB Convertible Notes into Citius Shares following the Effective Time (the " Unconverted LMB Note Shares "). For the avoidance of doubt and notwithstanding such reservation of shares, the reserved Merger Shares to be issued in connection with LMB Convertible Notes shall be included in the percentage ownership calculation pursuant to which Citius shall own fifty-one (51%) percent of Citius and LMB shall own forty-nine (49%) percent of Citius after the Effective Time.

 

(e) Cancellation of Shares . Each LMB Share that is owned by LMB as treasury stock and each LMB Share, if any, that is owned by Citius or SubCo immediately prior to the Effective Time shall no longer be outstanding and shall automatically be canceled and shall cease to exist, and no consideration shall be delivered in exchange therefor.

 

(f) Treatment of Dissenting Shares . Notwithstanding anything in this Agreement to the contrary, holders of LMB Common Stock who properly demand appraisal of such shares pursuant to, and who comply in all respects with, the provisions of Section 262 of the DGCL (" Dissenting Shares ") shall not have such shares converted into the right to receive the Merger Consideration set forth in Section 1.7(b) , but instead such holders shall be entitled to such rights (and only such rights) as are granted under Section 262 of the DGCL; provided , however , that the number of Dissenting Shares shall represent no more than seven percent (7%) of the LMB capital stock issued and outstanding immediately prior to the Effective Time. Beginning at the Effective Time, Dissenting Shares shall no longer be outstanding and shall automatically be canceled and extinguished and shall cease to exist, and except as otherwise provided by law, each holder of Dissenting Shares shall cease to have any rights with respect thereto other than the rights granted pursuant to Section 262 of the DGCL. Notwithstanding the foregoing, if any holder shall fail to validly perfect or shall otherwise waive, withdraw or lose the right to appraisal under Section 262 of the DGCL or if a court of competent jurisdiction shall determine that such holder is not entitled to the relief provided by Section 262 of the DGCL, then the rights of such holder under Section 262 of the DGCL shall cease and such Dissenting Shares shall be deemed to have been converted at the Effective Time into, and shall become, the right to receive the Merger Consideration set forth in Section 1.7(b) .

 

Section 1.8 Adjustment of Merger Consideration . The Merger Consideration shall be appropriately adjusted to reflect the effect of any stock split, reverse stock split, stock dividend (including any dividend or distribution of securities convertible into Citius Common Stock), reorganization, recapitalization, reclassification or other like change with respect to Citius Common Stock occurring on or after the date hereof and prior to the Effective Time.

 

 
9
 

 

Section 1.9 Exchange of Shares .

 

(a) Exchange . Immediately prior to the Effective Time, Citius shall designate for exchange, in accordance with this Section 1.9 , certificates representing the Citius Shares issuable pursuant to Sections 1.7(b) and 1.7(c) in exchange for outstanding LMB Shares and LMB Note Shares, as applicable. At or after the Effective Time, Citius shall cause its transfer agent to deliver the appropriate Merger Consideration in exchange for all LMB Shares and LMB Note Shares, as applicable, that are issued and outstanding immediately prior to the Effective Time (excluding LMB Shares underlying LMB Warrants and LMB Options identified on Schedule 1.11(i) hereto) whether represented by certificates (the " Certificates ") or not represented by certificates (the " Book-Entry Shares "). Notwithstanding anything to the contrary contained in this Section 1.8 , Citius Shares issued as Merger Consideration can be delivered in book-entry form.

 

(b) Exchange Procedures. As soon as reasonably practical after the Effective Time, Citius shall mail (or cause to be mailed) to each holder of record of LMB Shares or LMB Note Shares, as applicable: (i) a letter of transmittal (which shall be in such form and have such provisions as Citius and LMB mutually and reasonably specify) (the " Letter of Transmittal "); and (ii) instructions for use in effecting the surrender of the Certificates or Book-Entry Shares in exchange for the Merger Consideration. Upon proper surrender of a Certificate or Book-Entry Share for exchange and cancellation to Citius or to such agents as may be appointed by Citius, together with such Letter of Transmittal, duly executed, and any other documents as may be reasonably required, the holder of such LMB Shares or LMB Note Shares, as applicable, shall be entitled to receive in exchange therefor the Merger Consideration which such holder has the right to receive in respect of LMB Shares or LMB Note Shares, as applicable, formerly represented by such Certificate or Book-Entry Shares, and the Certificate or Book-Entry Shares so surrendered shall forthwith be canceled. Until surrendered as contemplated by this Section 1.9 , (x) each Certificate or Book-Entry Share shall be deemed at any time after the Effective Time to represent only the right to receive upon such surrender the Merger Consideration as contemplated by Sections 1.7(b) and 1.7(c) and (y) a holder of LMB Shares or LMB Note Shares, as applicable, shall not receive any dividends or distributions in respect of any Citius Shares which they may otherwise be entitled to; provided that once the LMB Shares or LMB Note Shares, as applicable, are properly surrendered, the holder shall receive, without interest, any dividends or distributions with a record date after the Closing Date and payable with respect to the Citius Shares, if any, they are entitled to receive. In the event of a transfer of ownership of LMB Shares or LMB Note Shares, as applicable, that is not registered in the transfer records of LMB, a certificate representing the proper number of shares of Citius Common Stock pursuant to Section 1.7 may be issued to a transferee if the Certificate representing such LMB Shares or LMB Note Shares, as applicable (or, if such LMB Shares or LMB Note Shares, as applicable, are Book-Entry Shares, proper evidence of such transfer), is presented to Citius, accompanied by all documents required to evidence and effect such transfer and by evidence that any applicable stock transfer Taxes have been paid.

 

(c) No Further Ownership Rights in LMB Common Stock . The shares of Citius Common Stock issued in accordance with the terms of this Section 1.9 upon conversion of any LMB Shares or LMB Note Shares, as applicable, shall be deemed to have been issued in full satisfaction of all rights pertaining to such LMB shares or LMB Note Shares, as applicable. From and after the Effective Time, there shall be no further registration of transfers on the stock transfer books of the Surviving Corporation of LMB Shares or LMB Note Shares, as applicable, that were outstanding immediately prior to the Effective Time. If, after the Effective Time, any Certificates formerly representing LMB Shares or LMB Note Shares, as applicable (or Book-Entry Shares), are presented to Citius for any reason, they shall be canceled and exchanged as provided in this Section 1.9 .

 

 
10
 

 

(d) No Fractional Shares . No certificates or scrip representing fractional shares of Citius Common Stock shall be issued upon the conversion of LMB Shares or LMB Note Shares, as applicable, pursuant to Section 1.7 , and such fractional share interests shall not entitle the owner thereof to vote or to any rights of a holder of Citius Common Stock. Notwithstanding any other provision of this Agreement, any fractional Citius Shares resulting from the conversion contemplated herein shall not be issued by Citius, and such Citius Shares shall be rounded up to the nearest whole number of Citius Shares.

 

(e) No Liability . None of LMB, Citius, SubCo or the Surviving Corporation shall be liable to any Person in respect of any portion of Merger Consideration delivered to a public official pursuant to any applicable abandoned property, escheat or similar law. Any portion of the Merger Consideration that remains undistributed to the holders of Certificates for two (2) years after the Effective Time (or immediately prior to such earlier date on which the Merger Consideration would otherwise escheat to, or become the property of, any Governmental Entity) shall, to the extent permitted by applicable law, become the property of the Surviving Corporation, free and clear of all claims or interest of any Person previously entitled thereto.

 

(f) Lost Certificates . If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming such Certificate to be lost, stolen or destroyed and, if required by Citius in its reasonable business judgment, the execution of an indemnity agreement against any claim that may be made against it with respect to such Certificate, Citius will issue in exchange for such lost, stolen or destroyed Certificate the Citius Shares to which the holders thereof are entitled pursuant to Section 1.7 .

 

Section 1.10 Restricted Citius Shares .

 

(a) All Citius Shares issued in exchange for and upon conversion of LMB Shares or LMB Note Shares, as applicable, in accordance with the terms hereof may not be sold or transferred unless (i) such Citius Shares are sold pursuant to an effective registration statement under the Securities Act of 1933, as amended (the " Securities Act ") or (ii) Citius or its transfer agent shall have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the Citius Shares to be sold or transferred may be sold or transferred pursuant to an exemption from such registration or (iii) such shares are sold or transferred pursuant to Rule 144 under the Act (or a successor rule) (" Rule 144 "). Each certificate for Citius Shares issuable pursuant to this Agreement shall bear a legend substantially in the following form, as appropriate:

 

 
11
 

 

THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO CITIUS. THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.

 

(b) Piggy Back Rights . If at any time on or after the Effective Time, Citius proposes to file a registration statement under the Securities Act (a " Registration Statement ") with respect to an offering of securities owned by officers, directors or ten percent (10%) of the shareholders of Citius, excluding securities purchased in an offering, then Citius shall (x) give written notice of such proposed filing to the holders of LMB Shares or LMB Note Shares, as applicable, as soon as practicable but in no event less than ten (10) days before the anticipated filing date of the Registration Statement, which notice shall describe the amount and type of securities to be included in such Registration Statement, the intended method(s) of distribution, and the name of the proposed managing underwriter or underwriters, if any, of the offering, and (y) offer to the holders of LMB Shares or LMB Note Shares, as applicable, in such notice the opportunity to register the sale of such number of LMB Shares or LMB Note Shares, as applicable, as such holders may request in writing within five (5) days following receipt of such notice (a " Piggy Back Registration "). Citius shall cause the LMB Shares or LMB Note Shares, as applicable, to be included in such registration and shall cause the managing underwriter or underwriters of a proposed underwritten offering to permit LMB Shares or LMB Note Shares, as applicable, requested to be included in a Piggy Back Registration on the same terms and conditions as any similar securities of Citius and to permit the sale or other disposition of such LMB Shares or LMB Note Shares, as applicable, in accordance with the intended method(s) of distribution thereof. All holders of LMB Shares or LMB Note Shares, as applicable, proposing to distribute their securities through a Piggy Back Registration that involves an underwriter or underwriters shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such Piggy Back Registration.

 

 
12
 

 

Section 1.11 Treatment of LMB Options and LMB Warrants .

 

(a) LMB Options . As of the Effective Time, each vested and unvested outstanding LMB Option that LMB granted pursuant to LMB's 2013 Stock Plan (the " LMB Stock Plan ") shall continue to have, and shall be subject to the terms and conditions of each agreement pursuant to which such LMB Option was subject as of the Effective Time, except that:

 

(i) each LMB Option set forth in Schedule 1.11(i) shall be exercisable for that number of whole shares of Citius Common Stock equal to the product, rounded up to the nearest whole number, of (A) the aggregate number of shares of LMB Common Stock subject to such LMB Option at the Effective Time multiplied by (B) the Exchange Ratio. The exercise price per share of Citius Common Stock issuable pursuant to each LMB Option shall be equal to the exercise price per share of LMB Common Stock under such LMB Option at the Effective Time divided by the Exchange Ratio, rounded up to the nearest whole cent; and

 

(ii) except for changes to the LMB Options expressly provided for in the LMB Stock Plan by reason of the consummation of the transactions contemplated hereby, the assumption and substitution of LMB Options as provided herein shall not give the holders of such LMB Options additional benefits or additional (or accelerated) vesting rights which such holders did not have as of the Effective Time, or relieve the holders of such LMB Options of any obligations or restrictions applicable to their LMB Options or the shares obtainable upon exercise of the LMB Options. The adjustment provided for herein with respect to any LMB Options that are "incentive stock options" (as defined in Section 422 of the Code) shall be effected in a manner that is consistent with continued treatment of such LMB Options as "incentive stock options" under Section 424(a) of the Code. The LMB Stock Plan and the LMB Options granted pursuant to the LMB Stock Plan shall be assumed by Citius, and no further options to purchase or acquire shares of LMB Common Stock or other awards or rights shall be granted under the LMB Stock Plan after the Effective Time. The duration and other terms of the new options provided for in this Section 1.11(a) shall be the same as the original LMB Options except that all references to LMB shall be references to Citius. The parties understand and agree that a sufficient number of shares of Citius Common Stock shall be reserved from the Merger Shares for issuance and delivery upon the exercise of the LMB Options.

 

(b) LMB Warrants . As of the Effective Time, each outstanding LMB Warrant shall be converted into a warrant to acquire Citius Common Stock as provided for in this Section  1.11(b) . As of the Effective Time, each LMB Warrant shall continue to have, and shall be subject to, the terms and conditions of each agreement pursuant to which such LMB Warrant was subject as of the Effective Time, except that:

 

(i) each LMB Warrant shall be exercisable for that number of whole shares of Citius Common Stock equal to the product, rounded up to the nearest whole number, of (A) the aggregate number of shares of LMB Common Stock subject to such LMB Warrant at the Effective Time multiplied by (B) the Exchange Ratio. The exercise price per share of Citius Common Stock issuable pursuant to each LMB Warrant shall be equal to the exercise price per share of LMB Common Stock under such LMB Warrant at the Effective Time divided by the Exchange Ratio, rounded up to the nearest whole cent; and

 

 
13
 

 

(ii) Except for changes to the LMB Warrants expressly provided for in the agreement governing such LMB Warrant by reason of the consummation of the transactions contemplated hereby, the assumption and substitution of LMB Warrants as provided herein shall not give the holders of such LMB Warrants additional benefits or additional (or accelerated) rights which such holders did not have as of the Effective Time, or relieve the holders of such LMB Warrants of any obligations or restrictions applicable to their LMB Warrants or the shares obtainable upon exercise of the LMB Warrants. The duration and other terms of the new LMB Warrants provided for in this Section 1.11(b) shall be the same as the original LMB Warrants except that all references to LMB shall be references to Citius. The parties understand and agree that a sufficient number of shares of Citius Common Stock shall be reserved from the Merger Shares for issuance and delivery upon the exercise of the LMB Warrants.

 

Section 1.12 Further Assurances . If at any time after the Effective Time the Surviving Corporation shall consider or be advised that any deeds, bills of sale, assignments or assurances or any other acts or things are necessary, desirable or proper (a) to vest, perfect or confirm, of record or otherwise, in the Surviving Corporation, its right, title or interest in, to or under any of the rights, privileges, powers, franchises, properties or assets of either of SubCo or LMB, or (b) otherwise to carry out the purposes of this Agreement (including cooperating with the filing of future Tax Returns, as necessary), the Surviving Corporation and its proper officers and directors or their designees shall be authorized to execute and deliver in the name and on behalf of SubCo and LMB all such deeds, bills of sale, assignments and assurances and to do, in the name and on behalf of either SubCo or LMB, all such other acts and things as may be necessary, desirable or proper to vest, perfect or confirm the Surviving Corporation's right, title or interest in, to or under any of the rights, privileges, powers, franchises, properties or assets of SubCo or LMB and otherwise to carry out the purposes of this Agreement.

 

Section 1.13 Closing . Unless this Agreement has been terminated pursuant to Article VI below, the closing of the transactions contemplated by this Agreement (the " Closing ") and all actions specified in this Agreement to occur at the Closing shall take place at the offices of Sichenzia Ross Friedman Ference LLP, at 10:00 a.m., local time, no later than the second Business Day following the day on which the last of the conditions set forth in Article V (other than those conditions that are by their nature to be satisfied at the Closing, but subject to the fulfillment or waiver of those conditions) shall have been fulfilled or waived (if permissible) or at such other time and place as Citius and LMB shall agree (the " Closing Date ").

 

Section 1.14 Tax Consequences . It is intended that the Merger shall qualify as a "reorganization" within the meaning of Section 368(a) of the Code. Each of the parties hereto adopts this Agreement as a "plan of reorganization" within the meaning of Treasury Regulations Sections 1.368-2(g) and 1.368-3(a). All of the parties hereto agree to (a) file all Tax Returns on the basis of treating the Merger as a "reorganization" within the meaning of Section 368(a) of the Code, (b) otherwise report the Merger for federal, state and local income Tax purposes in a manner consistent with such characterization and (c) not take a reporting position that is inconsistent with such characterization.

 

 
14
 

 

ARTICLE II

 

REPRESENTATIONS AND WARRANTIES OF LMB

 

LMB hereby represents and warrants to Citius and SubCo, as qualified by the disclosure schedule delivered by LMB to Citius and SubCo concurrently herewith (the " LMB Disclosure Schedule ") (which LMB Disclosure Schedule shall be arranged in sections corresponding to the numbered and lettered sections of this Article II , and any information disclosed in any such section of the LMB Disclosure Schedule, if it is readily apparent that the disclosure contained in such section would clearly apply to other representations and warranties contained in this Article II , would also apply to such other representations and warranties), as follows:

 

Section 2.1 Organization, Standing and Power . The entities set forth in Section 2.1 of the LMB Disclosure Schedule (the " Subsidiaries ") are all of the Subsidiaries of LMB. LMB and each Subsidiary thereof is a corporation duly organized, validly existing and in good standing or active status under the laws of the jurisdiction in which it is incorporated and has all requisite corporate power and authority to own, lease and operate its properties and to carry on its business as it is now being conducted, except where any failure to be so organized, existing or in good standing or active status or to have such power or authority would not, or would not reasonably be expected to, individually or in the aggregate, have a LMB Material Adverse Effect. LMB is duly qualified or licensed to do business, and is in good standing, in each jurisdiction where the character of the properties owned, leased or operated by it or the nature of its activities makes such qualification or licensing necessary, except for any failure to be so qualified or licensed or in good standing which would not, or would not reasonably be expected to, individually or in the aggregate, have a LMB Material Adverse Effect.

 

Section 2.2 Certificate of Incorporation and Bylaws . LMB has heretofore furnished or otherwise made available to Citius and SubCo a complete and correct copy of the certificate of incorporation (the " LMB Certificate of Incorporation ") and bylaws (the " LMB Bylaws ") of LMB, as amended and in effect on the date hereof and all minutes of LMB's board of directors since January 1, 2015, other than those with respect to consideration and approval of the Merger and related transactions. The LMB Certificate of Incorporation and LMB Bylaws are in full force and effect. LMB is not in violation of any provisions of the LMB Certificate of Incorporation or LMB Bylaws in any material respect.

 

Section 2.3 Capital Structure .

 

(a) The authorized capital stock of LMB consists of 30,000,000 shares of LMB Common Stock. Except as set forth in Section 2.3(a) of the LMB Disclosure Schedule, as of the date of this Agreement, LMB does not have any outstanding shares of capital stock or options, warrants, calls, rights, puts or Contracts to which LMB is a party or by which LMB is bound obligating LMB to issue, deliver, sell, redeem or otherwise acquire, or cause to be issued, delivered, sold, redeemed or otherwise acquired, any additional shares of capital stock (or other voting securities or equity equivalents) of LMB or obligating LMB to grant, extend or enter into any such option, warrant, call, right, put or Contract. All of the outstanding LMB Shares are validly issued, fully paid, non-assessable and free of preemptive rights. Except as set forth in Section 2.3(a) of the LMB Disclosure Schedule, as of the date of this Agreement, LMB does not have any outstanding bonds, debentures, notes or other obligations, the holders of which have the right to vote (or convertible into or exercisable for securities having the right to vote) with the stockholders of LMB on any matter. There are no Contracts to which LMB or its respective officers or directors are a party concerning the voting of any capital stock of LMB.

 

 
15
 

 

(b) There are no registration rights and there are no voting trusts, proxies or other agreements or understandings with respect to any equity security of LMB. There is no stockholder rights plan that will be applicable or triggered by the entry into this Agreement or the consummation of the other transactions contemplated hereunder.

 

(c) Each outstanding share of capital stock (or other voting security or equity equivalent, as the case may be) of the Subsidiaries of LMB is duly authorized, validly issued, fully paid and non-assessable and each such share (or other voting security or equity equivalent, as the case may be) is owned by LMB, free and clear of all security interests, liens, claims, pledges, options, rights of first refusal, limitations on voting rights, charges and other Encumbrances of any nature whatsoever.

 

Section 2.4 Authority .

 

(a) (i) On or prior to the date of this Agreement, the board of directors of LMB (the " LMB Board ") has (x) determined that this Agreement and the transactions contemplated hereby (including the Merger) are advisable and in the best interests of LMB and its stockholders, and (y) approved and adopted this Agreement, and the transactions contemplated hereby (including the Merger), and (ii) prior to the Closing, LMB shall have received the LMB Stockholder Approval. No additional approvals are required from the LMB Board or the LMB stockholders in connection with the Merger or the other transactions contemplated hereby.

 

(b) LMB has all requisite corporate power and authority to enter into this Agreement and, subject to obtaining the LMB Stockholder Approval, to perform its obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement by LMB and the consummation by it of the transactions contemplated hereby has been duly and validly authorized by all necessary corporate action on the part of LMB and, except for obtaining the LMB Stockholder Approval, no other corporate proceedings on the part of LMB (other than the filing of appropriate Merger documents as required by the DGCL) and no other stockholder votes are necessary to authorize this Agreement or to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by LMB and (assuming the valid authorization, execution and delivery of this Agreement by Citius and SubCo and the validity and binding effect of this Agreement on Citius and SubCo) constitutes the legal, valid and binding obligation of LMB, enforceable against LMB in accordance with its terms, except to the extent enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors' rights generally and by the effect of general principles of equity (regardless of whether enforcement is considered in a proceeding in equity or at law) (the " Bankruptcy and Equity Exception ").

 

 
16
 

 

Section 2.5 Consents and Approvals; No Violation .

 

(a) The execution and delivery of this Agreement by LMB does not, and the performance of this Agreement by LMB (including the consummation of the Merger) will not, (i) conflict with or violate any provision of the LMB Certificate of Incorporation or LMB Bylaws or any equivalent organizational documents of LMB, (ii) conflict with or violate any law applicable to LMB, or (iii) require any consent or approval under, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, any Contract, LMB permit or other instrument or obligation.

 

(b) The execution and delivery of this Agreement by LMB does not, and the performance of this Agreement by LMB will not, require any consent, approval, authorization or Permit of, or filing with or notification to, any Governmental Entity or any other Person, except the filing and recordation of the Certificate of Merger as required by the DGCL.

 

Section 2.6 Regulatory Compliance .

 

(a) To the Knowledge of LMB, (i) there is no civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning letter, proceeding or request for information pending against LMB, and (ii) LMB has no liability (whether actual or contingent) for failure to comply with the Federal Food, Drug, and Cosmetic Act (the " FDCA "), 21 U.S.C. §301 et. seq., and all applicable regulations promulgated by the United States Food and Drug Administration (" FDA ") (collectively, " FDA Law and Regulation ") or any law or regulation of a comparable foreign regulatory or Governmental Entity. There has not been any material violation of any FDA Law and Regulation or any law or regulation of a comparable foreign regulatory or Governmental Entity by LMB in its product development efforts, submissions, record keeping and reports to FDA or a comparable Governmental Entity that could reasonably be expected to require or lead to investigation, corrective action or enforcement, or regulatory or administrative action; provided that, to the extent the foregoing activities have been performed on LMB's behalf by any third party contractors, the representation and warranty made in this sentence shall only be made to the extent of LMB's Knowledge after exercise of reasonable diligence in requiring such contractors to comply with applicable FDA Law and Regulation or any law or regulation of a comparable foreign regulatory or Governmental Entity.

 

(b) To the Knowledge of LMB, each of the product candidates of LMB is being, and at all times has been, developed, tested, manufactured, labeled, promoted and stored, as applicable, in material compliance with FDA Law and Regulation and requirements of comparable foreign regulatory and Governmental Entities and, to the extent the foregoing activities have been performed on LMB's behalf by any third party contractors, LMB has exercised reasonable diligence in requiring such contractors to comply with applicable FDA Law and Regulation or any law or regulation of a comparable foreign regulatory or Governmental Entity.

 

 
17
 

 

(c) To the Knowledge of LMB, the clinical trials, studies and other preclinical tests conducted by LMB were, and if still pending, are, being conducted in all material respects in accordance with all experimental protocols, informed consents, procedures and controls of LMB and applicable FDA and foreign requirements including, but not limited to, good clinical practices, good laboratory practices, and FDA Law and Regulation including the protection of human subjects and, to the extent the foregoing activities have been performed on LMB's behalf by any third party contractors, LMB has exercised reasonable diligence in requiring such contractors to comply with applicable FDA Law and Regulation or any law or regulation of a comparable foreign regulatory or Governmental Entity. LMB has not received any written notice from the FDA or any other regulatory or Governmental Entity requiring the termination or suspension or material modification of any animal study, preclinical study or clinical trial conducted by or on behalf of LMB and, to the Knowledge of LMB, there is no reasonable basis for any termination, suspension, or material modification, for, in each case, purposes of the protection of subject health or safety, of any ongoing human clinical trial being conducted by or on behalf of LMB.

 

(d) With respect to all third party manufacturers and suppliers of key raw materials (each a " Third Party Manufacturer ") used by LMB, (i) to the Knowledge of LMB, each such Third Party Manufacturer (A) has complied and is complying, in each case in all material respects, with all applicable laws, rules, and regulations, including the FDA Law and Regulation and any similar state or foreign laws and (B) has all material Permits to perform its obligations as a Third Party Manufacturer and all such Permits are in full force and effect and (ii) LMB has exercised reasonable diligence in requiring Third Party Manufacturers to comply with applicable FDA Law and Regulation or any law or regulation of a comparable foreign regulatory or Governmental Entity.

 

(e) In connection with LMB's business, no director, officer, employee or agent of LMB has (x) made any untrue statement of material fact or fraudulent statement to the FDA or any other Governmental Entity, (y) failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Entity or (z) committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide the basis for the FDA or any other Governmental Entity to invoke its policy respecting "Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities," as set forth in CPG. Section 120.100.

 

(f) LMB has complied with all applicable security and privacy standards regarding protected health information pursuant to the Health Insurance Portability and Accountability Act (" HIPAA ") or any foreign equivalent and applicable privacy laws.

 

(g) To the extent applicable, LMB has applied to the FDA and all comparable foreign regulatory or Governmental Entities for and received approval of all material registrations, applications, licenses, requests for exemptions, Permits and other regulatory authorizations (the " FDCA Permits ") necessary to conduct the business of LMB as currently conducted. LMB is in material compliance with all such FDCA Permits. To the Knowledge of LMB, no suspension, revocation, cancellation or withdrawal of the FDCA Permits is threatened and there is no basis for believing that such FDCA Permits will not be renewable upon expiration or will be suspended, revoked, cancelled, modified or withdrawn.

 

Section 2.7 Undisclosed Liabilities . LMB has no material liabilities (absolute, accrued, contingent or otherwise) of a nature required to be disclosed on a balance sheet or in the related notes to financial statements prepared in accordance with United States generally accepted accounting principles (" GAAP "), except liabilities (a) reflected or reserved against in LMB's financial statements and (b) set forth in Section 2.7 of the LMB Disclosure Schedule.

 

 
18
 

 

Section 2.8 Litigation . Except as set forth in Section 2.8 of the LMB Disclosure Schedule, there is no Action by or before any Governmental Entity or other Person pending or, to the Knowledge of LMB, threatened against LMB, and it is not subject to any Order that could prevent the consummation of the transactions contemplated by this Agreement.

 

Section 2.9 Taxes . Except as and to the extent disclosed in Section 2.9 of the LMB Disclosure Schedule:

 

(a) All federal income Tax Returns and all other material Tax Returns required to be filed by or on behalf of LMB have been properly filed with the appropriate taxing authorities in all jurisdictions in which such Tax Returns are required to be filed, and all such Tax Returns, as amended, are accurate and complete in all material respects; provided , however , that regardless of what may be reported on such Tax Returns, LMB makes no representation regarding the amount of any net operating losses that are available to it or have been reported by LMB for any federal, state or other Tax purposes, and LMB makes no representation regarding any limitation on use of its net operating losses that might apply either before or after the Closing Date under Section 382 of the Code or any other applicable limitations under any Tax laws, rules or regulations. All material Taxes payable by or on behalf of LMB (whether or not shown in a Tax Return) have been fully paid or adequately provided for in accordance with GAAP, and adequate reserves or accruals for Taxes have been provided in accordance with GAAP with respect to any period for which Tax Returns have not yet been filed or for which Taxes are not yet due and owing or for which Taxes are being contested in good faith. LMB has not executed or filed with the IRS or any other taxing authority any agreement, waiver or other document or arrangement extending or having the effect of extending the period for assessment or collection of Taxes (including, but not limited to, any applicable statute of limitation), and no power of attorney with respect to any Tax matter is currently in force and no request for any such waiver or extension is currently pending. Section 2.9 of the LMB Disclosure Schedule contains a list of all jurisdictions (whether foreign or domestic) to which any Tax is payable by or on behalf of LMB and with whom Tax Returns are required to be filed by or on its behalf, and a list of any jurisdictions (whether foreign or domestic) in which LMB is not in good standing as a result of Tax obligations.

 

(b) To the Knowledge of LMB, no audit or other proceeding by any taxing authority is ongoing or pending with respect to any Taxes due from or with respect to LMB, and there is no dispute with respect to any liability for Taxes of LMB either claimed, raised, or threatened in writing. There are no liens for Taxes on any of the assets of LMB.

 

(c) LMB (i) has complied in all material respects with all applicable laws, rules and regulations relating to the payment and withholding of Taxes; and (ii) has duly and timely withheld from any compensation payable and from distributions to any stockholder or payments to any creditor and has paid over to the appropriate taxing authorities all material amounts required to be withheld and paid over on or prior to the due date thereof under all applicable laws.

 

 
19
 

 

(d) LMB has not received written notice from any taxing authority in a jurisdiction in which LMB does not file a Tax Return stating that LMB is or may be subject to taxation by that jurisdiction.

 

(e) LMB (i) is not a party to any Tax sharing, Tax indemnity or similar agreement or arrangement, other than any agreement or arrangement between LMB and any of its respective Subsidiaries, pursuant to which it will have any obligation to make any payments after the Closing and (ii) does not have any liability for the Taxes of any Person other than LMB and its Subsidiaries (x) under Treasury Regulation §1.1502-6 (or similar provision of state, local or foreign law), (y) as transferee or successor or (z) by contract.

 

(f) Within the past two (2) years, LMB has not distributed stock of another Person in a transaction intended to be governed by Section 355 of the Code, nor has the stock of LMB been distributed in a transaction intended to be governed by Section 355 of the Code.

 

(g) LMB has not engaged in a "reportable transaction" as defined in Treasury Regulation Section 1.6011-4, or any transaction that is the same as, or substantially similar to, any "listed transactions" as defined in Treasury Regulation Section 1.6011-4(b)(2).

 

(h) LMB has not been at any time a United States Real Property Holding

 

Corporation within the meaning of Section 897(c)(2) of the Code.

 

(i) LMB (i) has not elected to change, nor is LMB required to change, a method of accounting for Tax purposes pursuant to Section 481 of the Code or otherwise that will have a continuing effect following the Closing or (ii) is not the subject of any closing agreement with respect to Taxes that will have a continuing effect following the Closing.

 

(j) LMB has not made any payments and is not obligated to make any payments, nor is LMB a party to any agreement that under certain circumstances could obligate it to make any payments, that will not be deductible under either Sections 280G or 162(m) of the Code.

 

(k) To the Knowledge of LMB, there are no excess loss accounts, deferred intercompany transactions, or other items of income, gain, loss, deduction or credit of LMB under the federal consolidated return regulations or other comparable or similar provisions of state law that must be recognized or may be triggered as a result of the consummation of the transactions contemplated by this Agreement.

 

(l) LMB does not have, and has never had, a permanent establishment in any country outside of the United States and is not, and has never been, subject to Tax in a jurisdiction outside of the United States. LMB has not entered into a gain recognition agreement pursuant to Treasury Regulation Section 1.367(a)-8. LMB has not transferred an intangible, the transfer of which would be subject to the rules of Section 367(d) of the Code.

 

Section 2.10 Environmental Matters . LMB is in compliance in all material respects with (a) all Environmental Laws and (b) the requirements of all Permits issued under such Environmental Laws with respect to LMB. There are no pending or, to the Knowledge of LMB, threatened Actions relating to Environmental Laws against LMB.

 

 
20
 

 

Section 2.11 Intellectual Property .

 

(a) To the Knowledge of LMB, (i) LMB's use of (and practice of any technology claimed by) all patents, patent rights (including patent applications and licenses), know-how, trade secrets, trademarks (including trademark applications), trademark rights, trade names, trade name rights, service marks, service mark rights, copyrights and other proprietary intellectual property rights utilized in, or reasonably necessary to conduct, LMB's business as currently conducted (collectively, the " LMB Intellectual Property ") does not infringe on, misappropriate, or otherwise violate the intellectual property rights of any third party, and is in accordance in all material respects with any applicable licenses or other agreements pursuant to which LMB acquired the right to use such LMB Intellectual Property and (ii) LMB owns sufficient rights and/or interest in the LMB Intellectual Property to conduct its business as currently conducted without infringement, misappropriation, or violation of any third party's intellectual property rights.

 

(b) LMB has not received any notice, written or otherwise, and has no Knowledge of, (i) any claim that is pending or threatened, Order, or proceeding with respect to any LMB Intellectual Property or LMB's practice of any third party's intellectual property rights, (ii) any allegation by any third party that LMB has infringed, misappropriated, or violated any intellectual property rights of any third party, or (iii) any notice of any alleged or actual breach of any license or other agreement pursuant to which LMB acquired the right to use any LMB Intellectual Property. To the Knowledge of LMB, based on reasonable diligence and inquiry, there is no reasonable basis for any third party to claim of intellectual property right infringement, misappropriation, or violation against LMB with respect to the conduct of LMB's business.

 

(c) LMB has maintained commercially reasonable practices to protect the confidentiality of its confidential information and trade secrets and has required all employees, consultants, and other Persons or entities to whom it provided access to its confidential information (other than attorneys, accountants, and others with professional duties of confidentiality, to whom this requirement shall not apply) to execute written agreements requiring them to maintain the confidentiality of such information and to limit his, her or its use of such information on commercially reasonable terms

 

Section 2.12 Contracts .

 

(a) LMB is not a party to or bound by any Contract that would prohibit or materially delay the consummation of the Merger or any of the other transactions contemplated by this Agreement.

 

(b) Except as set forth in Section 2.12(b) of the LMB Disclosure Schedule, LMB has not received any claim of default, notice of termination, notice of violation of covenant or other notice of third party dissatisfaction under any Contract or agreement that extends beyond one year in duration and involves consideration of more than One Million Dollars ($1,000,000) in the aggregate over the remaining term of such Contract or agreement (each a " Material LMB Contract ").

 

 
21
 

 

(c) LMB is not in breach or violation of, or default under, any Material LMB Contract, which breach, violation or default would have a LMB Material Adverse Effect.

 

(d) Each Material LMB Contract is a legal, valid and binding agreement of LMB, subject to the Bankruptcy and Equity Exception.

 

(e) LMB has not received any notice, written or otherwise, with respect to a claim of default, notice of termination, notice of violation of covenant or other notice of third party dissatisfaction under any Material LMB Contract, and LMB is not in breach or violation of, or default under, any Material LMB Contract.

 

(f) To the Knowledge of LMB, no other party is in breach or violation of, or default under, any Material LMB Contract.

 

(g) Except as set forth in Section 2.12(g) of the LMB Disclosure Schedule, neither the execution of this Agreement nor the consummation of the transactions contemplated hereunder shall constitute a default under, give rise to cancellation rights under, or otherwise adversely affect any of the material rights of LMB under any Material LMB Contract.

 

(h) LMB has furnished or made available to Citius true and complete copies of all Material LMB Contracts, including any amendments thereto.

 

Section 2.13 Labor and Other Employment Matters .

 

(a) LMB is in material compliance with all applicable laws respecting labor, employment, fair employment practices, terms and conditions of employment, workers' compensation, occupational safety, plant closings, and wages and hours.

 

(b) Except as disclosed in Section 2.13(b) of the LMB Disclosure Schedule, neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will (either alone or in conjunction with any other event, such as termination of employment) (i) result in any payment (including, without limitation, severance, parachute or otherwise) becoming due to any director or any employee of LMB or its Affiliates from LMB or its Affiliates under any LMB Plan (as hereinafter defined) or otherwise, (ii) significantly increase any benefits otherwise payable under any LMB Plan or (iii) result in any acceleration of the time of payment or vesting of any material benefits.

 

(c) Except as disclosed in Section 2.13(c) of the LMB Disclosure Schedule, LMB is not (i) subject to any obligation to pay health insurance premiums or make any other payments under any health insurance plan, (ii) obligated to make any payments to or provide any benefits under COBRA to any former employee, or (iii) to the Knowledge of LMB, subject to any outstanding worker's compensation claims.

 

 
22
 

 

Section 2.14 Employee Benefits; ERISA .

 

(a) (i) Each plan, program, policy, practice, Contract, agreement or other arrangement providing for employment, compensation, retirement, pension, deferred compensation, loans, severance, separation, relocation, repatriation, expatriation, visas, work permits, termination pay, performance awards, bonus, incentive, stock option, stock purchase, stock bonus, phantom stock, stock appreciation right, supplemental retirement, profit sharing, fringe benefits, cafeteria benefits, medical benefits, life insurance, disability benefits, accident benefits, salary continuation, accrued leave, vacation, sabbatical, sick pay, sick leave, unemployment benefits or other benefits, whether written or unwritten, including each "voluntary employees' beneficiary association" under Section 501(c)(9) of the Code and each "employee benefit plan" within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (" ERISA "), in each case, for active, retired or former employees, directors or consultants, which is currently sponsored, maintained, contributed to, or required to be contributed to or with respect to which any potential liability is borne by LMB or any trade or business (whether or not incorporated) that is or at any relevant time was treated as a single employer with LMB within the meaning of Section 414 of the Code (an " ERISA Affiliate ") (collectively, the " LMB Plans ") complies in all material respects with its terms, the terms of each applicable collective bargaining agreement, ERISA, the Code and all other applicable statutes and governmental rules and regulations, (ii) no LMB Plan, nor any trust created thereunder, has failed to satisfy the minimum funding standard as described in Section 302 of ERISA, whether or not waived, (iii) neither LMB nor any ERISA Affiliate has withdrawn, and neither has knowledge of any facts or conditions that could result in a withdrawal, from any "multiemployer plan" (as defined in Section 3(37) of ERISA), and (iv) no liability under Title IV of ERISA has occurred or is reasonably expected to occur.

 

(b) No LMB Plan provides, or reflects or represents any liability of LMB to provide, retiree life insurance, retiree health benefits or other retiree employee welfare benefits to any Person for any reason, except as may be required by COBRA or other applicable laws. LMB has not represented, promised or contracted (whether in oral or written form) to any employee of LMB or any other Person that such employee or other Person would be provided with retiree life insurance, retiree health benefit or other retiree employee welfare benefits, except to the extent required by applicable law.

 

(c) For each LMB Plan, LMB has furnished to Citius a copy of such plan (i) if the LMB Plan has been reduced to writing, the current plan document together with all amendments thereto, (ii) if the LMB Plan has not been reduced to writing, a written summary of all material plan terms, (iii) each trust or other funding arrangement (if applicable), (iv) each summary plan description, or other summary of the LMB Plan that describes which employees of LMB are covered by the LMB Plan, what benefits are provided, and who pays for such benefits, (v) the most recently filed IRS Form 5500 (if applicable), (vi) the most recently received IRS determination letter or IRS notification letter for each such LMB Plan that is an employee pension benefit plan (other than a plan that is unfunded and covers only employees who are among the select group of management or highly compensated employees of LMB) (" LMB Qualified Plan "), and (vii) if applicable, the most recently prepared actuarial report and/or financial statement.

 

(d) Each employee welfare benefit plan is in compliance in all respects with the Patient Protection and Affordable Care Act and its companion bill, the Health Care and Education Reconciliation Act of 2010 (collectively, the " ACA "), and the rules and regulations promulgated there under and no federal income Taxes or penalties have been imposed or could be imposed or are due for noncompliance with ACA or for failure to provide minimum coverage to Employees.

 

 
23
 

 

(e) LMB has made all contributions, premiums or payments required to be made with respect to any LMB Plan on or before their due dates. No Action is pending or threatened with respect to any LBM Plan (other than claims for benefits in the ordinary course). No event has occurred regarding any LMB Qualified Plan that is reasonably likely to result in the loss of the qualification of such plan under Section 401(a) of the Code or the exempt status of any trust under Section 501(a) of the Code. With respect to each LMB Plan, all required payments, premiums, contributions, distributions, reimbursements or accruals for all periods (or partial periods) ending prior to or as of the Closing Date shall have been timely made or properly accrued with the provisions of each of LMB Plans, applicable law and GAAP.

 

Section 2.15 Brokers . Except as set forth in Section 2.15 of the LMB Disclosure Schedule, no broker, investment banker or other Person, is entitled to any broker's, finder's or other similar fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of LMB.

 

Section 2.16 Certain Business Practices; Compliance with Laws . Neither LMB nor, to the Knowledge of LMB, any directors or officers, agents or employees of LMB, has offered, paid or agreed to pay to any person or entity (including any governmental official) or solicited, received or agreed to receive from any such person or entity, directly or indirectly, any money or anything of value for the purpose or with the intent of (a) obtaining or maintaining business for LMB, (b) facilitating the purchase or sale of any product or service, or (c) avoiding the imposition of any fine or penalty, in any manner which is in violation of any applicable law. To the Knowledge of LMB, (a) LMB has conducted and continues to conduct business in accordance with all laws applicable to LMB and LMB is not in violation of any such law, and (b) LMB is not under any investigation, been charged by a court of competent jurisdiction with or given written notice of any violation with respect to any violation of any applicable law.

 

Section 2.17 Reorganization . LMB has not taken any action and is not aware of any fact or circumstance that could reasonably be likely to prevent the Merger from qualifying as a "reorganization" within the meaning of Section 368(a) of the Code.

 

Section 2.18 Related Party Transactions . Other than LMB Convertible Notes issued by LMB to certain executive officers, directors or stockholders of LMB, no executive officer or director of LMB or any person owning 5% or more of the shares of LMB Common Stock (or any of such person's immediate family members or Affiliates or associates) is a party to any Contract with or binding upon LMB or any of its respective assets, rights or properties or has any interest in any property owned by Citius or any Citius Operating Sub or has engaged in any transaction with any of the foregoing within the last twelve (12) months.

 

Section 2.19 Representations Complete . Neither the representations and warranties of LMB set forth herein nor the related LMB Disclosure Schedule contain any misstatement of a material fact or omit to state a material fact necessary to prevent the statements made therein from being misleading.

 

 
24
 

 

ARTICLE III

 

REPRESENTATIONS AND WARRANTIES OF CITIUS AND SUBCO

 

Citius and SubCo hereby, jointly and severally, represent and warrant to LMB, as qualified by the disclosure schedule delivered by Citius and SubCo concurrently herewith (the " Citius Disclosure Schedule ") (which Citius Disclosure Schedule shall be arranged in sections corresponding to the numbered and lettered sections of this Article III , and any information disclosed in any such section of the Citius Disclosure Schedule, if it is readily apparent that the disclosure contained in such section would clearly apply to other representations and warranties contained in this Article III , would also apply to such other representations and warranties), as follows:

 

Section 3.1 Organization, Standing and Power .

 

(a) Citius is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada and has the requisite corporate or other power and authority to own, lease and operate its properties and assets and to carry on its business as it is now being conducted.

 

(b) As of the Closing, the entities set forth in Section 3.1 of the Citius Disclosure Schedule attached hereto (including the SubCo) (collectively, the " Citius Operating Subs ") will be all of the Subsidiaries of Citius, and each of which is duly organized and validly existing under the laws of the jurisdiction of its organization and has the requisite corporate power and authority to own, lease and operate its properties and assets and to carry on its business as it is now being conducted. Other than the Citius Operating Subs (as of the Closing Date), Citius does not, directly or indirectly, own any capital stock, ownership, equity, profits or voting interest or similar interest in, or any interest convertible into or exchangeable or exercisable for any equity or similar interest in, any corporation, partnership, limited liability company, joint venture or other business association or entity, and, except as contemplated in this Agreement, Citius has not agreed and is not obligated to make nor is bound by any written or oral agreement, contract, binding understanding, instrument, note, option, warranty, commitment or undertaking of any nature, as of the date hereof or as may hereafter be in effect under which it may become obligated to make, any future investment in or capital contribution to any other entity.

 

(c) Prior to the Closing, Citius will deliver or make available to LMB complete and correct copies, as amended, of its Articles of Incorporation (the " Citius Articles of Incorporation ") and Bylaws (the " Citius Bylaws ") that shall be the Articles of Incorporation and Bylaws of Citius at the Effective Time, as well as the Articles of Incorporation and Bylaws of the Citius Operating Subs as amended and in effect on the date hereof and all minutes of Citius' board of directors since January 1, 2015, other than those with respect to consideration and approval of the Merger and related transactions. The Citius Articles of Incorporation and Citius Bylaws are in full force and effect. Citius is not in violation of any of the provisions of such Articles of Incorporation and Bylaws.

 

 
25
 

 

Section 3.2 Capital Structure .

 

(a) The authorized capital stock of Citius consists of 90,000,000 shares of Citius Common Stock and 10,000,000 shares of Citius Preferred Stock. At the close of business on the date hereof and on the Closing Date (subject to any Permitted Issuances), 35,159,553 shares of Citius Common Stock were and will be issued and outstanding, all of which were validly issued, fully paid, non-assessable and free of preemptive rights.

 

(b) Except as disclosed in the Citius SEC Documents, there are no registration rights and there are no voting trusts, proxies or other similar agreements or understandings with respect to any equity security of Citius or with respect to any equity security of any Citius Operating Sub. There is no stockholder rights plan that will be applicable or triggered by the entry into this Agreement or the consummation of the other transactions contemplated hereunder. There exists no agreement or undertaking pursuant to which any Person or entity is or could require the spin-off or other transaction involving the separation of a Citius Operating Sub from Citius. As of the date of this Agreement and on the Closing Date, except as set forth in Section 3.2(b) of the Citius Disclosure Schedule, (i) there exist no options, warrants or other securities convertible into or exercisable for shares of stock of Citius capital stock, (ii) there are no rights to purchase or receive shares of Citius capital stock and (iii) there is no agreement or undertaking pursuant to which any Person or entity is or could become entitled to request Citius or Citius Operating Subs to issue of new shares of Citius. Notwithstanding the foregoing sentence, between the date hereof and the Closing Date, Citius shall be entitled to enter into the Permitted Issuances.

 

(c) Each outstanding share of capital stock (or other voting security or equity equivalent, as the case may be) of each Citius Operating Sub is duly authorized, validly issued, fully paid and non-assessable and, except as set forth in Section 3.2(c) of the Citius Disclosure Schedule, each such share (or other voting security or equity equivalent, as the case may be) is owned by Citius, free and clear of all security interests, liens, claims, pledges, options, rights of first refusal, limitations on voting rights, charges and other Encumbrances of any nature whatsoever.

 

(d) All Citius Shares issuable upon the conversion of LMB Shares or the LMB Note Shares, as applicable, at the Effective Time in accordance with this Agreement will be, when so issued, duly authorized, validly issued, fully paid, non-assessable and free of preemptive rights.

 

Section 3.3 Authority .

 

(a) On or prior to the date of this Agreement, the SubCo's board of directors (the " SubCo Board "), as well as the Citius Board and the stockholder of SubCo have approved this Agreement and the transactions contemplated hereby, including the Merger. No additional approvals are required from the SubCo Board, the Citius Board or the Citius stockholders in connection with the Merger or the other transactions contemplated hereby.

 

 
26
 

 

(b) Each of Citius and SubCo has all requisite corporate power and authority to enter into this Agreement, to perform its obligations hereunder, and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement by Citius and SubCo and the consummation by Citius and SubCo of the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action on the part of Citius and SubCo (other than the filing of the Certificate of Merger as required by the DGCL) and no other corporate proceedings on the part of Citius and SubCo are necessary to authorize this Agreement or to consummate the transactions contemplated hereby. This Agreement has been duly executed and delivered by each of Citius and SubCo and (assuming the valid authorization, execution and delivery of this Agreement by LMB and the validity and binding effect of this Agreement on LMB) constitutes the legal, valid and binding obligation of each of Citius and SubCo, enforceable against each of Citius and SubCo in accordance with its terms, except to the extent enforceability may be limited by the Bankruptcy and Equity Exception.

 

Section 3.4 SEC Documents and Other Reports .

 

(a) Citius has timely filed with the Securities and Exchange Commission (" SEC ") all reports, schedules, forms, statements, prospectuses, registration statements and other documents, as such documents may be amended or supplemented, required to be filed with or furnished to the SEC by it since January 1, 2015 (collectively, together with any exhibits and schedules thereto and other information incorporated therein, the " Citius SEC Documents "). As of their respective filing dates, or, if amended, as of the date of the last amendment prior to the date of this Agreement, the Citius SEC Documents complied in all material respects with the requirements of applicable laws and, at the respective times they were filed, none of the Citius SEC Documents contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. Except to the extent set forth in the preceding sentence, Citius makes no representation or warranty whatsoever concerning any Citius SEC Document as of any time other than the date or period with respect to which it was filed for any filing prior to September 2014. The financial statements (including, in each case, any notes thereto) of Citius included in the Citius SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto, were prepared in accordance with GAAP (except, in the case of the unaudited statements, as permitted by Form 10-Q of the SEC) applied on a consistent basis during the periods involved (except as may be indicated therein or in the notes thereto) and fairly presented in all material respects the consolidated financial position of Citius and its consolidated Subsidiaries as at the respective dates thereof and the consolidated results of their operations and their consolidated cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments and to any other adjustments described therein that are neither individually nor in the aggregate material in amount). Except as disclosed in the Citius SEC Documents filed with the SEC prior to the date of this Agreement or as required by GAAP, Citius has not made or adopted any material change in its accounting methods, practices or policies.

 

(b) Except as disclosed in the Citius SEC Documents, each of the principal executive officer and the principal financial officer of Citius has made all certifications required by Rule 13a-14 or 15d-14 under the Exchange Act and Sections 302 and 906 of the Sarbanes- Oxley Act of 2002 (including the rules and regulations promulgated thereunder, the " Sarbanes- Oxley Act ") with respect to the Citius SEC Documents, and the statements contained in such certifications are true and accurate in all material respects. For purposes of this Agreement, "principal executive officer" and "principal financial officer" shall have the meanings given to such terms in the Sarbanes-Oxley Act. Citius is in compliance in all material respects with the applicable provisions of Sarbanes-Oxley Act.

 

 
27
 

 

(c) Citius has made available to LMB true and complete copies of all written comment letters from the staff of the SEC relating to the Citius SEC Documents and all written responses of Citius thereto through the date of this Agreement. Except as disclosed in the Citius SEC Documents, as of the date of this Agreement, there are no outstanding or unresolved comments in comment letters received from the SEC staff with respect to any Citius SEC Documents, and none of the Citius SEC Documents is the subject of ongoing SEC review. Except as disclosed in the Citius SEC Documents, as of the date of this Agreement, to the Knowledge of Citius, there are no SEC inquiries or investigations, other governmental inquiries or investigations or internal investigations pending or threatened regarding Citius, including, but not limited to, any accounting practices of Citius.

 

(d) Except as disclosed in the Citius SEC Documents, Citius has established and maintains a system of "internal controls over financial reporting" (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is sufficient to provide reasonable assurance (i) regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, (ii) that receipts and expenditures of Citius are being made only in accordance with authorizations of management and the Citius Board, and (iii) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of the assets of Citius that could have a material effect on the financial statements of Citius.

 

(e) Except as disclosed in the Citius SEC Documents, the "disclosure controls and procedures" (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) of Citius are designed to ensure that all information (both financial and non-financial) required to be disclosed by Citius in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to the management of Citius as appropriate to allow timely decisions regarding required disclosure and to make the certifications of the chief executive officer and chief financial officer of Citius required under the Exchange Act with respect to such reports. Citius has disclosed, based on its most recent evaluation of such disclosure controls and procedures prior to the date of this Agreement, to its auditors and the audit committee of the Citius Board and in Section 3.4(e) of the Citius Disclosure Schedule (i) any significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting that could adversely affect in any material respect ability of Citius to record, process, summarize and report financial information, and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in Citius' internal controls over financial reporting. For purposes of this Agreement, the terms "significant deficiency" and "material weakness" shall have the meaning assigned to them in Public Company Accounting Oversight Board Auditing Standard 2, as in effect on the date of this Agreement.

 

 
28
 

 

Section 3.5 Financial Statements .

 

(a) True and complete copies of (i) the audited consolidated balance sheet of Citius (including the Citius Operating Subs) for the fiscal year ended as of September 30, 2015 (the " Balance Sheet Date "), and the related audited consolidated statements of income and cash flows and (ii) the unaudited condensed consolidated balance sheet of Citius (including the Citius Operating Subs) for the quarter ended December 31, 2015, and the related unaudited condensed consolidated statements of income and cash flows (collectively, the " Financial Statements ") have been delivered by Citius to LMB.

 

(b) Except as disclosed in the Citius SEC Documents, there exist no material liabilities or obligations of Citius and the Citius Operating Subs that are required by GAAP to be disclosed, reflected or reserved against in the Financial Statements, except (i) as disclosed, reflected or reserved against in the Financial Statements, (ii) for liabilities and obligations incurred in the ordinary course of business consistent with past practice since December 31, 2015, and (iii) for liabilities and obligations related to, arising under or incurred in connection with this Agreement and the transactions contemplated herein. Except as disclosed in the Citius SEC Documents, neither Citius nor any of the Citius Operating Subs is a party to, or has any commitment to become a party to, any joint venture, off balance sheet partnership or any similar Contract (including any Contract or arrangement relating to any transaction or relationship between or among Citius and any of the Citius Operating Subs, on the one hand, and any unconsolidated Affiliate, including any structured finance, special purpose or limited purpose entity or Person, on the other hand, or any "off balance sheet arrangements" (as defined in Item 303(a) of Regulation S-K under the Exchange Act), where the result, purpose or intended effect of such Contract is to avoid disclosure of any material transaction involving, or material liabilities of, Citius or any of the Citius Operating Subs in Citius or any of the Citius Operating Subs published financial statements or other Citius SEC Documents.

 

Section 3.6 Litigation . Except as disclosed in the Citius SEC Documents, there is no Action by or before any Governmental Entity or other Person pending or, to the Knowledge of Citius, threatened against Citius or any Citius Operating Sub, and neither Citius nor any Citius Operating Sub is subject to any Order, that could materially prevent the consummation of the transactions contemplated by this Agreement.

 

Section 3.7 Consents and Approvals; No Violation .

 

(a) The execution and delivery of this Agreement by each of Citius and SubCo do not, and the performance of this Agreement by each of Citius and SubCo will not, (i) conflict with or violate any provision of the Citius Articles of Incorporation or Citius Bylaws or any equivalent organizational documents of any Citius Operating Sub (including SubCo), (ii) conflict with or violate any law applicable to Citius or any Citius Operating Sub, or (iii) except for those already obtained, require any consent or approval under, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, any Contract or other instrument or obligation.

 

 
29
 

 

(b) The execution and delivery of this Agreement by Citius do not, and the performance of the Agreement by Citius will not, require any consent, approval, authorization or Permit of, or filing with or notification to, any Governmental Entity or any other Person, except for those already obtained or under the Securities Exchange Act of 1934, as amended (the " Exchange Act "), the Securities Act and the filing and recordation of the Certificate of Merger as required by the DGCL.

 

Section 3.8 Regulatory Compliance .

 

(a) Except as disclosed in the Citius SEC Documents, there is no civil, criminal or administrative action, suit, demand, claim, complaint, hearing, investigation, demand letter, warning letter, proceeding or request for information pending against Citius or any Citius Operating Sub, and, to the Knowledge of Citius, Citius has no liability (whether actual or contingent) for failure to comply with FDA Law and Regulation or any law or regulation of a comparable foreign regulatory or Governmental Entity. There has not been any material violation of any FDA Law and Regulation or any law or regulation of a comparable foreign regulatory or Governmental Entity by Citius or any Citius Operating Sub in its product development efforts, submissions, record keeping and reports to FDA or a comparable Governmental Entity that could reasonably be expected to require or lead to investigation, corrective action or enforcement, regulatory or administrative action, provided that, to the extent the foregoing activities have been performed on Citius' or any Citius Operating Sub's behalf by any third party contractors, the representation and warranty made in this sentence shall only be made to the extent of Citius' Knowledge after exercise of reasonable diligence in requiring such contractors to comply with applicable FDA Law and Regulation or any law or regulation of a comparable foreign regulatory or Governmental Entity.

 

(b) Except as disclosed in the Citius SEC Documents, to the Knowledge of Citius, each of the product candidates of Citius and Citius Operating Subs are being, and at all times have been, developed, tested, manufactured, labeled, promoted and stored, as applicable, in material compliance with FDA Law and Regulation and requirements of comparable foreign regulatory and Governmental Entities and, to the extent the foregoing activities have been performed on Citius' behalf by any third party contractors, Citius has exercised reasonable diligence in requiring such contractors to comply with applicable FDA Law and Regulation or any law or regulation of a comparable foreign regulatory or Governmental Entity.

 

(c) Except as disclosed in the Citius SEC Documents, to the Knowledge of Citius, the clinical trials, studies and other preclinical tests conducted by Citius and any Citius Operating Sub were, and if still pending, are, being conducted in all material respects in accordance with all experimental protocols, informed consents, procedures and controls of Citius and applicable FDA and foreign requirements including, but not limited to, good clinical practices, good laboratory practices, and FDA Law and Regulation including the protection of human subjects and, to the extent the foregoing activities have been performed on Citius' behalf by any third party contractors, Citius has exercised reasonable diligence in requiring such contractors to comply with applicable FDA Law and Regulation or any law or regulation of a comparable foreign regulatory or Governmental Entity. Neither Citius nor any Citius Operating Sub has received any written notice from the FDA or any other regulatory or Governmental Entity requiring the termination or suspension or material modification of any animal study, preclinical study or clinical trial conducted by or on behalf of Citius or any Citius Operating Sub and, to the Knowledge of Citius, there is no reasonable basis for any termination, suspension, or material modification, for, in each case, purposes of the protection of subject health or safety, of any ongoing human clinical trial being conducted by or on behalf of Citius or any Citius Operating Sub.

 

 
30
 

 

(d) Except as disclosed in the Citius SEC Documents, with respect to all Third Party Manufacturers used by Citius or any Citius Operating Sub, (i) to the Knowledge of Citius, each such Third Party Manufacturer (A) has complied and is complying, in each case in all material respects, with all laws, including FDA Law and Regulation and any similar state or foreign laws and (B) has all material Permits to perform its obligations as a Third Party Manufacturer and all such Permits are in full force and effect and (ii) Citius and all Citius Operating Subs have exercised reasonable diligence in requiring all Third Party Manufacturers to comply with applicable FDA Law and Regulation or any law or regulation of a comparable foreign regulatory or Governmental Entity.

 

(e) Except as disclosed in the Citius SEC Documents, in connection with Citius' and Citius Operating Subs' businesses, no director, officer, employee or agent of Citius or any Citius Operating Sub has (x) made any untrue statement of material fact or fraudulent statement to the FDA or any other Governmental Entity, (y) failed to disclose a material fact required to be disclosed to the FDA or any other Governmental Entity or (z) committed an act, made a statement, or failed to make a statement that would reasonably be expected to provide the basis for the FDA or any other Governmental Entity to invoke its policy respecting "Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities," as set forth in CPG. Section 120.100.

 

(f) Except as disclosed in the Citius SEC Documents, Citius and all Citius Operating Subs have complied with all applicable security and privacy standards regarding protected health information pursuant to HIPAA or any foreign equivalent and applicable privacy laws.

 

(g) Except as disclosed in the Citius SEC Documents, to the extent applicable, Citius and all Citius Operating Subs have applied to the FDA and all comparable foreign regulatory or Governmental Entities for and received all FDCA Permits necessary to conduct the business of Citius and all Citius Operating Subs as currently conducted. Citius and all Citius Operating Subs are in material compliance with all such FDCA Permits. To the Knowledge of Citius, no suspension, revocation, cancellation or withdrawal of the FDCA Permits is threatened and there is no basis for believing that such FDCA Permits will not be renewable upon expiration or will be suspended, revoked, cancelled, modified or withdrawn.

 

Section 3.9 Intellectual Property . Except as disclosed in the Citius SEC Documents:

 

(a) to the Knowledge of Citius, (i) the use of (and practice of any technology claimed by) all patents, patent rights (including patent applications and licenses), know-how, trade secrets, trademarks (including trademark applications), trademark rights, trade names, trade name rights, service marks, service mark rights, copyrights and other proprietary intellectual property rights utilized in, or reasonably necessary to conduct, Citius' and Citius Operating Subs' businesses as currently conducted (collectively, the " Citius Intellectual Property ") by Citius and the Citius Operating Subs does not infringe on, misappropriate, or otherwise violate the intellectual property rights of any third party, and is in accordance in all material respects with any applicable licenses or other agreements pursuant to which Citius or the Citius Operating Subs acquired the right to use such Citius Intellectual Property and (ii) Citius and the Citius Operating Subs own sufficient rights and/or interest in the Citius Intellectual Property to conduct their businesses as currently conducted without infringement, misappropriation, or violation of any third party's intellectual property rights;

 

 
31
 

 

(b) neither Citius nor any Citius Operating Sub has received any notice, written or otherwise, nor has any Knowledge of, (i) any claim that is pending or has been threatened in writing, Order or proceeding with respect to any Citius Intellectual Property or Citius' or any Citius Operating Sub's practice of any third party's intellectual property rights, (ii) any allegation by any third party that Citius or any Citius Operating Sub has infringed, misappropriated, or violated any intellectual property rights of any third party, or (iii) any notice of any alleged or actual breach of any license or other agreement pursuant to which Citius or any Citius Operating Sub acquired the right to use Citius Intellectual Property; and

 

(c) Citius and all Citius Operating Subs have maintained commercially reasonable practices to protect the confidentiality of their confidential information and trade secrets and have required all employees, consultants, and other persons or entities to whom they provided access to their confidential information (other than attorneys, accountants, and others with professional duties of confidentiality, to whom this requirement shall not apply) to execute written agreements requiring them to maintain the confidentiality of such information and to limit his, her or its use of such information on commercially reasonable terms.

 

Section 3.10 Brokers . No broker, investment banker or other Person, is entitled to any broker's, finder's or other similar fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Citius.

 

Section 3.11 Operations of SubCo . SubCo is a direct, wholly-owned Subsidiary of Citius, was formed solely for the purpose of engaging in the transactions contemplated hereby, has engaged in no other business activities and has conducted its operations only as contemplated hereby.

 

Section 3.12 Taxes . Except as and to the extent disclosed in Section 3.12 of the Citius Disclosure Schedule:

 

(a) Unless otherwise disclosed in the Citius SEC Documents, Citius and the Citius Operating Subs (i) have complied with all applicable Tax laws, (ii) have filed all necessary Tax Returns required to be filed by them, and such Tax Returns are accurate and complete in all material respects, and (iii) have paid all due and owing amounts of Tax, whether or not set forth on a Tax Return. For any Taxes not yet due and owing, Citius and the Citius Operating Subs have made adequate provision for such Taxes in the Financial Statements, in accordance with GAAP.

 

(b) The most recent Financial Statements of Citius and the Citius Operating Subs reflect adequate reserves (in accordance with GAAP) for all material Taxes payable through the date of such Financial Statements. Since the date of the most recent Financial Statements, neither Citius nor any of the Citius Operating Subs has incurred any material liability for Taxes arising outside the ordinary course of business consistent with past custom and practice.

 

 
32
 

 

(c) Unless otherwise disclosed in the Citius SEC Documents, all deficiencies asserted or assessed by a taxing authority against the Citius and the Citius Operating Subs have been paid in full or are adequately reserved in the Financial Statements, in accordance with GAAP.

 

(d) Unless otherwise disclosed in the Citius SEC Documents, there are no liens for Taxes on any of the assets of Citius and the Citius Operating Subs.

 

(e) As of the date of the Merger, (i) Citius will own all of the outstanding stock or other equity interests in SubCo, and (ii) Citius will be in "control" of SubCo within the meaning of Code § 368(c). Citius has no plan or present intention to sell, transfer or otherwise dispose of any of the stock of LMB following the Merger, and Citius has no present plan or intention to cause LMB to issue additional stock following the Merger, that in either case would result in Citius' not having "control" of LMB within the meaning of Section 368(c) of the Code.

 

(f) Citius and the Citius Operating Subs (i) have complied in all material respects with all applicable laws, rules and regulations relating to the payment and withholding of Taxes; and (ii) have duly and timely withheld from any compensation payable and from distributions to any stockholder or payments to any creditor and has paid over to the appropriate taxing authorities all material amounts required to be withheld and paid over on or prior to the due date thereof under all applicable laws.

 

(g) Neither Citius nor any Citius Operating Sub has received written notice from any taxing authority in a jurisdiction in which Citius or any Citius Operating Sub does not file a Tax Return stating that Citius or the Citius Operating Sub is or may be subject to taxation by that jurisdiction.

 

(h) Neither Citius nor any Citius Operating Sub (i) is a party to any Tax sharing, Tax indemnity or similar agreement or arrangement, other than any agreement or arrangement between Citius and the Citius Operating Subs, pursuant to which it will have any obligation to make any payments after the Closing and (ii) do not have any liability for the Taxes of any Person other than Citius and the Citius Operating Subs (x) under Treasury Regulation §1.1502-6 (or similar provision of state, local or foreign law), (y) as transferee or successor or (z) by contract.

 

(i) Within the past two (2) years, neither Citius nor any Citius Operating Sub has distributed stock of another Person in a transaction intended to be governed by Section 355 of the Code, nor has the stock of Citius or any Citius Operating Sub been distributed in a transaction intended to be governed by Section 355 of the Code.

 

(j) Neither Citius nor any Citius Operating Sub has engaged in a "reportable transaction" as defined in Treasury Regulation Section 1.6011-4, or any transaction that is the same as, or substantially similar to, any "listed transactions" as defined in Treasury Regulation Section 1.6011-4(b)(2).

 

 
33
 

 

(k) Neither Citius nor any Citius Operating Sub has been at any time a United States Real Property Holding Corporation within the meaning of Section 897(c)(2) of the Code.

 

(l) Neither Citius nor any Citius Operating Sub (i) has elected to change, nor is Citius or any Citius Operating Sub required to change, a method of accounting for Tax purposes pursuant to Section 481 of the Code or otherwise that will have a continuing effect following the Closing or (ii) is the subject of any closing agreement with respect to Taxes that will have a continuing effect following the Closing.

 

(m) Neither Citius nor any Citius Operating Sub has made any payments or is obligated to make any payments, nor is Citius nor any Citius Operating Sub a party to any agreement that under certain circumstances could obligate it to make any payments, that will not be deductible under either Sections 280G or 162(m) of the Code.

 

(n) To the Knowledge of Citius, there are no excess loss accounts, deferred intercompany transactions, or other items of income, gain, loss, deduction or credit of Citius or any Citius Operating Sub under the federal consolidated return regulations or other comparable or similar provisions of state law that must be recognized or may be triggered as a result of the consummation of the transactions contemplated by this Agreement.

 

(o) Neither Citius nor any Citius Operating Sub has, or ever has had, a permanent establishment in any country outside of the United States and is not, and has never been, subject to Tax in a jurisdiction outside of the United States. Neither Citius nor any Citius Operating Sub has entered into a gain recognition agreement pursuant to Treasury Regulation Section 1.367(a)-8. Neither Citius nor any Citius Operating Sub has transferred an intangible, the transfer of which would be subject to the rules of Section 367(d) of the Code.

 

Section 3.13 Contracts .

 

(a) Neither Citius nor any Citius Operating Sub is a party to or bound by any Contract that would prohibit or materially delay the consummation of the Merger or any of the other transactions contemplated by this Agreement.

 

(b) Except as set forth in Section 3.13(b) of the Citius Disclosure Schedule, neither Citius nor any Citius Operating Sub has received any claim of default, notice of termination, notice of violation of covenant or other notice of third party dissatisfaction under any Contract or agreement that extends beyond one year in duration and involves consideration of more than One Million Dollars ($1,000,000) in the aggregate over the remaining term of such Contract or agreement (each a " Material Citius Contract ").

 

(c) Neither Citius nor any Citius Operating Sub is in breach or violation of, or default under, any Material Citius Contract, which breach, violation or default would have a Citius Material Adverse Effect.

 

(d) Each Material Citius Contract is a legal, valid and binding agreement of Citius or the Citius Operating Sub party thereto, subject to the Bankruptcy and Equity Exception.

 

 
34
 

 

(e) Neither Citius nor any Citius Operating Sub has received any notice, written or otherwise, with respect to a claim of default, notice of termination, notice of violation of covenant or other notice of third party dissatisfaction under any Material Citius Contract, and neither Citius nor any Citius Operating Sub is in breach or violation of, or default under, any Material Citius Contract.

 

(f) To the Knowledge of Citius, no other party is in breach or violation of, or default under, any Material Citius Contract.

 

(g) Except as set forth in Section 3.13(g) of the Citius Disclosure Schedule, neither the execution of this Agreement nor the consummation of the transactions contemplated hereunder shall constitute a default under, give rise to cancellation rights under, or otherwise adversely affect any of the material rights of Citius or any Citius Operating Sub under any Material Citius Contract.

 

(h) Citius has furnished or made available to LMB true and complete copies of all Material Citius Contracts, including any amendments thereto.

 

Section 3.14 Environmental Matters . Except as disclosed in the Citius SEC Documents, Citius and the Citius Operating Subs are in compliance in all material respects with (a) all Environmental Laws and (b) the requirements of all Permits issued under such Environmental Laws with respect to Citius and the Citius Operating Subs. There are no pending or, to the Knowledge of Citius, threatened Legal Proceedings relating to Environmental Laws against Citius or any Citius Operating Sub.

 

Section 3.15 Insurance . Except as disclosed in the Citius SEC Documents, Citius and the Citius Operating Subs maintain insurance coverage with reputable insurers in such amounts and covering such risks as are in accordance with normal industry practice for companies engaged in businesses similar to that of Citius (taking into account the cost and availability of such insurance).

 

Section 3.16 Labor and Other Employment Matters . Except as disclosed in the Citius SEC Documents, Citius and each Citius Operating Sub is in material compliance with all applicable laws respecting labor, employment, fair employment practices, terms and conditions of employment, workers' compensation, occupational safety, wages and hours. Furthermore, none of the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby will (either alone or in conjunction with any other event, such as termination of employment) (i) result in any payment (including, without limitation, severance, parachute or otherwise) becoming due to any director or any employee of Citius, any Citius Operating Sub or their Affiliates from Citius, any Citius Operating Subs or their Affiliates, or (ii) result in any acceleration of the time of payment or vesting of any material benefits. Except as disclosed in Section 3.16 of the Citius Disclosure Schedule and Citius SEC Documents, Citius is not (i) subject to any obligation to pay health insurance premiums or make any other payments under any health insurance plan, (ii) obligated to make any payments to or provide any benefits under COBRA to any former employee, nor (iii) to the Knowledge of Citius, subject to any outstanding worker's compensation claims.

 

 
35
 

 

Section 3.17 Employee Benefits; ERISA . Except as disclosed in the Citius SEC Documents:

 

(a) (i) Each plan, program, policy, practice, Contract, agreement or other arrangement providing for employment, compensation, retirement, pension, deferred compensation, loans, severance, separation, relocation, repatriation, expatriation, visas, work permits, termination pay, performance awards, bonus, incentive, stock option, stock purchase, stock bonus, phantom stock, stock appreciation right, supplemental retirement, profit sharing, fringe benefits, cafeteria benefits, medical benefits, life insurance, disability benefits, accident benefits, salary continuation, accrued leave, vacation, sabbatical, sick pay, sick leave, unemployment benefits or other benefits, whether written or unwritten, including each "voluntary employees' beneficiary association" under Section 501(c)(9) of the Code and each "employee benefit plan" within the meaning of Section 3(3) ERISA, in each case, for active, retired or former employees, directors or consultants, which is currently sponsored, maintained, contributed to, or required to be contributed to or with respect to which any potential liability is borne by Citius or any trade or business (whether or not incorporated) that is or at any relevant time was treated as an ERISA Affiliate (collectively, the " Citius Plans ") complies in all material respects with its terms, the terms of each applicable collective bargaining agreement, ERISA, the Code and all other applicable statutes and governmental rules and regulations, (ii) no Citius Plan, nor any trust created thereunder, has failed to satisfy the minimum funding standard as described in Section 302 of ERISA, whether or not waived, (iii) neither Citius nor any ERISA Affiliate has withdrawn, and neither has knowledge of any facts or conditions that could result in a withdrawal, from any "multiemployer plan" (as defined in Section 3(37) of ERISA), and (iv) no liability under Title IV of ERISA has occurred or is reasonably expected to occur.

 

(b) No Citius Plan provides, or reflects or represents any liability of Citius to provide, retiree life insurance, retiree health benefits or other retiree employee welfare benefits to any Person for any reason, except as may be required by COBRA or other applicable laws. Citius has not represented, promised or contracted (whether in oral or written form) to any employee of Citius or any other Person that such employee or other Person would be provided with retiree life insurance, retiree health benefit or other retiree employee welfare benefits, except to the extent required by applicable law.

 

(c) For each Citius Plan, Citius has furnished to LMB a copy of such plan (i) if the Citius Plan has been reduced to writing, the current plan document together with all amendments thereto, (ii) if the Citius Plan has not been reduced to writing, a written summary of all material plan terms, (iii) each trust or other funding arrangement (if applicable), (iv) each summary plan description, or other summary of the Citius Plan that describes which employees of Citius are covered by the Citius Plan, what benefits are provided, and who pays for such benefits, (v) the most recently filed IRS Form 5500 (if applicable), (vi) the most recently received IRS determination letter or IRS notification letter for each such Citius Plan that is an employee pension benefit plan (other than a plan that is unfunded and covers only employees who are among the select group of management or highly compensated employees of Citius) (" Citius Qualified Plan "), and (vii) if applicable, the most recently prepared actuarial report and/or financial statement.

 

 
36
 

 

(d) Each employee welfare benefit plan is in compliance in all respects with the ACA, and the rules and regulations promulgated there under and no federal income Taxes or penalties have been imposed or could be imposed or are due for noncompliance with ACA or for failure to provide minimum coverage to Employees.

 

(e) Citius has made all contributions, premiums or payments required to be made with respect to any Citius Plan on or before their due dates. No Action is pending or threatened with respect to any Citius Plan (other than claims for benefits in the ordinary course). No event has occurred regarding any Citius Qualified Plan that is reasonably likely to result in the loss of the qualification of such plan under Section 401(a) of the Code or the exempt status of any trust under Section 501(a) of the Code. With respect to each Citius Plan, all required payments, premiums, contributions, distributions, reimbursements or accruals for all periods (or partial periods) ending prior to or as of the Closing Date shall have been timely made or properly accrued with the provisions of each of Citius Plans, applicable law and GAAP.

 

Section 3.18 Absence of Certain Changes or Events . Since December 31, 2015, except in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby, the business of Citius and the Citius Operating Sub has been conducted in the ordinary course of business and there has not been or occurred any event that could reasonably be expected to have, individually or in the aggregate, a Citius Material Adverse Effect.

 

Section 3.19 Related Party Transactions . Except as disclosed in the Citius SEC Documents, no executive officer or director of Citius or any Citius Operating Sub or any person owning 5% or more of the shares of Citius Common Stock or Citius Preferred Stock (or any of such person's immediate family members or Affiliates or associates) is a party to any Contract with or binding upon Citius or any Citius Operating Sub or any of their respective assets, rights or properties or has any interest in any property owned by Citius or any Citius Operating Sub or has engaged in any transaction with any of the foregoing within the last twelve (12) months.

 

Section 3.20 Reorganization . Neither Citius nor any Citius Operating Sub has taken any action or is aware of any fact or circumstance that could reasonably be likely to prevent the Merger from qualifying as a "reorganization" within the meaning of Section 368(a) of the Code.

 

Section 3.21 Representations Complete . Neither the representations and warranties of Citius set forth herein nor the related Citius Disclosure Schedule contain any misstatement of a material fact or omit to state a material fact necessary to prevent the statements made therein from being misleading.

 

ARTICLE IV

 

ADDITIONAL AGREEMENTS

 

Section 4.1 Reasonable Best Efforts . Subject to the terms and conditions of this Agreement, each party will use its reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under applicable law to consummate the transactions contemplated by this Agreement, including preparing and filing as promptly as practicable all documentation to effect all necessary filings, notices, petitions, statements, submissions of information, applications and other documents, and to obtain all Permits which are material to LMB or Citius, taken as a whole, with respect to the transactions contemplated by this Agreement.

 

 
37
 

 

Section 4.2 Public Announcements . Citius and LMB will not issue any press release with respect to the transactions contemplated by this Agreement or otherwise issue any written public statements with respect to such transactions without prior consultation with the other party, except as may be required by applicable law (but then shall still provide a copy of the disclosure to the other party), and agreeing on the content thereof.

 

Section 4.3 Notification of Certain Matters . Citius shall use its reasonable best efforts to give prompt notice to LMB, and LMB shall use its reasonable best efforts to give prompt notice to Citius, of (a) the occurrence, or non-occurrence, of any event the occurrence, or non- occurrence, of which it is aware and which would be reasonably likely to cause (i) any representation or warranty of the notifying party contained in this Agreement to be untrue or inaccurate at the Effective Time such that the applicable condition to closing set forth in Article V would, or would reasonably be expected to, fail to be satisfied or (ii) any covenant, condition or agreement of the notifying party contained in this Agreement not to be complied with or satisfied such that the applicable condition to closing set forth in Article V would, or would reasonably be expected to, fail to be satisfied, or (b) any failure of the notifying party to comply in a timely manner with or satisfy any covenant, condition or agreement to be complied with or satisfied by it hereunder; provided , however , that the delivery of any notice pursuant to this Section 4.4 shall not limit or otherwise affect the remedies available hereunder to the party receiving such notice.

 

Section 4.4 Citius Financial Statements . To the extent unaudited financial statements for an interim quarterly period subsequent to the Balance Sheet Date would be required by the SEC, Citius shall deliver such additional financial statements to LMB when available.

 

Section 4.5 Reservation of Citius Common Stock . Effective at or prior to the Effective Time, Citius shall reserve (free from preemptive rights) out of its authorized but unissued shares of Citius Common Stock, for the purposes of effecting the conversion of the issued and outstanding LMB Shares, LMB Note Shares, LMB Options, LMB Warrants and any Unconverted LMB Note Shares, as applicable, pursuant to this Agreement, sufficient Citius Shares (equal to no less than the Merger Shares) to provide for such conversion.

 

Section 4.6 Stockholder Litigation . Subject to the agreement of LMB's insurance carrier, LMB shall give Citius the opportunity to participate in the defense or settlement of any stockholder litigation against LMB and/or their respective directors or officers relating to the transactions contemplated by this Agreement by providing written notice of such litigation to Citius within a reasonable time after LMB learns of the litigation. LMB agrees that it shall not settle or offer to settle any litigation against LMB or any of its respective directors or officers by any stockholder of LMB relating to this Agreement, the Merger, any other transaction contemplated by this Agreement or otherwise, for an amount greater than covered by its insurance carrier, without the prior written consent of Citius (such consent not to be unreasonably withheld, conditioned or delayed).

 

 
38
 

 

Section 4.7 LMB Stockholder Approval . As of the date hereof, LMB has delivered to Citius an executed agreement in the form attached hereto as Exhibit B pursuant to which LMB stockholders beneficially owning a majority of the outstanding shares of LMB Common Stock have voted their LMB Shares in favor of the Merger and related transactions. Notwithstanding the foregoing, nothing in this Agreement shall prohibit or otherwise impair the right or ability of any LMB stockholder to exercise his or her fiduciary duties in his or her capacity as a director of LMB.

 

Section 4.8 Indemnification of Officers and Directors .

 

(a) From the Effective Time through the sixth (6th) anniversary of the date on which the Effective Time occurs, Citius shall, and shall cause the Surviving Corporation to, jointly and severally, indemnify and hold harmless each person who is now, or has been at any time prior to the date hereof, or who becomes prior to the Effective Time, a director or officer of LMB (the " D&O Indemnified Parties "), against all claims, losses, liabilities, damages, judgments, fines and reasonable fees, costs and expenses, including fees and disbursements of legal counsel, incurred in connection with any claim, action, suit, proceeding or investigation, whether civil, criminal, administrative or investigative, arising out of or pertaining to the fact that the D&O Indemnified Party is or was a director or officer of LMB, whether asserted or claimed prior to, at or after the Effective Time, to the fullest extent permitted under the DGCL for directors or officers of Delaware corporations. Each D&O Indemnified Party will be entitled to advancement of expenses incurred in the defense of any such claim, action, suit, proceeding or investigation from each of Citius and the Surviving Corporation, jointly and severally, upon receipt by Citius or the Surviving Corporation from the D&O Indemnified Party of a written request therefor; provided that any person to whom expenses are advanced provides an undertaking, to the extent required by the DGCL or other applicable law, to repay such advances if it is ultimately determined that such person is not entitled to indemnification.

 

(b) The certificate of incorporation and bylaws of Citius shall contain, and Citius shall cause the certificate of incorporation and bylaws of the Surviving Corporation to so contain, provisions no less favorable with respect to indemnification, advancement of expenses and exculpation of present and former directors and officers of LMB than are presently set forth in the LMB Charter and LMB Bylaws, which provisions shall not be amended, modified or repealed for a period of six (6) years' time from the Effective Time in a manner that would adversely affect the rights thereunder of individuals who, at or prior to the Effective Time, were officers or directors of LMB.

 

(c) For a period of six (6) years from the Effective Time, Citius shall cause to be maintained in effect customary policies of directors' and officers' liability insurance and fiduciary liability insurance with respect to matters arising on or before the Effective Time through a provider reasonably selected by Citius.

 

(d) Citius shall pay all expenses, including reasonable attorneys' fees, that may be incurred by the persons referred to in this Section 4.8 in connection with their enforcement of their rights provided in this Section 4.8 but only if and to the extent that such persons are successful on the merits of such enforcement action.

 

 
39
 

 

(e) The provisions of this Section 4.8 are intended to be in addition to the rights otherwise available to the current and former officers and directors of Citius and LMB by law, charter, statute, bylaw or agreement, and shall operate for the benefit of, and shall be enforceable by, each of the D&O Indemnified Parties, their heirs and their representatives.

 

(f) In the event Citius or the Surviving Corporation or any of their respective successors or assigns (i) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger, or (ii) transfers all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that the successors and assigns of Citius or the Surviving Corporation, as the case may be, shall succeed to the obligations set forth in this Section 4.8 .

 

Section 4.9 Tax Matters . After the Effective Time, Citius, either directly or through LMB as long as LMB is within Citius' "qualified group" within the meaning of Treasury Regulations § 1.368-1(d)(4)(ii) (the " Qualified Group "), will continue at least one significant historic business line of LMB, or use at least a significant portion of LMB's historic business assets in a business, in each case within the meaning of Treasury Regulations § 1.368-1(d), except that LMB's historic business assets may be transferred (a) to a corporation that is another member of Citius' Qualified Group, or (b) to an entity taxed as a partnership if (i) one or more members of Citius' Qualified Group have active and substantial management functions as a partner with respect to Citius' historic business or (ii) members of Citius' Qualified Group in the aggregate own an interest in the partnership representing a significant interest in LMB's historic business, in each case within the meaning of Treasury Regulations § 1.368-1(d)(4)(iii). In addition, Citius shall prepare and timely file (or cause the Surviving Corporation to prepare and timely file), consistent with Section 1.14 , including, without limitation, any statements required to be filed with federal income Tax Returns for the taxable year of the Merger pursuant to Treasury Regulations § 1.368-3, all Tax Returns of LMB that are required to be filed after the Closing Date relating to a Tax period of LMB ending on or prior to the Closing Date or a Tax period of LMB beginning before and ending after the Closing Date. All such Tax Returns shall be prepared in a manner that is consistent with the past custom and practice of LMB, except as required under applicable law. Notwithstanding any other provision herein, LMB shall be responsible for filing all Tax Returns required to be filed for the Tax period ending May 31, 2015.

 

ARTICLE V

 

CONDITIONS PRECEDENT TO THE MERGER

 

Section 5.1 Conditions to Each Party's Obligation to Effect the Merger . The respective obligations of each party to effect the Merger shall be subject to the fulfillment or waiver by Citius and LMB at or prior to the Closing Date of the following conditions:

 

(a) No Injunctions or Restraints . No temporary restraining order, preliminary or permanent injunction or other judgment, Order or decree issued by a court or agency of competent jurisdiction preventing the consummation of the Merger shall have been issued and remain in effect, and no law shall have been enacted, issued, enforced, entered, or promulgated that prohibits or makes illegal the consummation of the Merger.

 

 
40
 

 

(b) No Litigation . There shall not be pending any Action by any Governmental Entity seeking to prohibit the consummation of the Merger or any other material transactions contemplated by this Agreement that is reasonably likely to succeed.

 

(c) No Action to Prevent Qualification as a "Reorganization" . The parties shall take no action or knowingly fail to take any action where such action or failure to act could reasonably be expected to prevent the Merger from qualifying as a "reorganization" within the meaning of Section 368(a) of the Code.

 

Section 5.2 Conditions to Obligation of Citius to Effect the Merger . The obligation of Citius to effect the Merger shall be subject to the fulfillment, or waiver by Citius, at or prior to the Effective Time of the following additional conditions:

 

(a) Performance of Obligations . LMB shall have performed its agreements contained in this Agreement required to be performed on or prior to the Closing Date.

 

(b) Representations and Warranties . The representations and warranties of LMB contained in this Agreement shall be true and correct in all material respects (except for such representations and warranties that are qualified by their terms by a reference to materiality or LMB Material Adverse Effect, which representations and warranties as so qualified will be true in all respects) as of the date of this Agreement and as of the Closing Date as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such earlier date).

 

(c) Consents and Approvals . LMB shall have received all necessary consents and approvals from all relevant Governmental Entities, and LMB shall have made all necessary filings or notices to Governmental Entities. LMB shall have obtained all consents and approvals of each Person that is not a Governmental Entity that is required to have been obtained by LMB in connection with the transactions contemplated hereby.

 

(d) Officer's Certificate . Citius shall have received from LMB a certificate of an executive officer of LMB (i) as to the satisfaction of the conditions set forth in this Section 5.2 , (ii) attaching a certified copy of resolutions duly adopted by the LMB Board approving this Agreement and consummation of the Merger and the transactions contemplated hereby, and (iii) attaching a certified copy of resolutions duly adopted by the LMB stockholders approving the Merger and the transactions contemplated hereby.

 

(e) Mazur Investment . Prior to the Closing, Citius shall have closed upon the Mazur Investment.

 

Section 5.3 Conditions to Obligations of LMB to Effect the Merger . The obligations of LMB to effect the Merger shall be subject to the fulfillment, or waiver by LMB, at or prior to the Effective Time of the following additional conditions:

 

(a) Performance of Obligations . Each of Citius and SubCo shall have performed each of its agreements contained in this Agreement required to be performed on or prior to the Closing Date.

 

 
41
 

 

(b) Representations and Warranties . The representations and warranties of Citius and SubCo contained in this Agreement shall be true and correct in all material respects (except for such representations and warranties that are qualified by their terms by a reference to materiality or Citius Material Adverse Effect, which representations and warranties as so qualified will be true in all respects)as of the date of this Agreement and as of the Closing Date as if made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of such earlier date).

 

(c) Consents and Approvals . Citius and SubCo shall have received all necessary consents and approvals from all relevant Governmental Entities, and Citius and SubCo shall have made all necessary filings or notices to Governmental Entities. Citius and SubCo shall have obtained all consents and approvals of each Person that is not a Governmental Entity that is required to have been obtained by Citius and SubCo in connection with the transactions contemplated hereby.

 

(d) SEC Reports . Citius shall have timely filed with the SEC all reports, forms, schedules, statements and other documents required to be filed or furnished by Citius with the SEC, or distributed or otherwise disseminated to Citius' stockholders in connection with the transactions contemplated herein, and any amendments or supplements thereto, when filed, furnished, distributed or disseminated, as applicable, and such reports, forms, schedules, statements and other documents shall have complied in all material respects as to form and with the requirements of applicable law as of the Closing Date.

 

(e) Employment Agreement . At or prior to the Closing, Citius shall enter into the Employment Agreement pursuant to which Myron Holubiak shall serve as the Chief Executive Officer of Citius. All other key employees of LMB, as identified in Section 5.3(e) of the LMB Disclosure Schedule, will continue to be employed by the Surviving Corporation.

 

(f) Citius Financing . Prior to or simultaneously with the Closing, Citius shall close or have closed upon the Citius Financing.

 

(g) Officer's Certificate . LMB shall have received from Citius a certificate of an executive officer of Citius (i) as to the satisfaction of the conditions set forth in this Section 5.3 , and (ii) attaching a certified copy of resolutions duly adopted by the Citius Board and the SubCo Board approving this Agreement and consummation of the Merger and the transactions contemplated hereby.

 

 
42
 

 

ARTICLE VI

 

TERMINATION

 

Section 6.1 Termination . This Agreement may be terminated and the Merger may be abandoned at any time prior to the Effective Time:

 

(a) by mutual written consent of Citius and LMB, duly authorized, or by mutual action of their respective Boards of Directors;

 

(b) by Citius in the event that the Dissenting Shares represent more than seven percent (7%) of the LMB capital stock issued and outstanding immediately prior to the Effective Time;

 

(c) by either Citius or LMB:

 

(i) if the Merger shall not have been consummated on or before March 31, 2016 (as mutually extended until the Outside Date); provided , however , that the right to terminate this Agreement under this Section 6.1(c)(i) shall not be available to any party whose material breach of a representation, warranty or covenant in this Agreement has been a principal cause of the failure of the Merger to be consummated on or before the Outside Date; or

 

(ii) if any Governmental Entity of competent jurisdiction shall have issued an Order or taken any other action permanently restraining, enjoining or otherwise prohibiting the Merger, and, in each case, such Order or action shall have become final and non- appealable; provided , however , that the right to terminate under this Section 6.1(c)(ii) shall not be available to any party whose material breach of a representation, warranty or covenant in this Agreement has been the principal cause of such action;

 

(d) by Citius ( provided it is not then in material breach of any of its obligations under this Agreement) (i) upon a material breach of any representation, warranty, covenant or agreement on the part of LMB as set forth in this Agreement, or if any representation or warranty of LMB shall have become untrue, in either case such that the applicable conditions set forth in Article V would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become untrue; provided , however , if such breach is curable by LMB, Citius may not terminate this Agreement under this Section 6.1(d) for so long as LMB continues to exercise its best efforts to cure such breach, unless such breach is not cured within thirty (30) days after notice of such breach is provided by Citius to LMB, or (ii) if the LMB Board (or any subgroup or committee thereof) withdraws, modifies or changes its recommendation of this Agreement or the Merger in a manner adverse to Citius or shall have resolved to do any of the foregoing; or

 

(e) by LMB ( provided that it is not then in material breach of any of its obligations under this Agreement) (i) upon a material breach of any representation, warranty, covenant or agreement on the part of Citius or SubCo as set forth in this Agreement, or (ii) if any representation or warranty of Citius or SubCo shall have become untrue, in either case such that the applicable conditions set forth in Article V would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become untrue; provided , however , if such breach is curable by Citius or SubCo, LMB may not terminate this Agreement under this Section 6.1(e) for so long as Citius continues to exercise its best efforts to cure such breach, unless such breach is not cured within thirty (30) days after notice of such breach is provided by LMB to Citius.

 

The right of any party hereto to terminate this Agreement pursuant to this Section 6.1 shall remain operative and in full force and effect regardless of any investigation made by or on behalf of any party hereto, any Person controlling any such party or any of their respective officers or directors, whether prior to or after the execution of this Agreement.

 

 
43
 

 

Section 6.2 Effect of Termination . In the event of termination of this Agreement by either Citius or LMB, as provided in Section 6.1 , this Agreement shall forthwith become void, and there shall be no liability hereunder on the part of LMB, Citius or SubCo, or their respective officers or directors (except for confidentiality agreements, Section 4.2 , this Section 6.2 and the entirety of Article VII and Article VIII , all of which shall survive the termination). Nothing contained in this Section 6.2 shall relieve any party hereto from any liability for any breach of a representation or warranty contained in this Agreement or the breach of any covenant contained in this Agreement or prevent a party from exercising its rights under Section 8.8 .

 

ARTICLE VII

 

INDEMNIFICATION

 

Section 7.1 Survival of Representations and Warranties .

 

(a) The representations and warranties of LMB contained in this Agreement shall survive the Closing Date until the twelve (12) month anniversary of the Closing Date; provided , however , that (i) the representations and warranties made pursuant to Sections 2.1 , 2.3 , 2.4 and 2.15 (" Fundamental Representations ") shall survive indefinitely, and (ii) the representations and warranties made pursuant to Section 2.9 shall survive until the expiration of the relevant statute of limitations. If written notice of a claim has been given prior to the expiration of the applicable representations and warranties by a Citius Indemnified Party to LMB, then the relevant representations and warranties shall survive as to such claim, until such claim has been finally resolved.

 

(b) The representations and warranties of Citius contained in this Agreement shall survive the Closing Date until the twelve (12) month anniversary of the Closing Date; provided , however , that (i) the representations and warranties made pursuant to Sections 3.1 , 3.2 , 3.3 and 3.10 shall survive indefinitely, and (ii) the representations and warranties made pursuant to Section 3.12 shall survive until the expiration of the relevant statute of limitations. If written notice of a claim has been given prior to the expiration of the applicable representations and warranties by a LMB Indemnified Party to Citius, then the relevant representations and warranties shall survive as to such claim, until such claim has been finally resolved.

 

 
44
 

 

Section 7.2 Indemnification . Subject to the terms and conditions of this Article VII :

 

(a) LMB (prior to the Merger) and the Surviving Corporation (following the Merger) shall indemnify, defend and hold harmless Citius and its directors, officers, stockholders and Affiliates (each a " Citius Indemnified Party ") from and against any and all Damages or amounts that are paid in settlement (collectively, the " Indemnification Liabilities "), based in whole or in part on or arising in whole or in part out of or related to the breach of any representation, warranty or covenant made by LMB in this Agreement or in any document delivered pursuant hereto.

 

(b) Leonard Mazur and Myron Holubiak shall personally, jointly and severally, indemnify, defend and hold harmless Citius and its directors, officers, stockholders and Affiliates from and against any liability based in whole or in part on or arising in whole or in part out of or related to any breach of the representations set forth in Sections 2.3 and 2.15 hereof.

 

(c) Citius shall indemnify, defend and hold harmless LMB and its directors, officers, stockholders and Affiliates (each a " LMB Indemnified Party ") from and against any and all Indemnification Liabilities, based in whole or in part on or arising in whole or in part out of or related to the breach of any representation, warranty or covenant made by Citius in this Agreement or in any document delivered pursuant hereto.

 

Section 7.3 Notice of Claim; Third Party Claims .

 

(a) An Indemnified Party shall give the Indemnifying Party notice of any matter that an Indemnified Party has determined has given or could give rise to a right of indemnification under this Agreement, within five (5) Business Days of such determination, stating the amount of the Indemnification Liabilities, if known, and method of computation thereof, and containing a reference to the provisions of this Agreement in respect of which such right of indemnification is claimed or arises. Within ten (10) Business Days after receiving notice of a claim for indemnification, the Indemnifying Party shall, by written notice to the Indemnified Party, either concede or deny liability for the claim in whole or in part. Any payment shall be made in immediately available funds equal to the amount of such claim so payable. If the Indemnifying Party denies liability in whole or in part or advises that the matters set forth in the notice are, or will be, subject to contest or legal proceedings not yet finally resolved, then the Indemnifying Party shall make no payment (except for the amount of any conceded liability payable as set forth above) until the matter is resolved in accordance with this Agreement.

 

 
45
 

 

(b) If an Indemnified Party shall receive notice of any Action, audit, demand or assessment by a third party (each, a " Third Party Claim ") against it or which may give rise to a claim for Indemnification Liabilities under this Article VII , within five (5) Business Days after receipt of such claim, the Indemnified Party shall give the Indemnifying Party notice of such Third Party Claim; provided , however , that the failure to provide such notice shall not release the Indemnifying Party from any of its obligations under this Article VII , except to the extent that the Indemnifying Party is materially prejudiced by such failure, and shall not relieve the Indemnifying Party from any other obligation or liability that it may have to any Indemnified Party otherwise than under this Article VII . If within ten (10) Business Days after receiving the notice of the Third Party Claim, the Indemnifying Party (i) gives written notice to the Indemnified Party stating that the Indemnifying Party disputes and intends to defend against such claim, liability or expense at the Indemnifying Party's own cost and expense and (ii) provides assurance reasonably acceptable to such Indemnified Party that such indemnification will be paid fully and promptly if required and such Indemnified Party will not incur cost or expense during the proceeding, then counsel for the defense shall be selected by the Indemnifying Party (subject to the consent of such Indemnified Party, which consent shall not be unreasonably withheld or delayed) and such Indemnifying Party shall not be required to make any payment to the Indemnified Party with respect to such claim, liability or expense as long as the Indemnifying Party is conducting a good faith and diligent defense at its own expense; provided , however , that the assumption of defense of any such matters by the Indemnifying Party shall relate solely to the claim, liability or expense that is subject or potentially subject to indemnification under this Article VII . If the Indemnifying Party assumes such defense in accordance with the preceding sentence, it shall have the right, with the consent of such Indemnified Party, which consent shall not be unreasonably withheld, conditioned or delayed, to settle all indemnifiable matters related to claims by third parties which are susceptible to being settled, provided the Indemnifying Party's obligation to indemnify such Indemnified Party therefor will be fully satisfied only by payment of money by the Indemnifying Party pursuant to a settlement which includes a complete release of such Indemnified Party. The Indemnifying Party shall keep such Indemnified Party reasonably apprised of the status of the claim, liability or expense and any resulting suit, proceeding or enforcement Action, shall furnish such Indemnified Party with all documents and information that such Indemnified Party shall reasonably request and shall consult with such Indemnified Party prior to acting on major matters, including settlement discussions. Notwithstanding anything herein stated, such Indemnified Party shall at all times have the right to fully participate in such defense at its own expense directly or through counsel; provided , however , if the named parties to the Action or proceeding include both the Indemnifying Party and the Indemnified Party and counsel for the Indemnified Party reasonably determines that representation of both parties by the same counsel would be inappropriate under applicable standards of professional conduct, then the reasonable expense of separate counsel for such Indemnified Party shall be paid by the Indemnifying Party, provided that such Indemnifying Party shall be obligated to pay for only one counsel for the Indemnified Party in any jurisdiction. If no such notice of intent to dispute and defend is given by the Indemnifying Party, or if such diligent good faith defense is not being or ceases to be conducted, such Indemnified Party may undertake the defense of (with counsel selected by such Indemnified Party), and shall have the right to compromise or settle such claim, liability or expense (exercising reasonable business judgment) with the consent of the Indemnifying Party. If such claim, liability or expense is one that by its nature cannot be defended solely by the Indemnifying Party, then such Indemnified Party shall make available all information and assistance that the Indemnifying Party may reasonably request and shall cooperate with the Indemnifying Party in such defense.

 

Section 7.4 Limitation on Indemnification Obligations of Seller . The liability of LMB and the Surviving Corporation to the Citius Indemnified Parties under Section 7.2(a) shall be subject to the following limitations:

 

 
46
 

 

(a) Deductible . Subject to Section 7.4(c) , LMB and the Surviving Corporation shall not be liable for indemnity under Section 7.2(a) unless the aggregate amount of Indemnification Liabilities incurred by the Citius Indemnified Parties exceeds fifty thousand dollars ($50,000) (the " Deductible "), in which case LMB and the Surviving Corporation shall be liable for the amount of such Indemnification Liabilities in excess of such Deductible; provided , however , with respect to any individual claim or series of related claims based on a similar set of operative facts, LMB and the Surviving Corporation shall have no indemnification obligation unless and until the aggregate amount (without duplication) of Indemnification Liabilities of the Citius Indemnified Parties relating to such claim or claims is greater than twenty-five thousand dollars ($25,000), after which point LMB and the Surviving Corporation shall, subject to the Deductible, be obligated to indemnify the Citius Indemnified Parties from and against all such Indemnification Liabilities in excess of twenty-five thousand dollars ($25,000) under such claim or series of related claims.

 

(b) Caps . Subject to Section 7.4(c) , (i) the maximum amount of Indemnification Liabilities for which LMB and the Surviving Corporation shall be liable for indemnity under Section 7.2(a) (with respect to breaches of representations and warranties which survive for the 12-month period after Closing) shall not exceed one million dollars ($1,000,000), and (ii) the maximum amount of Damages for which LMB and the Surviving Corporation shall be liable for indemnity under Section 7.2(a) (with respect to breaches of the Fundamental Representations) shall not exceed one million dollars ($1,000,000); provided , however , this Section 7.4(b) shall not apply to a breach as identified in Section 7.2(b) .

 

(c) Exceptions to Limitations . The limitations on the indemnification obligations of LMB and the Surviving Corporation set forth in Sections 7.4(a) and 7.4(b) shall not apply to any fraud by LMB.

 

(d) Additional Indemnification Limitations . Absent fraud, no Indemnified Party shall be entitled to recover from an Indemnifying Party for and the Citius Indemnified Parties and LMB Indemnified Parties waive any right to recover punitive, special, indirect, exemplary, and consequential damages (including lost income, revenue or profits, multiples of earnings, or any diminution in value) arising in connection with or with respect to any claim under this Agreement.

 

Section 7.5 Adjustments to Indemnification Payments . All indemnification payments under Article VII shall be reduced by insurance proceeds actually received by the Indemnified Party (net of any costs to recover, increases to premiums, or other resulting costs). An Indemnified Party shall use commercially reasonable efforts to pursue available insurance claims to which it may be reasonably entitled in connection with any Indemnification Liabilities it incurs (which shall not include litigation), and the parties shall cooperate with each other in pursuing claims with respect to any Indemnification Liabilities.

 

Section 7.6 Exclusive Remedy . The parties acknowledge and agree that, from and after the Closing, the indemnification provisions of this Article VII shall be the sole and exclusive recourse and remedy of the parties with respect to LMB, the Surviving Corporation, Citius, SubCo, this Agreement and the transactions contemplated herein, including for breach, inaccuracy or default of any of the representations, warranties, covenants and agreements set forth in this Agreement or any other transaction document; provided , the foregoing shall not apply with respect to fraud or any equitable remedies.

 

 
47
 

 

ARTICLE VIII

 

GENERAL PROVISIONS

 

Section 8.1 Notices . All notices and other communications hereunder shall be in writing and shall be deemed given when delivered personally, one day after being delivered to a nationally recognized overnight courier or on the Business Day received (or the next Business Day if received after 5:00 p.m. local time or on a weekend or day on which banks are closed) or when sent by electronic mail (with a confirmatory copy sent by overnight courier) to the parties at the following addresses (or at such other address for a party as shall be specified by like notice):

 

(a)

if to Citius or SubCo, to:

 

 

Citius Pharmaceuticals, Inc.

63 Great Road

Maynard, MA 01754

Attention: Leonard Mazur

Email: lmazur@lmbrx.com

 

with a copy to:

 

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, New York 10006

Attention: Arthur Marcus, Esq.

Email: amarcus@srff.com

 

 

 

 

(b)

if to LMB, to:

 

 

 

 

 

Leonard-Meron Biosciences, Inc.

11 Commerce Drive, 1st Floor

Cranford, NJ 07016

Attention: Myron Holubiak

Email: mholubiak@lmbrx.com

 

with a copy to:

 

Wyrick Robbins Yates & Ponton LLP

4101 Lake Boone Trail, Suite 300

Raleigh, NC 27607

Attention: W. David Mannheim, Esq.

Email: dmannheim@wyrick.com

 

 
48
 

 

Section 8.2 Interpretation . When a reference is made in this Agreement to a Section, such reference shall be to a Section of this Agreement unless otherwise indicated. The table of contents, table of defined terms and headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words "include," "includes" or "including" are used in this Agreement, they shall be deemed to be followed by the words "without limitation." The words "hereof," "herein" and "hereunder" and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. All terms defined in this Agreement shall have the defined meanings when used in any certificate or other document made or delivered pursuant thereto unless otherwise defined therein. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms and to the masculine as well as to the feminine and neuter genders of such term. Any agreement, instrument or statute defined or referred to herein or in any agreement or instrument that is referred to herein means such agreement, instrument or statute as from time to time amended, modified or supplemented, including (in the case of agreements or instruments) by waiver or consent and, in the case of statutes, by succession of comparable successor statutes and references to all attachments thereto and instruments incorporated therein. Each of the parties has participated in the drafting and negotiation of this Agreement. If an ambiguity or question of intent or interpretation arises, this Agreement must be construed as if it is drafted by all the parties, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of authorship of any of the provisions of this Agreement.

 

Section 8.3 Counterparts . This Agreement may be executed in counterparts, all of which shall be considered one and the same agreement, and shall become effective when one or more counterparts have been signed by each of the parties and delivered to the other parties. In the event that any signature is delivered by facsimile transmission or email attachment, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or email-attached signature page were an original thereof.

 

Section 8.4 Entire Agreement; No Third-Party Beneficiaries . This Agreement constitutes the entire agreement and supersedes all prior agreements and understandings, both written and oral, among the parties with respect to the subject matter of this Agreement. This Agreement is not intended to confer upon any Person other than the parties hereto (and the Indemnified Parties) any rights or remedies hereunder; provided , however , that following the Effective Time, each holder of LMB Shares or LMB Note Shares, as applicable, shall be entitled to enforce the provisions of Article I to the extent necessary to receive the Merger Consideration to which such holder is entitled pursuant to Article I ; provided further , however , that following the Effective Time, the LMB Indemnified Parties shall be entitled to enforce the provisions of Section 7.2(c) and any related indemnification provisions for the benefit of the LMB Indemnified Parties set forth in Article VII .

 

Section 8.5 Governing Law . This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than the State of New York.

 

Section 8.6 Amendment . This Agreement may not be amended except by an instrument in writing signed on behalf of each of the parties hereto.

 

Section 8.7 Waiver . At any time prior to the Effective Time, the parties hereto may, to the extent legally allowed: (i) extend the time for the performance of any of the obligations or other acts of the other parties hereto, (ii) waive any inaccuracies in the representations and warranties contained herein or in any document delivered pursuant hereto, and (iii) waive compliance with any of the covenants, agreements or conditions contained herein. Any agreement on the part of a party hereto to any such extension or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such party.

 

 
49
 

 

Section 8.8 Specific Performance; Submission to Jurisdiction . The parties agree that irreparable damage would occur if any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that each of the parties shall be entitled (in addition to any other remedy that may be available to it, including monetary damages) to seek an injunction or injunctions to prevent breaches of this Agreement and to seek to enforce specifically the terms and provisions of this Agreement exclusively in the Supreme Court of the State of New York, New York County, and any state appellate court therefrom within the State of New York, New York County, or in the United States District Court for the Southern District of New York. In addition, each of the parties irrevocably agrees that any legal action or proceeding with respect to this Agreement and the rights and obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and the rights and obligations arising hereunder brought by any other party hereto or its successors or assigns, shall be brought and determined exclusively in the Supreme Court of the State of New York, New York County, and any state appellate court therefrom within the State of New York, New York County, or in the United States District Court for the Southern District of New York. Each of the parties hereby irrevocably submits with regard to any such action or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts and agrees that it will not bring any action relating to this Agreement or any of the transactions contemplated by this Agreement in any court other than the aforesaid courts. Each of the parties hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement, (a) any claim that it is not personally subject to the jurisdiction of the above named courts for any reason other than the failure to serve, (b) any claim that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c) to the fullest extent permitted by the applicable law, any claim that (i) the suit, action or proceeding in such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper, or (iii) this Agreement, or the subject matter of this Agreement, may not be enforced in or by such courts. Citius, SubCo and LMB hereby consent to service being made through the notice procedures set forth in Section 8.1 and agree that service of any process, summons, notice or document by registered mail (return receipt requested and first-class postage prepaid) to the respective addresses set forth in Section 8.1 shall be effective service of process for any suit or proceeding in connection with this Agreement or the transactions contemplated by this Agreement.

 

Section 8.9 Waiver of Jury Trial . EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (a) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER, (b) EACH PARTY UNDERSTANDS AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (c) EACH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (d) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 8.9 .

 

 
50
 

 

Section 8.10 Assignment . Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties hereto (whether by operation of law or otherwise) without the prior written consent of the other parties.

 

Section 8.11 Expenses . All costs and expenses incurred by the parties in connection with this Agreement, including costs related to the preparation, negotiation, execution and delivery of the transaction documents and other costs associated with the Merger at closing shall be paid by Citius, whether or not the Merger shall be consummated.

 

Section 8.12 Severability . If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law or public policy, all other terms, conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic and legal substance of the transactions contemplated hereby are not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated by this Agreement may be consummated as originally contemplated to the fullest extent possible.

 

Section 8.13 Legal Representation . Each party hereto acknowledges that it has been given the opportunity to be represented by independent legal counsel in the preparation of this Agreement and hereby waives any allegations that it has not been represented by its own counsel. The language used in this Agreement will be deemed to be the language chosen by the parties with the advice of counsel to express their mutual intent, and no rules of strict construction will be applied against any party.

 

Section 8.14 Definitions .

 

(a) In this Agreement, the following terms have the meanings specified or referred to in this Section 8.14(a) and shall be equally applicable to both the singular and plural forms.

 

(i) " $ " means United States dollars.

 

(ii) " Action " means any claim, action, suit, proceeding, arbitration, mediation or investigation.

 

(iii) " Affiliate " means, with respect to any Person, any other Person which directly or indirectly controls, is controlled by or is under common control with such Person. The term "control" means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise, and the terms "controlled" and "controlling" have meanings correlative thereto.

 

(iv) " Business Day " means any day other than a Saturday, Sunday or a day on which the banks in New York are authorized by law or executive order to be closed.

 

 
51
 

 

(v) " Citius Material Adverse Effect " means a Material Adverse Effect with respect to Citius.

 

(vi) " Contract " means any contract, agreement, instrument, guarantee, indenture, note, bond, mortgage, Permit, franchise, concession, commitment, lease, license, arrangement, obligation or understanding, whether written or oral.

 

(vii) " Damages " means any and all damages, liabilities, obligations, penalties, fines, judgments, claims, deficiencies, losses, costs, expenses and assessments (including, without limitation, income and other taxes, interest, penalties and reasonable attorneys' and accountants' fees and disbursements).

 

(viii) " Encumbrance " means, with respect to any asset, any mortgage, deed of trust, lien, pledge, charge, security interest, title retention device, collateral assignment, adverse claim, restriction or other encumbrance of any kind in respect of such asset (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).

 

(ix) " Environmental Laws " means any national, federal, provincial, state or local law, statute, ordinance, rule, regulation, license, Permit, authorization, approval, consent, court order, judgment, decree, injunction, code requirement or agreement with any Governmental Entity (x) relating to pollution (or the cleanup thereof or the filing of information with respect thereto), human health or the protection of air, surface water, ground water, drinking water supply, land (including land surface or subsurface), plant and animal life or Damages for injury or loss of natural resources, or (y) concerning exposure to, or the use, storage, recycling, treatment, generation, transportation, processing, handling, labeling, production or disposal of Regulated Substances, in each case as amended and as now or hereafter in effect. The term "Environmental Laws" includes, without limitation, any common law or equitable doctrine (including, without limitation, injunctive relief and tort doctrines such as negligence, nuisance, trespass and strict liability) that may impose liability or obligations for injuries or Damages due to or threatened as a result of the presence of, exposure to, or ingestion of, any Regulated Substance.

 

(x) " Exchange Ratio " means the quotient of (a) the Merger Shares divided by (b) the LMB Equity Securities outstanding as of the Closing Date (after taking into account the conversion of all LMB Convertible Notes into LMB Note Shares).

 

(xi) " Governmental Entity " means any domestic or foreign governmental, administrative, judicial or regulatory authority.

 

(xii) " Indemnified Party " means a Citius Indemnified Party or a LMB Indemnified Party, as the case may be.

 

(xiii) " Indemnifying Party " means LMB or the Surviving Corporation pursuant to Section 7.2(a) or Citius pursuant to Section 7.2(c) , as the case may be.

 

 
52
 

 

(xiv) " IRS " means the Internal Revenue Service.

 

(xv) " Knowledge of LMB " means the actual knowledge of the directors, officers and key employees of LMB.

 

(xvi) " Knowledge of Citius " means the actual knowledge of the directors, officers and key employees of Citius and Citius Operating Subs.

 

(xvii) " Legal Requirement " means any and all laws (statutory, judicial or otherwise), ordinances, regulations, judgments, Orders, directives, injunctions, writs, decrees or awards of, and any Contracts with, any Governmental Entity, in each case as and to the extent applicable to a Person or such Person's business, operations or properties.

 

(xviii) " LMB Equity Securities " means, collectively, the LMB Shares, the LMB Note Shares, the Unconverted LMB Note Shares, the LMB Options and the LMB Warrants.

 

(xix) " LMB Material Adverse Effect " means a Material Adverse Effect with respect to LMB.

 

(xx) " Material Adverse Effect " means any change, effect, event or occurrence that has a material adverse effect on the assets, business, financial condition or results of operations of a Person taken as a whole or that would reasonably be expected to prevent or materially delay a party hereto from performing its obligations under this Agreement in any material respect or materially delay consummating the transactions contemplated hereby provided , however , that "Material Adverse Effect" shall not include any change, effect, event or occurrence, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions; (ii) conditions generally affecting the industries in which LMB or Citius operates; (iii) any changes in financial, banking or securities markets in general, including any disruption thereof and any decline in the price of any security or any market index or any change in prevailing interest rates; (iv) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation or worsening thereof; (v) any action required or permitted by this Agreement or any action taken (or omitted to be taken) with the written consent of or at the written request of the other parties hereto; (vi) any matter of which LMB or Citius is aware on the date hereof; (vii) any changes in applicable laws or accounting rules; (viii) the announcement, pendency or completion of the transactions contemplated by this Agreement, including losses or threatened losses of employees, customers, suppliers, distributors or others; (ix) any natural or man-made disaster or acts of God; or (x) any failure to meet any internal or published projections, forecasts or revenue or earnings predictions ( provided that the underlying causes of such failures (subject to the other provisions of this definition) shall not be excluded).

 

(xxi) " Merger Shares " means 33,940,878 Citius Shares.

 

(xxii) " Order " means any order, injunction, judgment, decree or ruling enacted, adopted, promulgated or applied by a Governmental Entity or arbitrator.

 

(xxiii) " Outside Date " means June 30, 2016.

 

 
53
 

 

(xxiv) " Permits " means any and all permits, rights, approvals, licenses, authorizations, legal status, orders or Contracts under any Legal Requirement or otherwise granted by any Governmental Entity.

 

(xxv) " Person " means any individual, corporation, partnership, limited liability company, joint venture, association, joint-stock company, estate, Governmental Entity, trust or unincorporated organization.

 

(xxvi) " Regulated Substances " means pollutants, contaminants, hazardous or toxic substances, compounds or related materials or chemicals, hazardous materials, hazardous waste, flammable explosives, radon, radioactive materials, asbestos, urea formaldehyde foam insulation, polychlorinated biphenyls, petroleum and petroleum products (including, but not limited to, waste petroleum and petroleum products) as regulated under applicable Environmental Laws.

 

(xxvii) " Subsidiary " means any corporation, partnership, limited liability company, joint venture, trust, association or other entity of which Citius or LMB, as the case may be (either alone or through or together with any other Subsidiary), owns, directly or indirectly, (i) 50% or more of the stock or other equity interests the holders of which are generally entitled to elect at least a majority of the Board of Directors or other governing body of such corporation, partnership, limited liability company, joint venture, trust, association or other entity or (ii) if there are no such voting interests, 50% or more of the equity interests in such corporation, partnership, limited liability company, joint venture, trust, association or other entity.

 

(xxviii) " Tax " or " Taxes " means any federal, state, local or foreign income, gross receipts, property, sales, use, license, excise, franchise, employment, payroll, withholding, alternative or added minimum, ad valorem, value-added, transfer or excise, tax, or other tax, custom, duty, governmental fee or other like assessment or charge of any kind whatsoever, together with any additions to tax, interest or penalty imposed by any Governmental Entity.

 

(xxix) " Tax Return " means any return, report or similar statement (including the attached schedules) required to be filed with respect to any Tax, including any information return, claim for refund, amended return or declaration of estimated Tax.

 

(xxx) " Treasury Regulations " means the temporary and final regulations promulgated by the United States Department of the Treasury pursuant to and in respect of provisions of the Code, as such regulations may be amended from time to time (including corresponding provisions of succeeding regulations).

 

 
54
 

 

(b) Each of the following terms is defined in the Section set forth opposite such term:

 

Defined Term

 

Section

 

 

 

ACA

 

2.14(d)

Agreement

 

Introduction

Balance Sheet Date

 

3.5(a)

Bankruptcy and Equity Exception

 

2.4(b)

Book-Entry Shares

 

1.9(a)

Certificate of Merger

 

1.2

Certificates

 

1.9(a)

Citius

 

Introduction

Citius Articles of Incorporation

 

3.1(c)

Citius Board

 

1.5(a)

Citius Bylaws

 

3.1(c)

Citius Common Stock

 

Recitals

Citius Disclosure Schedule

 

Article III

Citius Financing

 

1.6(b)

Citius Indemnified Party

 

7.2(a)

Citius Intellectual Property

 

3.9(a)

Citius Operating Subs

 

3.1(b)

Citius Options

 

Recitals

Citius Plans

 

3.17(a)

Citius Preferred Stock

 

Recitals

Citius Qualified Plan

 

3.17(c)

Citius SEC Documents

 

3.4(a)

Citius Share

 

1.7(b)

Citius Warrants

 

Recitals

Closing

 

1.13

Closing Date

 

1.13

Code

 

Recitals

Common Stock Consideration

 

1.7(b)

D&O Indemnified Parties

 

4.8(a)

Deductible

 

7.4(a)

DGCL

 

Recitals

Dissenting Shares

 

1.7(f)

Effective Time

 

1.2

Employment Agreement

 

Recitals

ERISA

 

2.14(a)

ERISA Affiliate

 

2.14(a)

Exchange Act

 

3.7(b)

FDA

 

2.6(a)

FDA Law and Regulation

 

2.6(a)

FDCA

 

2.6(a)

FDCA Permits

 

2.6(g)

Financial Statements

 

3.5(a)

Fundamental Representation

 

7.1(a)

GAAP

 

2.7

HIPAA

 

2.6(f)

Indemnification Liabilities

 

7.2(a)

Letter of Transmittal

 

1.9(b)

LMB

 

Introduction

 

 
55
 

 

LMB Board

 

2.4(a)(i)

LMB Bylaws

 

2.2

LMB Certificate of Incorporation

 

2.2

LMB Common Stock

 

Recitals

LMB Convertible Notes

 

Recitals

LMB Disclosure Schedule

 

Article II

LMB Indemnified Party

 

7.2(c)

LMB Intellectual Property

 

2.11(a)

LMB Note Shares

 

1.7(c)

LMB Note Stock Consideration

 

1.7(c)

LMB Options

 

Recitals

LMB Plans

 

2.14(a)

LMB Qualified Plan

 

2.14(c)

LMB Share

 

1.7(b)

LMB Stockholder Approval

 

Recitals

LMB Stock Plan

 

1.11(a)

LMB Warrants

 

Recitals

Material Citius Contract

 

3.13(b)

Material LMB Contract

 

2.12(b)

Mazur Investment

 

1.6(a)

Merger

 

Recitals

Merger Consideration

 

1.7(c)

Permitted Issuances

 

1.6

Piggy Back Registration

 

1.10(b)

Qualified Group

 

4.9

Registration Statement

 

1.10(b)

Rule 144

 

1.10(a)

Sarbanes-Oxley Act

 

3.4(b)

SEC

 

3.4(a)

Securities Act

 

1.10(a)

SubCo

 

Introduction

SubCo Board

 

3.3(a)

SubCo Common Stock

 

Recitals

Subsidiaries

 

2.1

Surviving Corporation

 

1.1

Third Party Claim

 

7.3(b)

Third Party Manufacturer

 

2.6(d)

Unconverted LMB Note Shares

 

1.7(d)

 

* * * * *

 

 
56
 

 

IN WITNESS WHEREOF, Citius, SubCo and LMB have caused this Agreement to be signed by their respective officers thereunto duly authorized all as of the date first written above.

 

 

 

CITIUS PHARMACEUTICALS, INC.

 

       
By: /s/ Leonard Mazur

 

 

Name:

Leonard Mazur

 

 

Title:

President and Chief Executive Officer

 

 

 

 

 

 

CITIUS LMB ACQUISITION CORP.

 

 

 

 

 

 

By:

/s/ Leonard Mazur

 

 

Name:

Leonard Mazur

 

 

Title:

Chief Executive Officer

 

 

 

 

 

 

LEONARD-MERON BIOSCIENCES, INC.

 

 

 

 

 

 

By:

/s/ Myron Holubiak

 

 

Name:

Myron Holubiak

 

 

Title:

President

 

 

ACCEPTED AND AGREED

(with respect to Section 7.1(b) only):

 

/s/ Leonard Mazur

 

Leonard Mazur

 

 

 

/s/ Myron Holubiak

 

Myron Holubiak

 

 

[Signature Page to Agreement and Plan of Merger]

 

 

57


 

 EXHIBIT 3.1

 

AMENDED AND RESTATED BYLAWS

OF

CITIUS PHARMACEUTICALS, INC.

 

Adopted and Effective as of March 30, 2016

 

I. CORPORATE OFFICES

 

1.1  Registered Office

 

The registered office of the corporation shall be in the City of Las Vegas, County of Clark, State of Nevada. The name of the registered agent of the corporation at such location is CSC Services of Nevada, Inc.

 

1.2 Other Offices

 

The board of directors may at any time establish other offices at any place or places where the corporation is qualified to do business.

 

II. MEETINGS OF STOCKHOLDERS

 

2.1  Place of Meetings

 

Meetings of the stockholders of Citius Pharmaceuticals, Inc., a Nevada corporation (the " Corporation "), will be held at any place, within or outside the State of Nevada, or by means of any remote electronic or other medium of communication authorized by the Nevada Revised Statutes, as the board of directors of the Corporation may designate for that purpose from time to time.

 

2.2 Annual Meeting

 
An annual meeting of the stockholders will be held each year on the date and at the time and place set by the board of directors. At the meeting, directors shall be elected and any other proper business may be transacted.

 

2.3 Special Meeting

 

Special meetings of the stockholders may be called at any time by the board of directors, the chairman of the board of directors, such person or persons as may be authorized by the articles of incorporation or these bylaws, or such person or persons duly designated by the board of directors whose powers and authority, as expressly provided in a resolution of the board of directors, include the power to call such meetings, but such special meetings may not be called by any other person.

 

 
1
 

 

2.4 Notice of Stockholders' Meetings

 

(a) Except to the extent otherwise required by law, all notices of meetings of stockholders will be in writing and will be sent or otherwise given in accordance with Section 2.4 of these bylaws not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder entitled to vote at such meeting. The notice will specify the place, if any, date, and hour of the meeting, the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called.

 

(b) Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation will also be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such consent will be revocable by the stockholder by written notice to the Corporation. Any such consent will be deemed revoked if (i) the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance with such consent, and (ii) such inability becomes known to the secretary or an assistant secretary of the Corporation or to the transfer agent, or other person responsible for the giving of notice; provided , however , the inadvertent failure to recognize such revocation will not invalidate any meeting or other action.

 

(c) Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation will be effective if given by a single written notice to stockholders who share an address if consented to by the stockholders at that address to whom such notice is given. Any such consent will be revocable by the stockholder by written notice to the Corporation. Any stockholder who fails to object in writing to the Corporation, within sixty (60) days of having been given written notice by the Corporation of its intention to send the single notice permitted under this subsection 2.4(c) , will be deemed to have consented to receiving such single written notice.

 

2.5 Manner of Giving Notice; Affidavit of Notice

 

(a) Written notice of any meeting of stockholders, if mailed, is given when deposited in the United States mail, postage prepaid, directed to the stockholder at his, her or its address as it appears on the records of the Corporation. An affidavit of the secretary or an assistant secretary or of the transfer agent or other agent of the Corporation that the notice has been given will, in the absence of fraud, be prima facie evidence of the facts stated therein.

 

(b) Notice given pursuant to this Section 2.5(b) will be deemed given: (i) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice; (ii) if by electronic mail, when directed to an electronic mail address at which the stockholder has consented to receive notice; (iii) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of such posting and the giving of such separate notice; and (iv) if by any other form of electronic transmission, when directed to the stockholder. An affidavit of the secretary, an assistant secretary or the transfer agent or other agent of the Corporation that the notice has been given by a form of electronic transmission will, in the absence of fraud, be prima facie evidence of the facts stated therein.

 

 
2
 

 

2.6 Quorum

 

The holders of a majority of the stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, will constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise provided by statute or by the articles of incorporation. If, however, such quorum is not present or represented at any meeting of the stockholders, then the chairman of the board of directors, or in the absence of such person, any officer entitled to preside at or to act as secretary of the meeting, will have power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present or represented. At such adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been transacted at the meeting as originally noticed.

 

2.7 Adjournments; Notice

 

Any meeting of stockholders may be adjourned to any other time and to any other place at which a meeting of stockholders may be held under these bylaws by the chairman of the board of directors, or in the absence of such person, by any officer entitled to preside at or to act as secretary of such meeting. When a meeting is adjourned to another time or place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting if the time and place thereof, and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, are announced at the meeting at which the adjournment is taken. At the adjourned meeting the Corporation may transact any business that might have been transacted at the original meeting. If the adjournment is for more than thirty (30) days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting will be given to each stockholder of record entitled to vote at the meeting.

 

2.8 Voting

 

The stockholders entitled to vote at any meeting of stockholders will be determined in accordance with the provisions of Section 2.11 of these bylaws. Except as otherwise provided in the articles of incorporation, each stockholder will be entitled to one vote for each share of capital stock held by such stockholder, and the affirmative vote of a majority of the shares represented at a meeting and entitled to vote thereat shall be necessary for the adoption of a motion or for the determination of all questions and business which shall come before the meeting.

 

2.9 Waiver of Notice

 

Whenever notice is required to be given under any provision of the Nevada Revised Statutes or the articles of incorporation or these bylaws, a written waiver thereof, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time stated therein, will be deemed equivalent to notice. Attendance of a person at a meeting will constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver or any waiver by electronic transmission of notice unless so required by the articles of incorporation or these bylaws.

 

 
3
 

 

2.10 Stockholder Action by Written Consent Without a Meeting

 

Unless otherwise provided in the articles of incorporation, any action required by the Nevada Revised Statutes to be taken at any annual or special meeting of stockholders of a corporation, or any action that may be taken at any annual or special meeting of such stockholders may be taken without a meeting, without prior notice, and without a vote if a consent in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. A telegram, cablegram or other electronic transmission consenting to an action to be taken and transmitted by a stockholder, proxyholder, or other person or persons authorized to act for a stockholder or proxyholder, will be deemed to be written, signed and dated for the purposes of this Section 2.10 , provided that any such telegram, cablegram or other electronic transmission sets forth or is delivered with information from which the Corporation can determine (a) that the telegram, cablegram or other electronic transmission was transmitted by the stockholder, proxyholder, or other authorized person or persons, and (b) the date on which such stockholder, proxyholder or other authorized person or persons transmitted such telegram, cablegram or electronic transmission. The date on which such telegram, cablegram or electronic transmission is transmitted will be deemed to be the date on which such consent was signed. No consent given by telegram, cablegram or other electronic transmission will be deemed to have been delivered until such consent is reproduced in paper form and until such paper form will have been delivered to the Corporation by delivery to its registered office in this State, its principal place of business or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation's registered office will be made by hand or by certified or registered mail, return receipt requested. Notwithstanding the foregoing limitations on delivery, consents given by telegram, cablegram or other electronic transmission may be otherwise delivered to the principal place of business of the Corporation or to an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded if, to the extent and in the manner provided by resolution of the board of directors of the Corporation. Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used, provided that such copy, facsimile or other reproduction will be a complete reproduction of the entire original writing.

 

2.11 Record Date for Stockholder Notice; Voting; Giving Consents

 

In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, or entitled to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the board of directors may fix, in advance, a record date that will not be more than sixty (60) nor less than ten (10) days before the date of such meeting, nor more than sixty (60) days prior to any other action.

 

If the board of directors does not so fix a record date:

 

(a) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders will be at the close of business on the day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held;

 

 
4
 

 

(b) the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting, when no prior action by the board of directors is necessary, will be the day on which the first written consent is expressed; and

 

(c) the record date for determining stockholders for any other purpose will be at the close of business on the day on which the board of directors adopts the resolution relating thereto.

 

A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders will apply to any adjournment of the meeting; provided , however , that the board of directors may fix a new record date for the adjourned meeting.

 

2.12 Proxies

 

Each stockholder entitled to vote at a meeting of stockholders or to express consent or dissent to corporate action in writing without a meeting may authorize another person or persons to act for him by a written proxy, signed by the stockholder and filed with the secretary of the Corporation, but no such proxy will be voted or acted upon after three (3) years from its date, unless the proxy provides for a longer period. A proxy will be deemed signed if the stockholder's name is placed on the proxy (whether by manual signature, typewriting, telegraphic transmission or otherwise) by the stockholder or the stockholder's attorney-in-fact. A duly executed proxy will be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power under Nevada Revised Statute 78.355. A proxy may be made irrevocable regardless of whether the interest with which it is coupled is an interest in the stock itself or an interest in the corporation generally.

 

2.13 List of Stockholders Entitled to Vote

 

The officer who has charge of the stock ledger of a corporation will prepare and make, at least ten (10) days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder. The Corporation will not be required to include electronic mail addresses or other electronic contact information on such list. Such list will be open to the examination of any stockholder for any purpose germane to the meeting for a period of at least ten (10) days prior to the meeting: (a) on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (b) during ordinary business hours, at the principal place of business of the Corporation. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be held at a place, then the list will be produced and kept at the time and place of the meeting during the whole time thereof, and may be examined by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list will also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list will be provided with the notice of the meeting.

 

 
5
 

 

2.14 Stockholder Proposals

 

(a) Any stockholder wishing to bring any other business before a meeting of stockholders, including, but not limited to, the nomination of persons for election as directors, must provide notice to the Corporation not more than ninety (90) and not less than sixty (60) days before the meeting, in writing by registered mail, return receipt requested, of the business to be presented by the stockholder at the stockholders' meeting.

 

(b) Any such notice will set forth the following as to each matter the stockholder proposes to bring before the meeting: (i) a brief description of the business desired to be brought before the meeting and the reasons for conducting such business at the meeting and, if such business includes a proposal to amend the bylaws of the Corporation, the language of the proposed amendment; (ii) the name and address, as they appear on the Corporation's books, of the stockholder proposing such business; (iii) the class and number of shares of the Corporation that are beneficially owned by such stockholder; and (iv) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to propose such business; and (v) any material interest of the stockholder in such business. Notwithstanding the foregoing provisions of this Section 2.14 , a stockholder will also comply with all applicable laws, rules and regulations, including, but not limited to, the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder with respect to the matters set forth in this Section 2.14 . In the absence of such notice to the Corporation meeting the above requirements, a stockholder will not be entitled to present any business at any meeting of stockholders.

 

III. DIRECTORS

 

3.1 Powers

 

Subject to the provisions of the Nevada Revised Statutes and any limitations in the articles of incorporation or these bylaws relating to action required to be approved by the stockholders or by the outstanding shares, the business and affairs of the Corporation will be managed and all corporate powers will be exercised by or under the direction of the board of directors.

 

3.2 Number of Directors

 

The number of directors constituting the board of directors will be fixed at six (6).

 

No reduction of the authorized number of directors will have the effect of removing any director before that director's term of office expires.

 

 
6
 

 

3.3 Election, Qualification and Term of Office of Directors

 

Except as provided in Sections 3.4 and 3.15 of these bylaws, directors will be elected at each annual meeting of stockholders to hold office until the next annual meeting. Directors need not be residents of Nevada or stockholders unless so required by the articles of incorporation or these bylaws, wherein other qualifications for directors may be prescribed. Each director, including a director elected to fill a vacancy, shall hold office until his or her successor is elected and qualified or until his or her earlier resignation or removal. E ach director will be a natural person.

 

3.4 Resignation and Vacancies

 

Any director may resign at any time upon notice given in writing or electronic transmission to the Corporation. The acceptance of a resignation is not required to make it effective. When one or more directors so resigns and the resignation is effective at a future date, a majority of the directors then in office, including those who have so resigned, will have the power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations will become effective, and each director so chosen will hold office as provided in this Section 3.4 in the filling of other vacancies.

 

Unless otherwise provided in the articles of incorporation or these bylaws:

 

(a) vacancies and newly created directorships resulting from any increase in the authorized number of directors elected by all of the stockholders having the right to vote as a single class may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director; and

 

(b) whenever the holders of any class or classes of stock or series thereof are entitled to elect one or more directors by the provisions of the articles of incorporation, vacancies and newly created directorships of such class or classes or series may be filled by a majority of the directors elected by such class or classes or series thereof then in office, or by a sole remaining director so elected.

 

If at any time, by reason of death or resignation or other cause, the Corporation has no directors in office, then any officer or any stockholder or an executor, administrator, trustee or guardian of a stockholder, or other fiduciary entrusted with like responsibility for the person or estate of a stockholder, may call a special meeting of stockholders in accordance with the provisions of these bylaws.

 

 
7
 

 

3.5 Place of Meetings; Meetings by Telephone

 

The board of directors of the Corporation may hold meetings, both regular and special, either within or outside the State of Nevada.

 

Unless otherwise restricted by the articles of incorporation or these bylaws, members of the board of directors, or any committee designated by the board of directors, may participate in a meeting of the board of directors, or any committee, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting will constitute presence in person at the meeting.

 

3.6 Regular Meetings

 

Regular meetings of the board of directors may be held without notice at such time and at such place as will from time to time be determined by the board of directors.

 

3.7 Special Meetings; Notice

 

Special meetings of the board of directors for any purpose or purposes may be called at any time by the chairman of the board of directors, the president, any vice president, the secretary or any director.

 

Notice of the time and place of special meetings will be delivered either personally or by mail, telex, facsimile, telephone or electronic transmission to each director, addressed to each director at such director's address and/or phone number and/or electronic transmission address as it is shown on the records of the Corporation. If the notice is mailed, it will be deposited in the United States mail at least four (4) days before the time of the holding of the meeting. If the notice is delivered personally or by telex, facsimile, telephone or electronic transmission, it will be delivered by telephone or transmitted at least twenty-four (24) hours before the time of the holding of the meeting. Any oral notice given personally or by telephone may be communicated either to the director or to a person at the office of the director who the person giving the notice has reason to believe will promptly communicate it to the director. The notice need not specify the purpose or the place of the meeting if the meeting is to be held at the principal executive office of the Corporation. Notice may be delivered by any person entitled to call a special meeting or by an agent of such person.

 

3.8 Quorum

 

At all meetings of the board of directors, a majority of the authorized number of directors will constitute a quorum for the transaction of business and the act of a majority of the directors present at any meeting at which there is a quorum will be the act of the board of directors, except as otherwise specifically provided by statute or by the articles of incorporation. If a quorum is not present at any meeting of the board of directors, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.

 

 
8
 

 

3.9 Waiver Of Notice

 

Whenever notice is required to be given under any provision of the Nevada Revised Statutes, the articles of incorporation or these bylaws, a written waiver thereof, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time stated therein, will be deemed equivalent to notice. Attendance of a person at a meeting will constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the directors, or meeting of a committee of directors, need be specified in any written waiver of notice unless so required by the articles of incorporation or these bylaws.

 

3.10 Adjourned Meeting; Notice

 

If a quorum is not present at any meeting of the board of directors, then the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present.

 

3.11 Board Action by Written Consent Without a Meeting

 

Unless otherwise restricted by the articles of incorporation or these bylaws, any action required or permitted to be taken at any meeting of the board of directors, or of any committee thereof, may be taken without a meeting if all members of the board of directors or committee, as the case may be, consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the board of directors or committee. Such filing will be in paper form if the minutes are maintained in paper form and will be in electronic form if the minutes are maintained in electronic form.

 

3.12 Fees and Compensation of Directors

 

Pursuant to Nevada Revised Statutes 78.140 and unless otherwise restricted by the articles of incorporation or these bylaws, the board of directors will have the authority to fix the compensation of directors.

 

3.13 Removal of Directors

 

Unless otherwise restricted by statute, by the articles of incorporation or by these bylaws, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors; provided that, whenever the holders of any class or classes of stock, or series thereof, are entitled to elect one or more directors by the provisions of the articles of incorporation, removal of any directors elected by such class or classes of stock, or series thereof, will be by the holders of a majority of the shares of such class or classes of stock, or series of stock, then entitled to vote at an election of directors.

 

 
9
 

 

No reduction of the authorized number of directors will have the effect of removing any director prior to the expiration of such director's term of office.

 

3.14 Chairman of the Board of Directors

 

The Corporation may also have, at the discretion of the board of directors, a chairman of the board of directors. The chairman of the board will, if such a person is elected, preside at the meetings of the board of directors, and exercise and perform such other powers and duties as may from time to time be assigned to him or her by the board of directors, or as may be prescribed by these bylaws.

 

3.15 Nominating Procedures

 

Nominations for the election of directors may only be made by the board of directors, by the nominating committee of the board of directors (or, if none, any other committee serving a similar function) or by any stockholder entitled to vote generally in elections of directors where the stockholder complies with the requirements of this Section 3.15 . Any stockholder of record entitled to vote generally in elections of directors may nominate one or more persons for election as directors at a meeting of stockholders only if written notice of such stockholder's intent to make such nomination or nominations has been given, either by personal delivery or by United States certified mail, postage prepaid, to the secretary of the Corporation (i) with respect to an election to be held at an annual meeting of stockholders, not more than ninety (90) days nor less than sixty (60) days in advance of such meeting, and (ii) with respect to an election to be held at a special meeting of stockholders called for the purpose of the election of directors, not later than the close of business on the tenth business day following the date on which notice of such meeting is first given to stockholders. Each such notice of a stockholder's intent to nominate a director or directors at an annual or special meeting will set forth the following: (A) the name and address, as they appear on the Corporation's books, of the stockholder who intends to make the nomination and the name and residence address of the person or persons to be nominated; (B) the class and number of shares of the Corporation which are beneficially owned by the stockholder; (C) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice; (D) a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nomination or nominations are to be made by the stockholder; (E) such other information regarding each nominee proposed by such stockholder as would be required to be disclosed in solicitations of proxies for election of directors, or as would otherwise be required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended, including any information that would be required to be included in a proxy statement filed pursuant to Regulation 14A had the nominee been nominated by the board of directors; and (F) the written consent of each nominee to be named in a proxy statement and to serve as director of the Corporation if so elected. No person will be eligible to serve as a director of the Corporation unless nominated in accordance with the procedures set forth in this Section 3.15 . If the chairman of the stockholders' meeting will determine that a nomination was not made in accordance with the procedures described by these bylaws, he will so declare to the meeting, and the defective nomination will be disregarded. Notwithstanding the foregoing provisions of this Section, a stockholder will also comply with all applicable requirements of the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder with respect to the matters set forth in this Section.

 

 
10
 

 

IV. COMMITTEES

 

4.1 Committees of Directors

 

The board of directors may, by resolution passed by a majority of the whole board of directors, designate one or more committees, with each committee to consist of one or more of the directors of the Corporation. The board of directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. Any such committee, to the extent provided in the resolution of the board of directors or in the bylaws of the Corporation, will have and may exercise all the powers and authority of the board of directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee will have the power or authority to (i) approve or adopt, or recommend to the stockholders, any action or matter expressly required by the Nevada Revised Statutes to be submitted to stockholders for approval, or (ii) adopt, amend or repeal any bylaws of the Corporation.

 

4.2 Committee Minutes

 

Each committee will keep regular minutes of its meetings and report the same to the board of directors when required.

 

4.3 Meetings and Action of Committees

 

Meetings and actions of committees will be governed by, and be held and taken in accordance with, the provisions of Article III of these bylaws, Section 3.5 (place of meetings and meetings by telephone), Section 3.6 (regular meetings), Section 3.7 (special meetings and notice), Section 3.8 (quorum), Section 3.9 (waiver of notice), Section 3.10 (adjourned meeting and notice), and Section 3.11 (board action by written consent without a meeting), with such changes in the context of those bylaws as are necessary to substitute the committee and its members for the board of directors and its members; provided , however , that the time of regular meetings of committees may also be called by resolution of the board of directors and that notice of special meetings of committees will also be given to all alternate members, who will have the right to attend all meetings of the committee. The board of directors may adopt rules for the governance of any committee not inconsistent with the provisions of these bylaws.

 

V. OFFICERS

 

5.1 Officers

 

The officers of the Corporation will be a chief executive officer, president, one or more vice presidents, a secretary and a treasurer, each of whom will be elected by the board of directors. The Corporation may also have, at the discretion of the board of directors, a chairman of the board, one or more assistant vice presidents, assistant secretaries, assistant treasurers, and any such other officers as may be appointed in accordance with the provisions of Section 5.3 of these bylaws. Any number of offices may be held by the same person.

 

 
11
 

 

5.2 Election of Officers

 

The officers of the Corporation, except such officers as may be appointed in accordance with the provisions of Sections 5.3 of these bylaws, will be chosen by the board of directors, subject to the rights, if any, of an officer under any contract of employment.

 

5.3 Subordinate Officers

 

The board of directors may appoint, or empower the president to appoint, such other officers and agents as the business of the Corporation may require, each of whom will hold office for such period, have such authority, and perform such duties as are provided in these bylaws or as the board of directors may from time to time determine.

 

5.4 Removal and Resignation of Officers

 

Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either with or without cause, by an affirmative vote of the majority of the board of directors at any regular or special meeting of the board of directors or by any officer upon whom such power of removal may be conferred by the board of directors.

 

Any officer may resign at any time by giving written notice to the Corporation. Any resignation will take effect at the date of the receipt of that notice or at any later time specified in that notice; and, unless otherwise specified in that notice, the acceptance of the resignation will not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party.

 

5.5 Vacancies in Offices

 

Any vacancy occurring in any office of the Corporation will be filled by the board of directors.

 

5.6 Chairman of the Board

 

The chairman of the board of directors will, if present, preside at meetings of the board of directors, and exercise and perform such other powers and duties as may from time to time be assigned to him by the board of directors or as may be prescribed by these bylaws. The chairman of the board of directors will be chosen by the board of directors. The chairman is ex-officio a member of all committees of the board of directors.

 

 
12
 

 

5.7 Chief Executive Officer

 

Subject to such supervisory powers, if any, as may be given by the board of directors to the chairman of the board, the chief executive officer of the corporation shall, subject to the control of the board of directors, have general supervision, direction and control of the business and the officers of the corporation. The chief executive officer shall preside at all meetings of the stockholders and, in the absence or nonexistence of a chairman of the board, at all meetings of the board of directors at which he or she is present. The chief executive officer shall have the general powers and duties of management usually vested in the office of chief executive officer of a corporation and shall have such other powers and duties as may be prescribed by the board of directors or these bylaws.

 

5.8 President

 

Subject to such supervisory powers, if any, as may be given by the board of directors to the chairman of the board or the chief executive officer, if there be such officers, the president shall, subject to the control of the board of directors, have general supervision, direction and control of the business and the officers of the corporation. In the absence or nonexistence of the chief executive officer, he or she shall preside at all meetings of the stockholders and, in the absence or nonexistence of a chairman of the board and chief executive officer, at all meetings of the board of directors at which he or she is present. He or she shall have the general powers and duties of management usually vested in the office of president of a corporation and shall have such other powers and duties as may be prescribed by the board of directors or these bylaws. The board of directors may provide in their discretion that the offices of president and chief executive officer may be held by the same person.

 

5.9 Vice Presidents

 

In the absence or disability of the chief executive officer and president, the vice presidents, if any, in order of their rank as fixed by the board of directors or, if not ranked, a vice president designated by the board of directors, will perform all the duties of the president and when so acting will have all the powers of, and be subject to all the restrictions upon, the president. The vice presidents will have such other powers and perform such other duties as from time to time may be prescribed for them by the board of directors, these bylaws, the president or the chairman of the board.

 

5.10 Secretary

 

The secretary or an agentof the Corporation will keep or cause to be kept, at the principal executive office of the Corporation or such other place as the board of directors may direct, a book of minutes of all meetings and actions of directors, committees of directors, and stockholders. The minutes will show the time and place of each meeting, whether regular or special (and, if special, how authorized and the notice given), the names of those present at directors' meetings or committee meetings, the number of shares present or represented at stockholders' meetings, and the proceedings thereof.

 

 
13
 

 

The secretary will keep, or cause to be kept, at the principal executive office of the Corporation or at the office of the Corporation's transfer agent or registrar, as determined by resolution of the board of directors, a share register, or a duplicate share register, showing the names of all stockholders and their addresses, the number and classes of shares held by each, the number and date of certificates evidencing such shares, and the number and date of cancellation of every certificate surrendered for cancellation.

 

The secretary will give, or cause to be given, notice of all meetings of the stockholders and of the board of directors required to be given by law or by these bylaws. The secretary will keep the seal of the Corporation, if one be adopted, in safe custody and will have such other powers and perform such other duties as may be prescribed by the board of directors or by these bylaws.

 

5.11 Treasurer

 

The treasurer will be the chief financial officer of the Corporation. The treasurer will keep and maintain, or cause to be kept and maintained, adequate and correct books and records of accounts of the properties and business transactions of the Corporation, including accounts of its assets, liabilities, receipts, disbursements, gains, losses, capital, retained earnings, and shares. The books of account will at all reasonable times be open to inspection by any director.

 

The treasurer will deposit all money and other valuables in the name and to the credit of the Corporation with such depositaries as may be designated by the board of directors. The treasurer will disburse the funds of the Corporation as may be ordered by the board of directors, will render to the president and directors, whenever they request it, an account of all of his or her transactions as treasurer and of the financial condition of the Corporation, and will have such other powers and perform such other duties as may be prescribed by the board of directors or these bylaws.

 

5.12 Representation of Shares of Other Corporations

 

The chairman of the board, the chief executive officer, the president, any vice president, the treasurer or the secretary of the Corporation, or any other person authorized by the board of directors or the chief executive officer, president or a vice president, is authorized to vote, represent, and exercise on behalf of the Corporation all rights incident to any and all shares of any other corporation or corporations standing in the name of the Corporation. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.

 

5.13 Authority and Duties of Officers

 

In addition to the foregoing authority and duties, all officers of the Corporation will respectively have such authority and perform such duties in the management of the business of the Corporation as may be designated from time to time by the board of directors.

 

 
14
 

 

5.14 Compensation

 

The officers of the Corporation will receive such compensation as will be fixed from time to time by the board of directors or a committee thereof. Unless otherwise determined by the board of directors, no officer is prohibited from receiving any compensation by reason of the fact that such officer is a director of the Corporation.

 

VI. INDEMNITY

 

6.1 Indemnification of Directors and Officers

 

The Corporation will, to the maximum extent and in the manner permitted by the Nevada Revised Statutes (as such law may from time to time be amended, but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights), indemnify each of its directors and officers (each such person sometimes referred to in this Section 6.1 as an "indemnitee") against Expenses (as herein defined), judgments, fines, penalties, ERISA excise taxes, settlements, loss, liability, and other amounts actually and reasonably incurred in connection with any Proceeding (as herein defined), arising by reason of such person's Official Capacity (as herein defined) or anything done or not done in such person's Official Capacity. For purposes of this Section 6.1 , a director or officer of the Corporation includes any person (a) who is or was a director or officer of the Corporation, (b) who is or was serving at the request of the Corporation as a director, officer, manager, member, partner, trustee, or other agent of another corporation, limited liability company, partnership, joint venture, trust or other enterprise, or (c) who was a director or officer of a corporation that was a predecessor corporation or other entity of the Corporation or of another enterprise at the request of such predecessor corporation or entity. Such indemnification will include the right to receive payment of any Expenses incurred by the indemnitee in connection with any Proceeding in advance of its final disposition, consistent with the provisions of applicable law as then in effect. The right of indemnification provided in this Section 6.1 will not be exclusive of any other rights to which those seeking indemnification may otherwise be entitled, and the provisions of this Section 6.1 will inure to the benefit of the heirs and legal representatives of any person entitled to indemnity under this Section 6.1 and will be applicable to Proceedings commenced or continuing after the adoption of this Section 6.1 , whether arising from acts or omissions occurring before or after such adoption. In furtherance, but not in limitation of the foregoing provisions, the following procedures, presumptions and remedies will apply with respect to advancement of Expenses and the right to indemnification under this Section 6.1 . Indemnitee will be entitled to indemnification and advancement against all Expenses reasonably incurred for serving as a witness by reason of indemnitee's Official Capacity in any Proceeding with respect to which indemnitee is not a party.

 

(a) Advancement of Expenses . All reasonable Expenses incurred by or on behalf of the indemnitee in connection with any Proceeding will be advanced to the indemnitee by the Corporation within twenty (20) days after the receipt by the Corporation of a statement or statements from the indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements will reasonably evidence the Expenses incurred by the indemnitee and, if required by law at the time of such advance, will include or be accompanied by an undertaking by or on behalf of the indemnitee to repay the amounts advanced if it should ultimately be determined that the indemnitee is not entitled to be indemnified against such Expenses pursuant to this Section 6.1 .

 

 
15
 

 

(b) Procedure for Determination of Entitlement to Indemnification.

 

(i) To obtain indemnification under this Section 6.1 , an indemnitee will submit to the secretary of the Corporation a written request, including such documentation and information as is reasonably available to the indemnitee and reasonably necessary to determine whether and to what extent the indemnitee is entitled to indemnification (the " Supporting Documentation "). The determination of the indemnitee's entitlement to indemnification will be made not later than sixty (60) days after receipt by the Corporation of the written request for indemnification together with the Supporting Documentation. The secretary of the Corporation will, promptly upon receipt of such a request for indemnification, advise the board of directors in writing that the indemnitee has requested indemnification, whereupon the Corporation will provide such indemnification, including without limitation advancement of Expenses, so long as the indemnitee is legally entitled thereto in accordance with applicable law.

 

(ii) The indemnitee's entitlement to indemnification under this Section 6.1 will be determined in one of the following ways: (A) by a majority vote of the Disinterested Directors (as hereinafter defined), even though less than a quorum of the board of directors; (B) by a committee of such Disinterested Directors, even though less than a quorum of the board of directors; (C) by a written opinion of Independent Counsel (as hereinafter defined) if (x) a Change of Control (as hereinafter defined) will have occurred and the indemnitee so requests or (y) a quorum of the board of directors consisting of Disinterested Directors is not obtainable or, even if obtainable, a majority of such Disinterested Directors so directs; (D) by the stockholders of the Corporation (but only if a majority of the Disinterested Directors, if they constitute a quorum of the board of directors, presents the issue of entitlement to indemnification to the stockholders for their determination); or (E) as provided in paragraph (c) below.

 

(iii) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to paragraph (b)(ii) above, a majority of the Disinterested Directors will select the Independent Counsel, but only an Independent Counsel to which the indemnitee does not reasonably object; provided , however , that if a Change of Control will have occurred, the indemnitee will select such Independent Counsel, but only an Independent Counsel to which the board of directors does not reasonably object.

 

(iv) The only basis upon which a finding that indemnification may not be made is that such indemnification is prohibited by law.

 

(v) The Corporation will pay all costs associated with its determination of indemnitee's eligibility for indemnification.

 

 
16
 

 

(c) Presumptions and Effect of Certain Proceedings . Except as otherwise expressly provided in this Section 6.1 , if a Change of Control will have occurred, the indemnitee will be presumed to be entitled to indemnification under this Section 6.1 upon submission of a request for indemnification together with the Supporting Documentation in accordance with paragraph (b)(i), and thereafter the Corporation will have the burden of proof to overcome that presumption in reaching a contrary determination. In any event, if the person or persons empowered under paragraph (b)(ii) above to determine entitlement to indemnification will not have been appointed or will not have made a determination within sixty (60) days after receipt by the Corporation of the request therefor together with the Supporting Documentation, the indemnitee will be deemed to be entitled to indemnification and the indemnitee will be entitled to such indemnification unless (A) the indemnitee misrepresented a material fact, or omitted a material fact necessary to make indemnitee's statement not misleading, in making the request for indemnification or in the Supporting Documentation or (B) such indemnification is prohibited by law. The termination of any Proceeding described in this Section 6.1 , or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, will not, of itself, adversely affect the right of the indemnitee to indemnification or create a presumption that the indemnitee did not act in good faith and in a manner that the indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation or, with respect to any criminal Proceeding, that the indemnitee had reasonable cause to believe that the indemnitee's conduct was unlawful.

 

(d) Remedies of Indemnitee.

 

(i) In the event that a determination is made pursuant to paragraph (b)(ii) that the indemnitee is not entitled to indemnification under this Section 6.1 : (A) the indemnitee will be entitled to seek an adjudication of his or her entitlement to such indemnification either, at the indemnitee's sole option, in (x) an appropriate court of the State of Nevada or any other court of competent jurisdiction, or (y) an arbitration to be conducted by a single arbitrator pursuant to the rules of the American Arbitration Association; (B) any such judicial Proceeding or arbitration will be de novo and the indemnitee will not be prejudiced by reason of such adverse determination; and (C) in any such judicial Proceeding or arbitration the Corporation will have the burden of proving that the indemnitee is not entitled to indemnification under this Section 6.1 .

 

(ii) If a determination will have been made or is deemed to have been made, pursuant to paragraph (b)(ii) or (iii), that the indemnitee is entitled to indemnification, the Corporation will be obligated to pay the amounts constituting such indemnification within five (5) days after such determination has been made or is deemed to have been made and will be conclusively bound by such determination unless (A) the indemnitee misrepresented a material fact, or omitted a material fact necessary to make indemnitee's statement not misleading, in making the request for indemnification or in the Supporting Documentation, or (B) such indemnification is prohibited by law. In the event that: (X) advancement of Expenses is not timely made pursuant to paragraph (a); or (Y) payment of indemnification is not made within five (5) days after a determination of entitlement to indemnification has been made or deemed to have been made pursuant to paragraph (b)(ii) or (iii), the indemnitee will be entitled to seek judicial enforcement of the Corporation's obligation to pay to the indemnitee such advancement of Expenses or indemnification. Notwithstanding the foregoing, the Corporation may bring an action, in an appropriate court in the State of Nevada or any other court of competent jurisdiction, contesting the right of the indemnitee to receive indemnification hereunder due to the occurrence of an event described in subclause (A) or (B) of this clause (ii) (a " Disqualifying Event "); provided , however , that in any such action the Corporation will have the burden of proving the occurrence of such Disqualifying Event.

 

 
17
 

 

(iii) The Corporation will be precluded from asserting in any judicial Proceedings or arbitration commenced pursuant to this paragraph (d) that the procedures and presumptions of this Section 6.1 are not valid, binding and enforceable and will stipulate in any such court or before any such arbitrator that the Corporation is bound by all the provisions of this Section 6.1 .

 

(iv) In the event that the indemnitee, pursuant to this paragraph (d), seeks a judicial adjudication of or an award in arbitration to enforce his or her rights under, or to recover damages for breach of, this Section 6.1 , the indemnitee will be entitled to recover from the Corporation, and will be indemnified by the Corporation against, any Expenses actually and reasonably incurred by the indemnitee if the indemnitee prevails in such judicial adjudication or arbitration. If it will be determined in such judicial adjudication or arbitration that the indemnitee is entitled to receive part but not all of the indemnification or advancement of Expenses sought, the Expenses incurred by the indemnitee in connection with such judicial adjudication will be prorated accordingly.

 

(e) Definitions . For purposes of this Article VI :

 

(i) " Change in Control " means a change in control of the Corporation of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A promulgated under the Securities Exchange Act of 1934, as amended (the " Exchange Act "), whether or not the Corporation is then subject to such reporting requirement; provided that, without limitation, such a change in control will be deemed to have occurred if (i) any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) is or becomes the "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Corporation representing twenty five percent (25%) or more of the combined voting power of the Corporation's then outstanding securities without the prior approval of at least a majority of the members of the board of directors in office immediately prior to such acquisition; (ii) the Corporation is a party to a merger, consolidation, sale of assets or other reorganization, or a proxy contest, as a consequence of which members of the board of directors in office immediately prior to such transaction or event constitute less than a majority of the board of directors thereafter; or (iii) during any period of two (2) consecutive years, individuals who at the beginning of such period constituted the board of directors (including for this purpose any new director whose election or nomination for election by the Corporation's stockholders was approved by a vote of at least a majority of the directors then still in office who were directors at the beginning of such period) cease for any reason to constitute at least a majority of the board of directors;

 

(ii) " Disinterested Director " means a director of the Corporation who is not a party to the Proceeding in respect of which indemnification or advancement of Expenses is sought by the indemnitee;

 

(iii) " Expenses " will include all direct and indirect costs including, but not limited to, attorneys' fees, retainers, court costs, transcript costs, fees of experts, witness fees, advisory fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with investigating, prosecuting, defending (or preparing to investigate, prosecute or defend) a Proceeding, or being or preparing to be a witness in a Proceeding;

 

 
18
 

 

(iv) " Independent Counsel " means a law firm or a member of a law firm that neither presently is, nor in the past five (5) years has been, retained to represent: (A) the Corporation or the indemnitee in any matter material to either such party or (B) any other party to the Proceeding giving rise to a claim for indemnification under this Section 6.1 . Notwithstanding the foregoing, the term "Independent Counsel" will not include any person who, under the applicable standards of professional conduct then prevailing under such persons relevant jurisdiction of practice, would have a conflict of interest in representing either the Corporation or the indemnitee in an action to determine the indemnitee's rights under this Section 6.1 ;

 

(v) " Official Capacity " means indemnitee's corporate status as an officer and/or director and any other fiduciary capacity in which indemnitee serves the Corporation, its subsidiaries or affiliates, and any other entity which indemnitee serves in such capacity at the request of any of the Corporation's board of directors or any committee of its board of directors, chief executive officer, chairman of the board of directors, or president. "Official Capacity" also refers to all actions which indemnitee takes or does not take while serving in such capacity; and

 

(vi) " Proceeding " includes any actual or threatened inquiry, investigation, action, suit, arbitration, or any other such actual or threatened action or occurrence, whether civil, criminal, administrative or investigative.

 

(f) Invalidity; Severability; Interpretation . If any provision or provisions of this Section 6.1 will be held to be invalid, illegal or unenforceable for any reason whatsoever: (i) the validity, legality and enforceability of the remaining provisions of this Section 6.1 (including, without limitation, all portions of any paragraph of this Section 6.1 containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) will not in any way be affected or impaired thereby; and (ii) to the fullest extent possible, the provisions of this Section 6.1 (including, without limitation, all portions of any paragraph of this Section 6.1 containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid; illegal or unenforceable) will be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable. Reference herein to laws, regulations or agencies will be deemed to include all amendments thereof, substitutions therefor and successors thereto.

 

(g) Contractual Rights; Applicability . The right to be indemnified or to the reimbursement or advancement of Expenses pursuant hereto (i) is a contract right based upon good and valuable consideration, pursuant to which the person entitled thereto may bring suit as if the provisions hereof were set forth in a separate written contract between the Corporation and the director or officer, (ii) is intended to be retroactive and will be available with respect to events occurring prior to the adoption hereof, and (iii) will continue to exist after the rescission or restrictive modification hereof.

 

6.2 Indemnification of Others

 

The Corporation will have the power, to the extent and in the manner permitted by the Nevada Revised Statutes, to indemnify each of its officers, employees and agents (other than directors) against Expenses, judgments, fines, settlements, and other amounts actually and reasonably incurred in connection with any Proceeding, arising by reason of the fact that such person is or was an agent of the Corporation. For purposes of this Section 6.2 , an officer, employee or agent of the Corporation (other than a director) includes any person (a) who is or was an officer, employee or agent of the Corporation, (b) who is or was serving at the request of the Corporation as a director, officer, manager, member, partner, trustee, employee or other agent of another corporation, limited liability company, partnership, joint venture, trust or other enterprise, or (c) who was an officer, employee or agent of a corporation that was a predecessor corporation or other entity of the Corporation or of another enterprise at the request of such predecessor corporation or entity.
  

 
19
 

 

6.3 Insurance

 

The Corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, manager, member, partner, trustee, employee or other agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust or other enterprise against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the Corporation would have the power to indemnify him or her against such liability under the provisions of the Nevada Revised Statutes.

 

VII. RECORDS AND REPORTS

 

7.1 Maintenance and Inspection of Records

 

The Corporation will, either at its principal executive office or at such place or places as designated by the board of directors, keep a record of its stockholders listing their names and addresses and the number and class of shares held by each stockholder, a copy of these bylaws as amended to date, accounting books, and other records.
 

Any stockholder of record, in person or by attorney or other agent, will, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose the Corporation's stock ledger, a list of its stockholders, and its other books and records and to make copies or extracts therefrom. A proper purpose will mean a purpose reasonably related to such person's interest as a stockholder. In every instance where an attorney or other agent is the person who seeks the right to inspection, the demand under oath will be accompanied by a power of attorney or such other writing that authorizes the attorney or other agent to so act on behalf of the stockholder. The demand under oath will be directed to the Corporation at its registered office in Nevada or at its principal place of business.
 

Any records maintained by the Corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be kept on, or by means of, or be in the form of, any information storage device or method, provided that the records so kept can be converted into clearly legible paper form within a reasonable time. The Corporation will so convert any records so kept upon the request of any person entitled to inspect such records pursuant to any provision of the articles of incorporation, these bylaws or the Nevada Revised Statutes. When records are kept in such manner, a clearly legible paper form or by means of the information storage device or method will be admissible in evidence, and accepted for all other purposes, to the same extent as an original paper record of the same information would have been, provided that the paper form accurately portrays the record.
  

 
20
 

 

 

7.2 Inspection by Directors

 

Any director will have the right to examine the Corporation's stock ledger, a list of its stockholders, and its other books and records for a purpose reasonably related to his or her position as a director.

 

VIII. GENERAL MATTERS

 

8.1 Checks

 

From time to time, the board of directors will determine by resolution which person or persons may sign or endorse all checks, drafts, other orders for payment of money, notes or other evidences of indebtedness that are issued in the name of or payable to the Corporation, and only the persons so authorized will sign or endorse those instruments.

 

8.2 Execution of Corporate Contracts and Instruments

 

The board of directors, except as otherwise provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on behalf of the Corporation; such authority may be general or confined to specific instances. Unless so authorized or ratified by the board of directors or within the agency power of an officer, no officer, agent or employee will have any power or authority to bind the Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount.

 

8.3 Stock Certificates

 

The shares of the Corporation will be represented by certificates, provided that the board of directors of the Corporation may provide by resolution or resolutions that some or all of any or all classes or series of its stock will be uncertificated shares. Any such resolution will not apply to shares represented by a certificate until such certificate is surrendered to the Corporation. Notwithstanding the adoption of such a resolution by the board of directors, every holder of stock represented by certificates and upon request every holder of uncertificated shares will be entitled to have a certificate signed by, or in the name of the Corporation by the chairman of the board of directors, or the president or vice president, and by the treasurer or an assistant treasurer, or the secretary or an assistant secretary of the Corporation representing the number of shares registered in certificate form. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, transfer agent or registrar at the date of issue. The stock certificates of the Corporation will be numbered and registered in the share ledger and transfer books of the corporation as they are issued. Any or all of the signatures on the certificate may be a facsimile.
  

 
21
 

 

8.4 Lost Certificates

 

Except as provided in this Section 8.4 , no new certificates for shares will be issued to replace a previously issued certificate unless the latter is surrendered to the Corporation and cancelled at the same time. The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or his or her legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate or uncertificated shares.

 

8.5 Construction; Definitions

 

Unless the context requires otherwise, the general provisions, rules of construction, and definitions in the Nevada Revised Statutes will govern the construction of these bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural number includes the singular, the masculine includes the feminine, and the term "person" includes both a corporation and a natural person.

 

8.6 Dividends

 

The directors of the Corporation, subject to any rights or restrictions contained in the articles of incorporation, may declare and pay dividends upon the shares of its capital stock pursuant to the Nevada Revised Statutes. Dividends may be paid in cash, in property, or in shares of the Corporation's capital stock.

 

The directors of the Corporation may set apart out of any of the funds of the Corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve. Such purposes will include but not be limited to equalizing dividends, repairing or maintaining any property of the Corporation, and meeting contingencies.

 

8.7 Fiscal Year

 

The fiscal year of the Corporation will end on September 30.

 

8.8 Seal

 

The Corporation may adopt a corporate seal which may be altered as desired, and may use the same by causing it or a facsimile thereof, to be impressed or affixed or in any other manner reproduced.

 

8.9 Transfer of Stock

 

Upon surrender to the Corporation or the transfer agent of the Corporation of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer, it will be the duty of the Corporation to issue a new certificate to the person entitled thereto, cancel the old certificate, and record the transaction in its books.
  

 
22
 

 

8.10 Stock Transfer Agreements and Restrictions

 

The Corporation will have the power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the Nevada Revised Statutes.

 

8.11 Electronic Transmission

 

For purposes of these bylaws, "electronic transmission" means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.

 

IX. AMENDMENTS

 

9 .1 By the Stockholders

 

These bylaws may be amended, altered, or repealed at any regular or special meeting of the stockholders if notice of the proposed alteration or amendment is contained in the notice of the meeting.

 

9.2 By the Board of Directors

 

These bylaws may be amended, altered, or repealed by the affirmative vote of a majority of the entire board of directors at any regular or special meeting of the board of directors.
  

 
23
 

 

CERTIFICATE OF ADOPTION OF  

AMENDED AND RESTATED BYLAWS

OF

CITIUS PHARMACEUTICALS, INC.

 

Certificate of Adoption

 

The undersigned hereby certifies that he is a duly elected, qualified, and acting officer of Citius Pharmaceuticals, Inc. (the " Corporation ")and that the foregoing bylaws, comprising twenty three (23) pages, were adopted as the amended and restated bylaws of the Corporation by the board of directors of the Corporation pursuant to an action by unanimous written consent of the board of directors of the Corporation and were recorded in the minutes of such company. The foregoing bylaws are to be effective as of March 30, 2016.

 

IN WITNESS WHEREOF, the undersigned has hereunto set his or her hand and affixed the corporate seal this 1st day of April, 2016.

 
       
By: /s/ Myron Holubiak

 

 

 

Myron Holubiak,

 

 

 

Chief Executive Officer

 

 

 

24


EXHIBIT 10.1

 

EMPLOYMENT AGREEMENT

 

This EMPLOYMENT AGREEMENT (the " Agreement "), is entered into effective as of March 1, 2016 (the " Effective Date "), by and between Citius Pharmaceuticals, Inc., a Nevada corporation with principal executive offices at 63 Great Road, Maynard Massachusetts 01754 (the " Company "), and Myron Holubiak, residing at 1544 Edly Cove Court, North Brunswick, New Jersey 08902 (the " Executive ").

 

W I T N E S S E T H:

 

WHEREAS, the Company desires to employ Executive as its Chief Executive Officer, and Executive desires to be employed by the Company, pursuant to the terms and conditions set forth herein.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained, the parties hereto hereby agree as follows:

 

1. Employment.

 

(a) Services . The Executive will be employed by the Company as its Chief Executive Officer. The Executive will report to the Board of Directors of the Company (the " Board ") and shall perform such duties as are consistent with a position as Chief Executive Officer (the " Services "). The Executive agrees to perform such duties faithfully, to devote substantially all of his working time, attention and energies to the business of the Company, and while he remains employed and subject to the terms of this Agreement, not to engage in any other business activity that is in conflict with his duties and obligations to the Company.

 

(b) Acceptance . Executive hereby accepts such employment and agrees to render the Services.

 

2. Term . The Executive's employment under this Agreement shall be deemed to commence on the Effective Date and shall continue for a term of three (3) years (the " Initial Term "), unless sooner terminated pursuant to Section 9 of this Agreement. This Agreement will automatically be extended for additional one (1) year periods (each an " Additional Term " and, together with the Initial Term, the " Term ") unless the Company notifies the Executive in writing that it intends to not extend this Agreement at least sixty (60) days prior to the expiration of the then current Term; provided, however, that the Company's failure to provide the Executive with such notice shall not constitute termination by the Executive for Good Reason (as defined in Section 9(d) hereof).

 

3. Best Efforts . The Executive shall devote substantially all of his business time, attention and energies to the business and affairs of the Company and shall use his best efforts to advance the best interests of the Company and shall not during the Term be actively engaged in any other business activity, whether or not such business activity is pursued for gain, profit or other pecuniary advantage, that will interfere with the performance by the Executive of his duties hereunder or the Executive's availability to perform such duties or that will adversely affect, or negatively reflect upon, the Company.  

 
1
 

 

4. Directorship . The Company shall use its best efforts to cause Executive to be elected as a voting member of its Board throughout the Term and shall include him in the management slate for election as a director at every stockholders meeting during the Term at which his term as a director would otherwise expire. The Executive agrees to accept election, and to serve during the Term, as a member of the Board without any compensation therefore other than as specified in this Agreement.

 

5. Compensation. As full compensation for the performance by the Executive of his duties under this Agreement, the Company shall pay the Executive as follows:

 

(a) Base Salary . The Company shall pay Executive an annual salary (the " Base Salary ") equal to Four Hundred and Fifty Thousand Dollars ($450,000) per year. Payment shall be made in accordance with the Company's normal payroll practices. The Base Salary will be reviewed by the Board no less frequently than annually.

 

(b) Annual Milestone Bonus . At the sole discretion of the Board, Executive may receive a discretionary bonus on each anniversary of the Effective Date during the Term (the " Annual Milestone Bonus ") in an amount up to fifty percent (50%) of his then current Base Salary based on the attainment by the Executive of certain financial, clinical development and business milestones (the " Milestones ") as established annually by the Board (or a committee thereof), after consultation with the Executive. The Annual Milestone Bonus shall be payable either as a lump-sum payment or in installments as determined by the Board in its sole discretion, provided, however , if the Board determines to pay the Executive in installments, such installments shall be no less frequently than monthly, and shall be over a time period not to exceed four (4) months, unless otherwise agreed by the Executive in writing. Notwithstanding the foregoing, the Annual Milestone Bonus, if any, for a given year will be paid in full no later than March 15 of the calendar year immediately following the calendar year for which the Annual Milestone Bonus, if any, is earned.

 

(c) Incentive Bonus . The Company shall pay the Executive periodic milestone-based incentive bonuses (each an " Incentive Bonus ") of:

 

(i) In the event that the Market Capitalization (as defined below) of the Company shall exceed One Hundred Million Dollars (US$100,000,000) for a period of thirty (30) consecutive trading days during the Term (the " First Capitalization Milestone "), the Company shall pay to the Executive a cash bonus of Two Hundred Fifty Thousand Dollars ($250,000). For purposes of this Agreement, " Market Capitalization " shall be determined by multiplying the total shares of the Company's Common Stock which are issued and outstanding by the last reported closing price of the Company's Common Stock on a nationally recognized exchange, NASDAQ, or in the over-the-counter market as reported by the National Quotation Bureau or similar organization. This bonus will be paid in a lump sum as soon as it can be arranged by the Company, but in no event shall payment be made later than March 15 of the calendar year immediately following the calendar year that includes the thirtieth (30 th ) consecutive trading day on which the First Capitalization Milestone threshold is attained; and

 

(ii) In the event that the Market Capitalization of the Company shall exceed Two Hundred Fifty Million Dollars (US$250,000,000) for a period of thirty (30) consecutive trading days during the Term (the " Second Capitalization Milestone "), the Company shall pay to the Executive a cash bonus of Five Hundred Thousand Dollars ($500,000). This bonus will be paid in a lump sum as soon as it can be arranged by the Company, but in no event shall payment be made later than March 15 of the calendar year immediately following the calendar year that includes the thirtieth (30 th ) consecutive trading day on which the Second Capitalization Milestone threshold is attained. 

 
2
 

 

(d) Withholding. The Company shall withhold all applicable federal, state and local taxes and social security and such other amounts as may be required by law from all amounts payable to the Executive under this Section 5.

 

(e) Expenses. The Company shall reimburse the Executive for all normal, usual and necessary expenses incurred by the Executive in furtherance of the business and affairs of the Company, including reasonable travel and entertainment, upon timely receipt by the Company of appropriate vouchers or other proof of the Executive's expenditures and otherwise in accordance with any expense reimbursement policy as may from time to time be adopted by the Company.

 

(f) Other Benefits. The Executive shall be entitled to all rights and benefits for which he shall be eligible under any benefit or other plans (including, without limitation, dental, medical, medical reimbursement and hospital plans, pension plans, employee stock purchase plans, profit sharing plans, bonus plans and other so-called " Fringe Benefits ") as the Company shall make available to its senior executives from time to time. The Company shall also name Executive as a covered person under any Directors & Officers insurance policies.

 

(g) Vacation. The Executive shall, during the Term, be entitled to a vacation of four (4) nonconsecutive weeks per annum, in addition to holidays observed by the Company. Unless otherwise provided by the Company's vacation policy, the Executive shall not be entitled to carry any unused, accrued vacation forward from one year of employment to the next, and any such vacation days will be forfeited without payment. In addition, the Executive will forfeit payment for any unused, accrued vacation upon termination of employment, subject to applicable law.

 

6. Confidential Information and Inventions .

 

(a) The Executive recognizes and acknowledges that in the course of his duties he is likely to receive confidential or proprietary information owned by the Company or third parties with whom the Company has an obligation of confidentiality, relating to and used in the Company's business (collectively, " Confidential and Proprietary Information "). Confidential and Proprietary Information shall include, but shall not be limited to, confidential or proprietary scientific or technical information, data, formulas and related concepts, business plans (both current and under development), client lists, promotion and marketing programs, trade secrets, or any other confidential or proprietary business information relating to development programs, costs, revenues, marketing, investments, sales activities, promotions, credit and financial data, manufacturing processes, financing methods, plans or the business and affairs of the Company or of any affiliate or client of the Company, and any and all information relating to the operation of the Company's business which the Company may from time to time designate as confidential or proprietary or that Executive reasonably knows should be, or has been, treated by the Company as confidential or proprietary. The Executive expressly acknowledges that the Confidential and Proprietary Information constitutes a protectable business interest of the Company. The Executive further agrees that if any information that the Company deems to be a trade secret is found by a court of competent jurisdiction not to be a trade secret, such information will, nevertheless, be considered Confidential and Proprietary Information for purposes of this Agreement. Confidential and Proprietary Information does not include any information that: (i) at the time of disclosure is generally known to, or readily ascertainable by, the public; (ii) becomes known to the public through no fault of Executive or other violation of this Agreement; or (iii) is disclosed to Executive by a third party under no obligation to maintain the confidentiality of the information. The Executive agrees, during and after the Term, except as reasonably necessary for the fulfillment of his duties under this Agreement: (i) not to use any such Confidential and Proprietary Information for himself or others; (ii) to keep confidential and not disclose or make accessible to any other person or entity any Confidential and Proprietary Information; and (iii) not to take any Company Confidential and Proprietary Information (including but not limited to writings, correspondence, notes, drafts, records, invoices, technical and business policies, computer programs or disks) from the Company's offices at any time. The Executive agrees to return immediately all Company material and reproductions (including but not limited, to writings, correspondence, notes, drafts, records, invoices, technical and business policies, computer programs or disks) thereof in his possession to the Company upon termination of employment, or at any time upon the Company's request.  

 
3
 

 

(b) Except with prior written authorization by the Company, the Executive agrees not to disclose or publish any of the Confidential and Proprietary Information, or any confidential, scientific, technical or business information of any other party to whom the Company owes an obligation of confidence, at any time during or after his employment with the Company. The restrictions in this Section 6(b) and in Section 6(a) above will not apply to any information that Executive is required to disclose by law, provided that Executive (i) notifies the Company of the existence and terms of such obligation, (ii) gives the Company a reasonable opportunity to seek a protective or similar order to prevent or limit such disclosure, and (iii) only discloses that information actually required to be disclosed.

 

(c) The Executive agrees that all inventions, discoveries, improvements and patentable or copyrightable works (" Inventions ") initiated, conceived or made by him, either alone or in conjunction with others, during the course of his employment by the Company or that result from work performed by Executive for the Company, shall be the sole property of the Company to the maximum extent permitted by applicable law and, to the extent permitted by law, shall be "works made for hire" as that term is defined in the United States Copyright Act (17 U.S.C.A., Section 101). The Company shall be the sole owner of all patents, copyrights, trade secret rights, and other intellectual property or other rights in connection therewith. The Executive hereby assigns to the Company all right, title and interest he may have or acquire in all such Inventions; provided, however, that the Board may in its sole discretion agree to waive the Company's rights pursuant to this Section 6(c) with respect to any Invention that is not directly or indirectly related to the Company's business. The Executive further agrees to assist the Company in every proper way (but at the Company's expense) to obtain and from time to time enforce patents, copyrights or other rights on such Inventions in any and all countries, and to that end the Executive will execute all documents necessary:

 

(i) to apply for, obtain and vest in the name of the Company alone (unless the Company otherwise directs) letters patent, copyrights or other analogous protection in any country throughout the world and when so obtained or vested to renew and restore the same; and

 

(ii) to defend any opposition proceedings in respect of such applications and any opposition proceedings or petitions or applications for revocation of such letters patent, copyright or other analogous protection.

 

(d) The Executive acknowledges that, while performing the services under this Agreement the Executive may locate, identify and/or evaluate patented or patentable inventions having commercial potential in the fields of pharmacy, pharmaceutical, biotechnology, healthcare, technology and other fields which may be of potential interest to the Company (the " Third-Party Inventions "). The Executive understands, acknowledges and agrees that all rights to, interests in or opportunities regarding, all Third-Party Inventions identified by the Company or either of the foregoing persons' officers, directors, employees (including the Executive), agents or consultants during the Term shall be and remain the sole and exclusive property of the Company or such affiliate and the Executive shall have no rights whatsoever to such Third-Party Inventions and will not pursue for himself or for others any transaction relating to the Third-Party Inventions which is not on behalf of the Company.

 

(e) The provisions of this Section 6 shall survive any termination or expiration of this Agreement.  

 
4
 

 

7. Non-Competition and Non-Solicitation . The Executive understands and recognizes that his services to the Company are special and unique and that in the course of performing such services the Executive will have access to and knowledge of Confidential and Proprietary Information (as defined in Section 6) and will become knowledgeable of and familiar with the Company's customers as well as the Company's business. The Executive acknowledges that, due to the unique nature of the Company's business, the loss of any of its clients or business flow or the improper use of its Confidential and Proprietary Information could create significant instability and cause substantial damage to the Company and therefore the Company has a strong legitimate business interest in protecting the continuity of its business interests and the restriction herein agreed to by the Executive narrowly and fairly serves such an important and critical business interest of the Company. Therefore, Executive covenants and agrees as follow:

 

(a) Definitions . As used in this Agreement, the following terms have the meanings given to such terms below:

 

(i) " Business " means (A) acquiring, developing and commercializing drug products focused on adjunctive cancer therapies; (B) acquiring, developing and commercializing drug products for the treatment of hemorrhoids; and (C) any other business that the Company is actively engaged in at the time of the date of termination, provided that this clause (C) shall only apply if Executive is involved with that other business.

 

(ii) " Customer " means (A) any person or entity who is or was a customer of the Company at the time of, or during the six (6) month period prior to, the date of Executive's termination and with whom Executive had dealings on behalf of the Company in the course of his employment with the Company, or about whom Executive received Confidential and Proprietary Information in the course of his employment with the Company, and (B) any prospective customer to whom, within the six (6) month period prior to the Executive's date of termination, the Company had submitted proposals to for services of which Executive has knowledge, whether or not such proposals have yet to be executed into contracts, provided that, the Company has a legitimate expectation of doing business with such prospective customer, and provided further that the Executive has had material business contacts with such prospective customer on behalf of the Company, whether such contact was initiated by the prospective customer or by Executive.

 

(iii) " Company Employee " means (A) any person who is an employee of the Company at the time of the date of Executive's termination of employment, and (B) any person who was an employee of the Company during the six (6) month period prior to, the termination of Executive's employment.

 

(iv) " Person " means any person, firm, partnership, joint venture, corporation or other business entity.

 

(v) " Restricted Period " means the period commencing on the date of Executive's termination of employment and ending twelve (12) months thereafter, provided, however, that this period will be tolled and will not run during any time Executive is in violation of this Section 7, it being the intent of the parties that the Restricted Period will be extended for any period of time in which Executive is in violation of this Section.  

 
5
 

 

(vi) " Restricted Territory " means any country in which the Company does business as of the Executive's date of termination, including without limitation each country to which the Executive directed or in which Executive performed employment-related activities on behalf of the Company at the time of, or during the six (6) month period prior to, the Executive's date of termination and each country in which the Company is actively preparing to conduct business within the six (6) month period immediately following the Executive's date of termination, provided that Executive is materially involved in such preparations; or if that geographic territory is deemed by a court of competent jurisdiction to be overly broad, the United States of America; or if that geographic territory is deemed by a court of competent jurisdiction to be overly broad, any state, province or similar geographic subdivision in which the Company does business as of the Executive's date of termination, including without limitation each state, province or similar geographic subdivision to which the Executive directed or in which Executive performed employment-related activities on behalf of the Company at the time of, or during the six (6) month period prior to, the date of termination.

 

(b) Non-Competition . During his employment with the Company, Executive will not, on his own behalf or on behalf of any other Person, engage in any business competitive with or adverse to that of the Company. In addition, during his employment with the Company and during the Restricted Period, Executive will not (i) engage in the Business in the Restricted Territory, or (ii) hold a position based in or with responsibility for all or part of the Restricted Territory, with any Person engaging in the Business, whether as employee, consultant, or otherwise, (A) in which Executive will have duties, or will perform or be expected to perform services for such Person, that is or are the same as or substantially similar to the position held by Executive or those duties or services actually performed by Executive for the Company within the twelve (12) month period immediately preceding the Executive's date of termination, or (B) in which Executive will use or disclose or be reasonably expected to use or disclose any Confidential and Proprietary Information of the Company for the purpose of providing, or attempting to provide, such Person with a competitive advantage with respect to the Business. For purposes of clarification, nothing contained in this Section 7(b) shall be deemed to prohibit the Executive from acquiring or holding, solely for investment, publicly traded securities of any corporation, some or all of the activities of which are competitive with the business of the Company so long as such securities do not, in the aggregate, constitute more than five percent (5%) of any class or series of outstanding securities of such corporation.

 

(c) Non-Solicitation . During his employment with the Company and during the Restricted Period, Executive will not, directly or indirectly, on Executive's own behalf or on behalf of any other Person:

 

(i) Call upon, solicit, divert, encourage or attempt to call upon, solicit, divert or encourage any Customer for purposes of marketing, selling or providing products or services to such Customer that are similar to or competitive with those offered by the Company;

 

(ii) Induce, encourage or attempt to induce or encourage any Customer to reduce, limit or cancel its business with the Company;

 

(iii) Induce, encourage or attempt to induce or encourage any Customer to purchase or accept products or services competitive with those offered by the Company from any Person (other than the Company) engaging in the Business;  

 
6
 

 

(iv) Otherwise interfere or engage in any conduct that would have the effect of interfering, in any manner, with the business relationship between the Company and any of the Company's Customers; or

 

(v) Solicit, induce, or attempt to solicit or induce any Company Employee or any independent contractor (who is then engaged by the Company or was engaged by the Company in the prior six (6) months) to terminate his or her employment or engagement with the Company or to accept employment or engagement with any Person engaging in the Business within the Restricted Territory.

 

(d) Direct Employment or Engagement by Customer . During his employment with the Company and during the Restricted Period, Executive will not be employed or engaged (as an employee, contractor, consultant or otherwise) directly by, or solicit employment or engagement by, any Person who, during the Term of this Agreement, was an agent or Customer of the Company with whom Executive worked during his employment with the Company in a position or capacity in which Executive will be performing services for such Customer that are the same as, or substantially similar to, those services provided by Executive for the Customer during Executive's employment with the Company. For the avoidance of doubt, the terms "agent" and "Customer" will not include any investment bank, investor, lender or other financial intermediary which may represent, invest in or otherwise deal with the Company.

 

(e) Enforcement . In the event that the Executive breaches or threatens to breach any provisions of Section 6 or this Section 7, then the Company will suffer irreparable harm and monetary damages would be inadequate to compensate the Company. Accordingly, in addition to any other rights which the Company may have, the Company shall (i) be entitled, without the posting of bond or other security, to seek injunctive relief to enforce the restrictions contained in such Sections and (ii) have the right to require the Executive to account for and pay over to the Company all compensation, profits, monies, accruals, increments and other benefits (collectively " Benefits ") derived or received by the Executive as a result of any transaction constituting a breach of any of the provisions of Sections 6 or 7, to the maximum extent permitted by law.

 

(f) Reasonableness and Severability . Each of the rights and remedies enumerated in Section 7(e) shall be independent of the others and shall be in addition to and not in lieu of any other rights and remedies available to the Company at law or in equity. The Executive hereby acknowledges and agrees that the covenants provided for pursuant to Section 7 are essential elements of Executive's employment by the Company and are reasonable with respect to their duration, geographic area and scope and in all other respects. If, at the time of enforcement of this Section 7, a court holds that the restrictions stated herein are unreasonable under the circumstances then existing, the parties hereto agree that the maximum duration, scope or geographic area legally permissible under such circumstances will be substituted for the duration, scope or area stated herein. If any of the covenants contained in this Section 7, or any part of any of them, is hereafter construed or adjudicated to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants or rights or remedies which shall be given full effect without regard to the invalid portions. No such holding of invalidity or unenforceability in one jurisdiction shall bar or in any way affect the Company's right to the relief provided in this Section 7 or otherwise in the courts of any other state or jurisdiction within the geographical scope of such covenants as to breaches of such covenants in such other respective states or jurisdictions, such covenants being, for this purpose, severable into diverse and independent covenants.  

 
7
 

 

(g) Remedies . In the event that an actual proceeding is brought in equity to enforce the provisions of Section 6 or this Section 7, the Executive shall not urge as a defense that there is an adequate remedy at law nor shall the Company be prevented from seeking any other remedies which may be available. The Executive agrees that he shall not raise in any proceeding brought to enforce the provisions of Section 6 or this Section 7 that the covenants contained in such Sections limit his ability to earn a living.

 

(h) Survival . The provisions of this Section 7 shall survive any termination of this Agreement.

 

8. Representations and Warranties .

 

(a) The Executive hereby represents and warrants to the Company as follows:

 

(i) Neither the execution or delivery of this Agreement nor the performance by the Executive of his duties and other obligations hereunder violate or will violate any statute, law, determination or award, or conflict with or constitute a default or breach of any covenant or obligation under (whether immediately, upon the giving of notice or lapse of time or both) any prior employment agreement, contract, or other instrument to which the Executive is a party or by which he is bound.

 

(ii) The Executive has the full right, power and legal capacity to enter and deliver this Agreement and to perform his duties and other obligations hereunder. This Agreement constitutes the legal, valid and binding obligation of the Executive enforceable against him in accordance with its terms. No approvals or consents of any persons or entities are required for the Executive to execute and deliver this Agreement or perform his duties and other obligations hereunder.

 

(b) The Company hereby represents and warrants to the Executive that this Agreement and the employment of the Executive hereunder have been duly authorized by and on behalf of the Company, including, without limitation, by all required action by the Board.

 

9. Termination. The Executive's employment hereunder shall be terminated immediately upon the Executive's death and may be otherwise terminated as follows:

 

(a) The Executive's employment hereunder may be terminated by the Board for Cause. Any of the following actions by the Executive shall constitute " Cause ":

 

(i) The willful failure, disregard or continuing refusal by the Executive to perform his duties hereunder;

 

(ii) Any act of willful or intentional misconduct, or a grossly negligent act by the Executive having the effect of injuring, in a material way (as determined in good-faith by a majority of the Board), the business or reputation of the Company, including but not limited to, any officer, director, or executive of the Company;   

 
8
 

 

(iii) Willful misconduct by the Executive in carrying out his duties or obligations under this Agreement, including, without limitation, insubordination with respect to lawful directions received by the Executive from the Board;

 

(iv) The Executive's indictment of any felony or a misdemeanor involving moral turpitude (including entry of a nolo contendere plea);

 

(v) The determination by the Board, based upon clear and convincing evidence, after a reasonable and good-faith investigation by the Company following a written allegation by another employee of the Company, that the Executive engaged in some form of harassment prohibited by law (including, without limitation, age, sex or race discrimination), unless the Executive's actions were specifically directed by the Board;

 

(vi) Any intentional misappropriation of the property of the Company, or embezzlement of its funds or assets (whether or not a misdemeanor or felony);

 

(vii) Breach by the Executive of any of the provisions of Sections 6, 7 or 8 of this Agreement; and

 

(viii) Breach by the Executive of any provision of this Agreement other than those contained in Sections 6, 7 or 8 which is not cured by the Executive within thirty (30) business days after notice thereof is given to the Executive by the Company.

 

Except as otherwise expressly provided for in this Section 9(a), any determination of Cause under Section 9(a) will be made by two-thirds of the Board voting on such determination. With respect to any such determination, the Board will act fairly and in utmost good faith and will give the Executive and his counsel an opportunity to appear and be heard at a meeting of the Board, and present evidence on the Executive's behalf.

 

(b) The Executive's employment hereunder may be terminated by the Board due to the Executive's Disability. For purposes of this Agreement, a termination for " Disability " shall occur (i) when the Board has provided a written termination notice to the Executive supported by a written statement from a reputable independent physician mutually selected by the Company and the Executive, or the Executive's legal representatives in the event he is unable to make such selection due to physical or mental incapacity, to the effect that the Executive shall have become so physically or mentally incapacitated as to be unable to resume, even with reasonable accommodation as may be required under the Americans With Disabilities Act, within the ensuing twelve (12) months, his employment hereunder by reason of physical or mental illness or injury, or (ii) upon rendering of a written termination notice by the Board after the Executive has been unable to substantially perform his duties hereunder, even with reasonable accommodation as may be required under the Americans With Disabilities Act, for 120 or more consecutive days, or more than 180 days in any consecutive twelve month period, by reason of any physical or mental illness or injury. For purposes of this Section 9(b), the Executive agrees to make himself available and to cooperate in any reasonable examination by a reputable independent physician mutually selected by the Company and the Executive, and paid for by the Company. Notwithstanding the foregoing, nothing herein shall give the Company the right to terminate Executive prior to discharging its obligations to Executive, if any, under the Family and Medical Leave Act, the Americans With Disabilities Act, or any other applicable law. The Company shall reimburse Executive for his actual cost of maintaining a supplementary long-term disability insurance policy during the Term up to a maximum reimbursement of $10,000 per year.
 

 
9
 

 

(c) The Executive's employment hereunder may be terminated by the Board (or its successor) by written notice to the Executive upon the occurrence of a Change of Control. For purposes of this Agreement, " Change of Control " means (i) the acquisition, directly or indirectly, following the date hereof by any person (as such term is defined in Section 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended), in one transaction or a series of related transactions, of securities of the Company representing in excess of fifty percent (50%) or more of the combined voting power of the Company's then outstanding securities if such person or his or its affiliate(s) do not own in excess of 50% of such voting power on the Effective Date of this Agreement, or (ii) the future disposition by the Company (whether direct or indirect, by sale of assets or stock, merger, consolidation or otherwise) of all or substantially all of its business and/or assets in one transaction or series of related transactions other than a merger (1) effected exclusively for the purpose of changing the domicile of the Company or (2) effected for the purpose of obtaining a public listing and/or publicly traded securities.

 

(d) The Executive's employment hereunder may be voluntarily terminated by the Executive for Good Reason. For purposes of this Agreement, " Good Reason " shall mean any of the following: (i) any material reduction by the Company of the Executive's duties, responsibilities, or authority as Chief Executive Officer of the Company which causes his position with the Company to become of less responsibility or authority than his position immediately following the Effective Date; (ii) any material reduction by the Company of the Executive's compensation or benefits payable hereunder (it being understood that a reduction of benefits applicable to all employees of the Company, including the Executive, shall not be deemed a reduction of the Executive's compensation package for purposes of this definition); (iii) any requirement by the Company that the Executive locate Company headquarters, or Executive's residence or primary place of employment, to a location outside a 30-mile radius of Cranford, New Jersey, or (iv) failure during the Term to nominate the Executive for election to the Board and to recommend to shareholders to vote in support of such nomination, or failure of the Board to appoint the Executive as Chief Executive Officer of the Company, or removal during the Term from the Board or as Chief Executive Officer of the Company, provided that such failure or removal is not in connection with either: (x) a termination of the Executive's employment hereunder by the Company for Cause, or (y) as a result of the failure of the stockholders of the Company to elect the Executive to the Board despite the Company's compliance with its obligations under Section 4 hereof; (v) a material breach by the Company of Section 8(b) of this Agreement which is not cured by the Company within 30 days after written notice thereof is given to the Company by the Executive, or (vi) a change in the lines of reporting such that the Executive no longer reports directly to the Board. However, notwithstanding the above, Good Reason shall not exist unless: (x) the Executive notifies the Board within ninety (90) days of the initial existence of one of the adverse events described above, and (y) the Company fails to correct the adverse event within thirty (30) days of such notice, and (z) the Executive's voluntary termination because of the existence of one or more of the adverse events described above occurs within 24 months of the initial existence of the event.

 

(e) The Executive's employment may be terminated by the Company without Cause by delivery of written notice to the Executive effective fifteen (15) days after the date of delivery of such notice.

 

(f) The Executive's employment may be terminated by the Executive in the absence of Good Reason by delivery of written notice to the Company effective fifteen (15) days after the date of delivery of such notice.  

 
10
 

 

10. Compensation upon Termination.

 

(a) Accrued Benefits . Upon termination of Executive's employment by either party regardless of the cause or reason, Executive shall be entitled to the following, referred to herein as the " Accrued Benefits ": (i) payment for any accrued, unpaid Base Salary through the termination date; (ii) payment for any Incentive Bonus earned and payable but not yet paid as of the date of termination, if any; and (iii) reimbursement for any approved business expenses that Executive has timely submitted for reimbursement in accordance with the Company's business expense reimbursement policy or practice. Except as otherwise expressly provided by this Agreement, the Company shall have no further payment obligations to Executive upon the termination of his employment.

 

(b) Change of Control Severance . If the Executive's employment is terminated by the Company during the Term in connection with or within six (6) months following the occurrence of a Change of Control, provided that Executive signs and does not revoke a general release of claims against the Company within the time period specified therein, in form and substance satisfactory to the Company (the " Release "), and provided further that such termination is a "separation from service" within the meaning of Treasury Regulation § 1.409A-1(h), then the Company shall provide the following benefits to Executive, referred to herein as the " Change of Control Separation Benefits ": (i) a lump sum payment equal to eighteen (18) months of Executive's then-current Base Salary (less applicable taxes and withholdings); (ii) the full Annual Milestone Bonus (items (i) and (ii) being the " Change of Control Separation Pay "); and (iii) provided that Executive properly and timely elects to continue his health insurance benefits under COBRA or applicable state continuation coverage law after the date of termination, reimbursement for Executive's applicable health continuation coverage premiums for a period of eighteen (18) months or until Executive becomes eligible for insurance benefits from another employer, whichever is earlier (the " Change of Control COBRA Reimbursement "). The Change of Control Separation Pay will be paid on the Company's first regular payday occurring sixty (60) days after the termination date. The Change of Control COBRA Reimbursement shall continue for the specified period provided that the Company has the right to discontinue the reimbursement payment and pay to the Executive a lump sum amount equal to the current COBRA premium times the number of months remaining in the specified period if the Company determines that continued payment of the COBRA reimbursement is discriminatory under Section 105(h) of the Internal Revenue Code.

 

(c) Other Severance Benefits . If the Executive's employment is terminated during the Term as a result of Executive's Disability pursuant to Section 9(b), by the Company without Cause pursuant to Section 9(e), or by Executive for Good Reason pursuant to Section 9(d), provided that Executive signs and does not revoke the Release within the time period specified therein, and provided further that such termination is a "separation from service" within the meaning of Treasury Regulation § 1.409A-1(h), then the Company shall provide the following benefits to Executive, referred to herein as the " Separation Benefits ": (i) the continued payment in installments of Executive's then-current Base Salary (less applicable taxes and withholdings) for a period of twelve (12) months following the date of termination (the " Separation Pay "); and (ii) provided that Executive properly and timely elects to continue his health insurance benefits under COBRA or applicable state continuation coverage law after the date of termination, reimbursement for Executive's applicable health continuation coverage premiums for a period of twelve (12) months or until Executive becomes eligible for insurance benefits from another employer, whichever is earlier (the " COBRA Reimbursement "). The first installment of the Separation Pay will be paid on the Company's first regular payday occurring sixty (60) days after the termination date in an amount equal to the sum of payments of Base Salary that would have been paid if he had remained in employment for the period from the termination date through the payment date. The remaining installments will be paid until the end of the 12-month period at the same rate as the Base Salary in accordance with the Company's normal payroll practices for its employees. The COBRA Reimbursement shall continue for the specified period provided that the Company has the right to discontinue the reimbursement payment and pay to the Executive a lump sum amount equal to the current COBRA premium times the number of months remaining in the specified period if the Company determines that continued payment of the COBRA reimbursement is discriminatory under Section 105(h) of the Internal Revenue Code. Executive understands that if he is eligible to receive the Separation Benefits, such Separation Benefits shall be in lieu of and not in addition to any other severance benefits otherwise provided for herein, including the severance benefits described in Section 10(b) of this Agreement. Notwithstanding the foregoing, if Executive is entitled to receive the Separation Benefits but violates any provisions of this Agreement or any other agreement entered into by Executive and the Company after termination of employment, the Company will be entitled to immediately stop paying any further installments of the Separation Benefits. If the Executive's employment is terminated during the Term as a result of Executive's death, then the Company shall provide to Executive's estate the continued payment of Executive's then-current Base Salary for a period of twelve (12) months following the date of termination, beginning on the Company's first regular payday following the date of such termination.   

 
11
 

 

(d) This Section 10 sets forth the only obligations of the Company with respect to the termination of the Executive's employment with the Company, except as otherwise required by law, and the Executive acknowledges that, upon the termination of his employment, he shall not be entitled to any payments or benefits which are not explicitly provided in Section 10. For purposes of clarification, if Executive's employment with the Company terminates upon expiration of the Term, Executive shall only be entitled to receive the Accrued Benefits described in Section 10(a).

 

(e) Upon termination of the Executive's employment hereunder for any reason, the Executive shall be deemed to have resigned as director of the Company, effective as of the date of such termination.

 

(f) The provisions of this Section 10 shall survive any termination of this Agreement.

 

11. 409A Restrictions . The intent of the parties to the Agreement is that the payments, compensation and benefits under this Agreement be exempt from or comply with Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively, " Section 409A ") and, in this connection, the following shall be applicable:

 

(a) To the greatest extent possible, this Agreement shall be interpreted to be exempt or in compliance with Section 409A.

 

(b) If any severance, compensation, or benefit required by the Agreement is to be paid in a series of installment payments, each individual payment in the series shall be considered a separate payment for purposes of Section 409A.

 

(c) If any severance, compensation, or benefit required by the Agreement that constitutes "nonqualified deferred compensation" within the meaning of Section 409A is considered to be paid on account of "separation from service" within the meaning of Section 409A, and Executive is a "specified employee" within the meaning of Section 409A, no payments of any of such severance, compensation, or benefit shall made for six (6) months plus one (1) day after such separation from service (the " New Payment Date "). The aggregate of any such payments that would have otherwise been paid during the period between the date of separation from service and the New Payment Date shall be paid to the Executive in a lump sum on the New Payment Date. Thereafter, any severance, compensation, or benefit required by the Agreement that remains outstanding as of the day immediately following the New Payment Date shall be paid without delay over the time period originally scheduled, in accordance with the terms of this Agreement.

 

(d) The provisions of this Section 11 shall survive any termination of this Agreement.

 

12. Miscellaneous .

 

(a) This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of New Jersey, without giving effect to its principles of conflicts of laws.

 

(b) The parties agree that any litigation arising out of or related to this Agreement or Executive's employment by the Company will be brought exclusively in any state or federal court in Union County, New Jersey. Each party (i) consents to the personal jurisdiction of said courts, (ii) waives any venue or inconvenient forum defense to any proceeding maintained in such courts, and (iii) agrees not to bring any proceeding arising out of or relating to this Agreement or Executive's employment by Company in any other court.  

 
12
 

 

(c) This Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective heirs, legal representatives, successors and permitted assigns.

 

(d) This Agreement, and the Executive's rights and obligations hereunder, may not be assigned by the Executive. The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company, including any successors or assigns in connection with any sale, transfer or other disposition of all or substantially all of its business or assets.

 

(e) This Agreement cannot be amended orally, or by any course of conduct or dealing, but only by a written agreement signed by the parties hereto.

 

(f) The failure of either party to insist upon the strict performance of any of the terms, conditions and provisions of this Agreement shall not be construed as a waiver or relinquishment of future compliance therewith, and such terms, conditions and provisions shall remain in full force and effect. No waiver of any term or condition of this Agreement on the part of either party shall be effective for any purpose whatsoever unless such waiver is in writing and signed by such party.

 

(g) All notices, requests, consents and other communications, required or permitted to be given hereunder, shall be in writing and shall be delivered personally or by an overnight courier service or sent by registered or certified mail, postage prepaid, return receipt requested, to the parties at the addresses set forth on the first page of this Agreement, and shall be deemed given when so delivered personally or by overnight courier, or, if mailed, five days after the date of deposit in the United States mails. Either party may designate another address, for receipt of notices hereunder by giving notice to the other party in accordance with this Section 12 (g).

 

(h) This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof. No representation, promise or inducement has been made by either party that is not embodied in this Agreement, and neither party shall be bound by or liable for any alleged representation, promise or inducement not so set forth.

 

(i) As used in this Agreement, "affiliate" of a specified person or entity shall mean and include any person or entity controlling, controlled by or under common control with the specified person or entity.

 

(j) The section headings contained herein are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement.

 

(k) This Agreement may be executed in any number of counterparts, each of which shall constitute an original, but all of which together shall constitute one and the same instrument.

 

[ Remainder of Page Intentionally Left Blank – Signature Page Follows ]

  

 
13
 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement and intend it to be effective as of the Effective Date by proper person thereunto duly authorized.

 

 

CITIUS PHARMACEUTICALS, INC.

 

       
By: /s/ Leonard Mazur

 

 

Name:

Leonard Mazur

 

 

Title:

Chairman of the Board

 

 

 

 

 

 

EXECUTIVE  

 

 

 

 

 

 

 

/s/ Myron Holubiak

 

 

 

Myron Holubiak

 

 

 

14


 

EXHIBIT 10.2

 

STOCK SUBSCRIPTION AGREEMENT

 

THIS STOCK SUBSCRIPTION AGREEMENT (the "Agreement"), dated as of March 30, 2016 is entered into by and between Citius Pharmaceuticals, Inc., a Nevada corporation (the " Corporation "), and Leonard Mazur, an individual with an address 32 Arden Road, Mountain Lakes, New Jersey 07046 (the " Subscriber ").

 

WITNESSETH

 

WHEREAS , the Corporation desires to issue and sell to the Subscriber, and the Subscriber desires to subscribe to and accept from the Corporation five million (5,000,000) shares of the Corporation's common stock, par value $0.001 per share (the "Common Stock") upon the terms and subject to the conditions hereinafter set forth.

 

NOW, THEREFORE , in consideration of the above, the parties hereby agree as follows:

 

1.

Purchase and Sale . Subject to the terms and conditions of this Agreement, on the Closing Date, the Subscriber shall purchase from the Corporation, and the Corporation shall sell and issue to the Subscriber five million (5,000,000) shares of Common Stock (the "Securities") at a price of $0.60 per share.

2.

Closing . The purchase and sale of the Securities shall take place on the date that the Corporation closes on the acquisition of Leonard-Meron Biosciences, Inc. ("LMB") (the "Closing"). At the Closing, the Corporation shall deliver to the Subscriber a stock certificate (the "Certificate") evidencing the Securities registered in the Subscriber's name against delivery to the Corporation of three million ($3,000,000) dollars (the "Purchase Price") by wire transfer of immediately available funds to an account designated by the Corporation prior to the Closing.

3.

Restricted Securities . All Securities issued in exchange for the Purchase Price in accordance with the terms hereof may not be sold or transferred unless (i) such Securities are sold pursuant to an effective registration statement under the Securities Act of 1933, as amended (the "Securities Act") or (ii) the Corporation or its transfer agent shall have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect that the Securities to be sold or transferred may be sold or transferred pursuant to an exemption from such registration or (iii) such Securities are sold or transferred pursuant to Rule 144 under the Act (or a successor rule) ("Rule 144"). The Certificate for Securities issuable pursuant to this Agreement shall bear a legend substantially in the following form, as appropriate:

 

THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO CITIUS. THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.

 

 
1
 

 

4.

Piggy Back Rights . If at any time on or after the Closing, the Corporation proposes to file a registration statement under the Securities Act (a "Registration Statement") with respect to an offering of securities owned by officers, directors or ten percent (10%) shareholders of the Corporation, excluding securities purchased in an offering, then the Corporation shall (x) give written notice of such proposed filing to the Subscriber as soon as practicable but in no event less than ten (10) days before the anticipated filing date of the Registration Statement, which notice shall describe the amount and type of securities to be included in such Registration Statement, the intended method(s) of distribution, and the name of the proposed managing underwriter or underwriters, if any, of the offering, and (y) offer to the Subscriber in such notice the opportunity to register the sale of such number of Securities as the Subscriber may request in writing within five (5) days following receipt of such notice (a "Piggy Back Registration"). The Corporation shall cause the Securities to be included in such registration and shall cause the managing underwriter or underwriters of a proposed underwritten offering to permit Securities requested to be included in a Piggy Back Registration on the same terms and conditions as any similar securities of the Corporation and to permit the sale or other disposition of such Securities in accordance with the intended method(s) of distribution thereof. The Subscriber proposing to distribute the Securities through aPiggy Back Registration that involves an underwriter or underwriters shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for suchPiggy Back Registration.

5.

Representations and Warranties of the Subscriber .

 

a.

Authorization . All action on the part of the Subscriber for the authorization, execution, delivery and performance by the Subscriber of this Agreement has been taken, and this Agreement constitutes a valid and binding obligation of the Subscriber, enforceable in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, or similar laws relating to or affecting the enforcement of creditors' rights.

b.

Restricted Securities . The Subscriber understands that the Securities are "restricted securities" and have not been registered under the Securities Act or any applicable state securities law and the Subscriber is acquiring the Securities as principal for its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law.

c.

Experienced Investor . The Subscriber is experienced in evaluating and investing in securities of companies similarly situated to the Corporation, and acknowledges that it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment in the Securities.

d.

Corporation Information . The Subscriber believes it has received all the information it considers necessary or appropriate for deciding whether to purchase the Securities. The Subscriber further represents that the Subscriber has had an opportunity to ask questions and receive answers from the Corporation regarding the terms and conditions of this Agreement, the Securities and the merger with LMB. In addition, the Subscriber represents that the Subscriber has had an opportunity to ask questions and receive answers from the Corporation regarding the business, properties, prospects and financial condition of the Corporation.

 

 
2
 

 

6.

Representations and Warranties of the Corporation .

 

a.

Organization and Qualification . The Corporation and each of its subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Corporation nor any subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.

b.

Authorization . All action on the part of the Corporation for the authorization, execution, delivery and performance by the Corporation of this Agreement has been taken, and this Agreement constitutes a valid and binding obligation of the Corporation, enforceable in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, or similar laws relating to or affecting the enforcement of creditors' rights.

c.

No Conflict . The execution and delivery by the Corporation of this Agreement does not and the consummation by the Corporation of the transactions contemplated hereby will not (with or without the giving of notice or the lapse of time or both), contravene, conflict with or result in a breach or violation of, or a default under, (i) the Company's certificate of incorporation or by-laws, (ii), any judgment, order, decree, statute, rule, regulation or other law applicable to the Corporation or (iii) in any material respects, any material contract, agreementor instrument by which the Corporation is bound.

 

 

 

 

d.  

Issuance of Securities . The Securities are duly authorized and, when issued and paid for in accordance with this Agreement, will be duly and validly issued, fully paid and nonassessable, free and clear of all liens imposed by the Corporation. 

 

7.

Miscellaneous .

 

a.

Notices . All notices and other communications which are required or may be given under this Agreement shall be in writing and shall be deemed to have been duly given (a) when delivered in person, (b) three (3) business day after being mailed with a nationally recognized overnight courier service, or (c) five (5) business days after being mailed by registered or certified first class mail, postage prepaid, return receipt requested, to the parties hereto at:

 

If to the Corporation, to:

Citius Pharmaceuticals, Inc.

63 Great Road
Maynard, MA 01754

If to the Subscriber, to: 

Leonard Mazur
32 Arden Road
Mountain Lakes, NJ 07046  

 

 
3
 

 

b.

Waiver of Breach. The waiver by any party hereto of a breach of any provision of this Agreement shall not operate nor be construed as a waiver of any subsequent breach.

c.

Binding Effect; Benefits. None of the parties hereto may assign his or its rights hereunder without the prior written consent of the other parties hereto, and any such attempted assignment without such consent shall be null and void and without effect. This Agreement shall inure to the benefit of, and shall be binding upon, the parties hereto and their respective successors, permitted assigns, heirs and legal representatives.

d.

Entire Agreement; Amendments. This Agreement contains the entire agreement and supersedes all prior agreements and understandings, oral or written, between the parties hereto with respect to the subject matter hereof. This Agreement may not be changed orally, but only by an agreement in writing signed by the party against whom any waiver, change, amendment, modification or discharge is sought.

e.

Severability. The invalidity of all or any part of any provision of this Agreement shall not render invalid the remainder of this Agreement or the remainder of such provision. If any provision of this Agreement is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable.

f.

Governing Law; Consent to Jurisdiction. This Agreement shall be governed by and construed in accordance with the law of the State of New York without giving effect to the principles of conflicts of law thereof. The parties hereto each hereby submits himself or itself for the sole purpose of this Agreement and any controversy arising hereunder to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan and the parties hereby waive any and all rights to trial by jury.

g.

Headings. The headings herein are inserted only as a matter of convenience and reference, and in no way define, limit or describe the scope of this Agreement or the intent of the provisions thereof.

h.

Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Signatures evidenced by facsimile transmission will be accepted as original signatures.

 

[Signature Page Follows]

 

 
4
 

 

[SIGNATURE PAGE TO STOCK SUBSCRIPTION AGREEMENT]

 

IN WITNESS WHEREOF, the parties have executed and delivered this Stock Subscription Agreement as of the date first written above.

 

 

 

CITIUS PHARMACEUTICALS, INC.

 

       
By: /s/ Myron Holubiak

 

 

Name:

Myron Holubiak

 

 

Title:

Director

 

 

 

 

 

 

 

 

 

 

SUBSCRIBER

 

 

 

 

 

 

Leonard Mazur

 

 

 

 

 

 

By: 

/s/ Leonard Mazur

 

 

 

 

 

  

5


EHHIBIT 10.3

 

VOTING AGREEMENT

 

THIS VOTING AGREEMENT (this " Agreement "), is made and entered into as of this 30th day of March, 2016, by and among Citius Pharmaceuticals, Inc., a Nevada corporation (the " Company "), Leonard Mazur, an individual with an address at 32 Arden Road, Mountain Lakes, New Jersey 07046 (the " Investor ") and those certain stockholders of the Company listed on Schedule B (together with any subsequent stockholders, who become parties hereto as "Key Holders" pursuant to Section 4.2 below, the " Key Holders ," and together collectively with the Investor, the " Stockholders ").

 

RECITALS

 

A. As of the date of this Agreement, the Company and Leonard-Meron Biosciences, Inc., a Delaware corporation ("LMB") have entered into an Agreement and Plan of Merger (the " Merger Agreement "), which provides for the merger of a wholly-owned subsidiary of the Company into LMB such that LMB survives as a wholly-owned subsidiary of the Company and the stockholders of LMB immediately prior to the merger become the stockholders of the Company after the merger (the " Merger ").

 

B. Pursuant to the terms of the Merger Agreement, prior to the closing of the Merger, the Company entered into that certain Subscription Agreement by and between the Company and the Investor pursuant to which the Company issued to the Investor 5,000,000 shares of the Company's common stock at a purchase price of $0.60 per share resulting in aggregate proceeds of $3,000,000.

 

C. As an inducement and a condition to enter into the Subscription Agreement, the Investor has requested that Stockholders agree, and Stockholders have agreed (in the Stockholders' capacity as such), to enter into this Agreement in order to facilitate the consummation of the Subscription Agreement and any accompanying transactions.

 

AGREEMENT

 

In consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, the parties agree as follows:

 

ARTICLE I
VOTING PROVISIONS REGARDING BOARD OF DIRECTORS

 

Section 1.1 Board Composition Each Stockholder agrees to vote, or cause to be voted, all Shares owned by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times until the Company is listed on a national securities exchange, in whatever manner as shall be necessary to ensure that at each annual or special meeting of stockholders at which an election of directors is held or pursuant to any written consent of the stockholders, the Investor or his duly appointed representative shall have the right to appoint a majority of the members of the board of directors (the " Board ") of the Company. For purposes of this Agreement, the term " Shares " shall mean and include any securities of the Company the holders of which are entitled to vote for members of the Board, including without limitation, all shares of Common Stock and preferred stock, by whatever name called, now owned or subsequently acquired by a Stockholder, however acquired, whether through stock splits, stock dividends, reclassifications, recapitalizations, similar events or otherwise.

 

 
1
 

   

Section 1.2 Failure to Designate a Board Member . In the absence of any designation from the Investor as specified above, the director previously designated by the Investor and then serving shall be reelected if still eligible to serve as provided herein.

 

Section 1.3 Removal of Board Members . Each Stockholder also agrees to vote, or cause to be voted, all Shares owned by such Stockholder, or over which such Stockholder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that:

 

(a) no director elected pursuant to Sections 1.1 or 1.2 of this Agreement may be removed from office other than for cause unless (i) such removal is directed or approved by the affirmative vote of the Investor; or (ii) the Investor is no longer so entitled to designate or approve such director. In the event such removal is directed or approved by the Investor, each Stockholder agrees to vote, or cause to be voted, all Shares owned by such Stockholder, or over which such Stockholder has voting control, in whatever manner as shall be necessary to ensure that such director be removed from office ;

 

(b) any vacancies created by the resignation, removal or death of a director elected pursuant to Sections 1.1 or 1.2 shall be filled pursuant to the provisions of this ARTICLE I ; and

 

All Stockholders agree to execute any written consents required to perform the obligations of this Agreement, and the Company agrees at the request of the Investor to call a special meeting of stockholders for the purpose of electing directors.

 

Section 1.4  No Liability for Election of Recommended Directors . No Stockholder, nor any Affiliate of any Stockholder, shall have any liability as a result of voting for any director designee in accordance with the provisions of this Agreement. For purposes of this Agreement, an individual, firm, corporation, partnership, association, limited liability company, trust or any other entity (collectively, a " Person ") shall be deemed an " Affiliate " of another Person who, directly or indirectly, controls, is controlled by or is under common control with such Person, including, without limitation, any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person.

 

Section 1.5  No "Bad Actor" Designees . The Investor hereby covenants and agrees (A) not to designate or participate in the designation of any director designee who, to the Investor's knowledge, is a Disqualified Designee and (B) that in the event the Investor becomes aware that any individual previously designated by the Investor is or has become a Disqualified Designee, the Investor shall as promptly as practicable take such actions as are necessary to remove such Disqualified Designee from the Board and designate a replacement designee who is not a Disqualified Designee. Any director designee to whom any Disqualification Event is applicable, except for a Disqualification Event as to which Rule 506(d)(2)(ii) or (iii) or (d)(3) is applicable, is hereinafter referred to as a " Disqualified Designee ". For purposes of this Agreement, the term " Disqualification Event " shall mean the "bad actor" disqualifying events described in Rule 506(d)(1)(i)-(viii) promulgated under the Securities Act of 1933, as amended (the " Securities Act ")

 

 
2
 

   

ARTICLE II
REMEDIES

 

Section 2.1 Covenants of the Company . The Company agrees to use its best efforts, within the requirements of applicable law, to ensure that the rights granted under this Agreement are effective and that the parties enjoy the benefits of this Agreement. Such actions include, without limitation, the use of the Company's best efforts to cause the nomination and election of the directors as provided in this Agreement.

 

Section 2.2 Irrevocable Proxy and Power of Attorney . Each Key Holder hereby constitutes and appoints as its proxy and hereby grants a power of attorney to the Investor, and each of them, with full power of substitution, with respect to the matters set forth herein, including, election of persons as members of the Board in accordance with ARTICLE I hereto, hereby authorizes the Investor to represent and vote, if and only if the party (i) fails to vote, or (ii) attempts to vote (whether by proxy, in person or by written consent), in a manner which is inconsistent with the terms of this Agreement, all of such party's Shares in favor of the election of persons as members of the Board determined pursuant to and in accordance with the terms and provisions of this Agreement. Each of the proxy and power of attorney granted pursuant to the immediately preceding sentence is given in consideration of the agreements and covenants of the Company and the parties in connection with the transactions contemplated by this Agreement and, as such, each is coupled with an interest and shall be irrevocable unless and until this Agreement terminates or expires pursuant to ARTICLE III hereof. Each party hereto hereby revokes any and all previous proxies or powers of attorney with respect to the Shares and shall not hereafter, unless and until this Agreement terminates or expires pursuant to ARTICLE III hereof, purport to grant any other proxy or power of attorney with respect to any of the Shares, deposit any of the Shares into a voting trust or enter into any agreement (other than this Agreement), arrangement or understanding with any person, directly or indirectly, to vote, grant any proxy or give instruc-tions with respect to the voting of any of the Shares, in each case, with respect to any of the matters set forth herein.

 

Section 2.3  Specific Enforcement . Each party acknowledges and agrees that each party hereto will be irreparably damaged in the event any of the provisions of this Agreement are not performed by the parties in accordance with their specific terms or are otherwise breached. Accordingly, it is agreed that each of the Company and the Stockholders shall be entitled to an injunction to prevent breaches of this Agreement, and to specific enforcement of this Agreement and its terms and provisions in any action instituted in any court of the United States or any state having subject matter jurisdiction.

 

Section 2.4  Remedies Cumulative . All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 

 
3
 

   

ARTICLE III
TERM

 

Section 3.1  Term . This Agreement shall be effective as of the date hereof and shall continue in effect until and shall terminate upon, and be conditioned upon, the Company being listed on a national securities exchange

 

ARTICLE IV
MISCELLANEOUS

 

Section 4.1 Additional Issuances to Stockholders . In the event that after the date of this Agreement, the Company issues capital stock to any of the Stockholders, then, such capital stock shall be subject to the terms of this Agreement.

 

Section 4.2 Transfers . Each permitted transferee or assignee of any Shares subject to this Agreement (except investors which acquire Shares subject to this Agreement pursuant to a sale in the public market) shall continue to be subject to the terms hereof, and, as a condition precedent to the Company's recognizing such transfer, each permitted transferee or assignee shall agree in writing to be subject to each of the terms of this Agreement by executing and delivering an Adoption Agreement substantially in the form attached hereto as Exhibit A. Upon the execution and delivery of an Adoption Agreement by any transferee, such transferee shall be deemed to be a party hereto as if such transferee were the transferor and such transferee's signature appeared on the signature pages of this Agreement and shall be deemed to be a Key Holder and Stockholder. The Company shall not permit the transfer of the Shares subject to this Agreement on its books or issue a new certificate representing any such Shares unless and until such transferee shall have complied with the terms of this Section 4.2 and Section 4.3. Each certificate, instrument, or book entry representing the Shares subject to this Agreement if issued on or after the date of this Agreement shall be notated by the Company with the legend set forth in Section 4.12.

 

Section 4.3 Successors and Assigns . No party hereto shall have any right to transfer any of its rights or duties under this Agreement except with the consent of the Company, the Key Holders holding a majority of the shares of Common Stock then held by all Key Holders; provided, however, that the Investor shall have the right to transfer any or all of its rights and obligations under this Agreement without the consent of any party. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

Section 4.4 Governing Law . This Agreement shall be governed by the internal law (and not the law of conflicts of laws) of the State of New York.

 

Section 4.5 Counterparts . This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

 
4
 

 

Section 4.6 Titles and Subtitles . The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

 

Section 4.7  Notices . All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient's next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth on Schedule A or Schedule B hereto, or to such email address, facsimile number or address as subsequently modified by written notice given in accordance with this Section 4.7. If notice is given to the Company, a copy shall also be sent to Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor, New York, NY 10006, Attn: Arthur Marcus, Esq.

 

Section 4.8 Consent Required to Amend or Waive . This Agreement may be amended and the observance of any term hereof may be waived (either generally or in a particular instance and either retroactively or prospectively) only by a written instrument executed by (a) the Company; (b) the Investor, and (c) the Key Holders holding a majority of the Shares then held by the Key Holders. Notwithstanding the foregoing:

 

(a) the consent of the Key Holders shall not be required for any amendment or waiver if such amendment or waiver either (A) is not directly applicable to the rights of the Key Holders hereunder; or (B) does not adversely affect the rights of the Key Holders in a manner that is different than the effect on the rights of the other parties hereto; and

 

(b) any provision hereof may be waived by the waiving party on such party's own behalf, without the consent of any other party.

 

The Company shall give prompt written notice of any amendment or waiver here-under to any party that did not consent in writing thereto. Any amendment or waiver affected in accordance with this Section 4.8 shall be binding on each party and all of such party's successors and permitted assigns, whether or not any such party, successor or assignee entered into or approved such amendment or waiver. For purposes of this Section 4.8, the requirement of a written instrument may be satisfied in the form of an action by written consent of the Stockholders circulated by the Company and executed by the Stockholder parties specified, whether or not such action by written consent makes explicit reference to the terms of this Agreement.

 

Section 4.9 Delays or Omissions .  No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default previously or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.

 

 
5
 

 

Section 4.10 Severability . The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.

 

Section 4.11 Entire Agreement . This Agreement (including the Exhibits hereto) constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.

 

Section 4.12  Share Certificate Legend . Each certificate, instrument, or book entry representing any Shares issued to the Stockholders as of the date hereof shall be notated by the Company with a legend reading substantially as follows:

 

 

"THE SHARES REPRESENTED HEREBY ARE SUBJECT TO A VOTING AGREEMENT, AS MAY BE AMENDED FROM TIME TO TIME, (A COPY OF WHICH MAY BE OBTAINED UPON WRITTEN REQUEST FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF THAT VOTING AGREEMENT, INCLUDING CERTAIN RESTRICTIONS ON TRANSFER AND OWNERSHIP SET FORTH THEREIN."

 

 

The Company, by its execution of this Agreement, agrees that it will cause the certificates instruments, or book entry evidencing the Shares issued as of the date hereof to be notated with the legend required by this Section 4.12 of this Agreement, and it shall supply, free of charge, a copy of this Agreement to any holder of such Shares upon written request from such holder to the Company at its principal office. The parties to this Agreement do hereby agree that the failure to cause the certificates, instruments, or book entry evidencing the Shares to be notated with the legend required by this Section 4.12 herein and/or the failure of the Company to supply, free of charge, a copy of this Agreement as provided hereunder shall not affect the validity or enforcement of this Agreement.

 

Section 4.13  Stock Splits, Stock Dividends, etc . In the event of any issuance of Shares of the Company's voting securities hereafter to any of the Stockholders (including, without limitation, in connection with any stock split, stock dividend, recapitalization, reorganization, or the like), such Shares shall become subject to this Agreement and shall be notated with the legend set forth in Section 4.12.

 

Section 4.14  Manner of Voting . The voting of Shares pursuant to this Agreement may be effected in person, by proxy, by written consent or in any other manner permitted by applica-ble law. For the avoidance of doubt, voting of the Shares pursuant to the Agreement need not make explicit reference to the terms of this Agreement.

 

Section 4.15  Further Assurances . At any time or from time to time after the date hereof, the parties agree to cooperate with each other, and at the request of any other party, to execute and deliver any further instruments or documents and to take all such further action as the other party may reasonably request in order to evidence or effectuate the consummation of the transactions contemplated hereby and to otherwise carry out the intent of the parties hereunder.

 

 
6
 

 

Section 4.16  Dispute Resolution . The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of New York in and to the jurisdiction of the United States District Court for the Southern District of New York for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of New York in or the United States District Court for the Southern District of New York, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

WAIVER OF JURY TRIAL:EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

 

Section 4.17  Costs of Enforcement . If any party to this Agreement seeks to enforce its rights under this Agreement by legal proceedings, the non-prevailing party shall pay all costs and expenses incurred by the prevailing party, including, without limitation, all reasonable attorneys' fees.

 

Section 4.18  Aggregation of Stock . All Shares held or acquired by a Stockholder and/or its Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement, and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.

 

[Remainder of Page Is Intentionally Left Blank]  

 

 
7
 

 

IN WITNESS WHEREOF, the parties have executed this Voting Agreement as of the date first written above.

 

 

CITIUS PHARMACEUTICALS, INC.  

 

 

 

 

By:

/s/ Myron Holubiak

 

Name:

Myron Holubiak

 

 

Title:

Director

 

 

 

 

 

KEY HOLDERS:

 

 
Signature:

 

 

Name:

 

 

 

 

 

 

 

 

 

INVESTOR:

 

 

 

 

 

 

 

/s/ Leonard Mazur

 

 

 

Leonard Mazur

 

 

 
8
 

 

SCHEDULE A

 

INVESTOR

 

Name and Address

Number of Shares Held

Leonard Mazur

32 Arden Road

Mountain Lakes, New Jersey 07046

19,916,746

  

 
9
 

 

SCHEDULE B

 

KEY HOLDERS

 

Name and Address

Number of Shares Held

Myron Holubiak

7,754,497

Reinier Beeuwkes

 

8,113,959

Geoffrey Clark

 

7,960,283

Neeta Wadekar

 

5,500,000

  

  

10


EXHIBIT 99.1

 

Citius Pharmaceuticals Completes Acquisition of Leonard-Meron Biosciences

 

 

·

Acquisition provides Citius with a phase 3 ready critical care product

 

 

 

 

·

Myron Holubiak appointed as President and Chief Executive Officer of Citius

 

 

 

 

·

LMB's senior executives join Citius and enhance management team

 

 

 

 

·

Merger creates numerous opportunities for growth

 

Maynard, MA; April, 4 th , 2016 (PR NEWSWIRE) – Citius Pharmaceuticals, Inc. (OTCQB: CTXR) ("Citius") today announced completion of the acquisition of Leonard-Meron Biosciences, Inc. ("LMB"). Pursuant to the acquisition, Citius acquired all of the outstanding shares of LMB common stock in exchange for shares of Citius common stock.

 

LMB is a private, late-stage specialty pharmaceutical company focused on the development and commercialization of critical care products with a concentration on anti-infective drugs. LMB's leading drug candidate, Mino-Lok™, is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections ("CRBSIs"). Mino-Lok™ is a patent-protected, novel solution containing minocycline, edetate (disodium EDTA), and ethyl alcohol, which act to break down bacterial biofilm, eradicate the bacteria, provide anti-clotting properties to maintain patency, and salvage the indwelling central venous catheter ("CVC"). Mino-Lok™ is entering phase 3 trials after demonstrating safety in its phase 2b trial conducted at the MD Anderson Cancer Center in Houston. Recently, the U.S. Food and Drug Administration ("FDA") granted a Qualified Infectious Disease Product ("QIDP") designation for Mino-Lok™. Receiving QIDP designation means that Mino-Lok™ is now eligible for Fast Track designation, Priority Review, and a five-year extension of market exclusivity.

 

"Management is excited with the acquisition which has provided us immediate access to Mino-Lok™, a phase 3 ready program in a billion-dollar industry," said Mr. Leonard Mazur, Chairman of the Board of Directors of Citius. "We are especially pleased with the expansion of our management team to include industry veteran, Mr. Myron Holubiak, who has assumed the position of our Chief Executive Officer and is now directing all of our business and development programs including our prescription hemorrhoid treatment. Mr. Holubiak has an extensive background in pharmaceutical general management, having been president of Roche Labs Inc., and also in a number of related disciplines including health economics, an increasingly important perspective in healthcare today. We are now prepared to seek additional opportunities to expand our product pipeline in critical care and associated treatment areas while conforming to our growth philosophy of developing and introducing drug products that address unmet medical needs and provide cost-effective solutions in today's healthcare world. We are at the forefront of an exciting time for Citius".

 

 
1
 

 

Prior to the acquisition, Mr. Leonard Mazur was the Chief Executive Officer and Chairman of the Board of Directors of Citius and a principal stockholder of LMB; and, Mr. Myron Holubiak was the President and Chief Executive Officer of LMB, a significant stockholder of LMB, and a director of Citius. Pursuant to the acquisition, Mr. Holubiak assumed the role of President and Chief Executive Officer of Citius and will continue as a director of Citius, and Mr. Mazur will remain as the Chairman of the Board of Citius. All key employees of LMB joined the combined company in their respective roles pursuant to the acquisition.

 

About Citius Pharmaceuticals, Inc.

 

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for healthcare markets where there are unmet needs using innovative, patented or proprietary formulations of pharmaceutical products. Citius seeks new and expanded indications for previously approved pharmaceutical products as a means to achieving leading market positions or potential market exclusivity. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development. We seek to achieve these objectives by utilizing the FDA's 505(b)(2) pathway for our new drug approvals. We believe this pathway is comparatively faster, lower risk and less expensive than the FDA's traditional new drug approval pathway. In addition, we focus on obtaining intellectual property protection with the objective of listing relevant patents in the FDA Orange Book in order to limit generic competition.

 

About Leonard-Meron Biosciences, Inc.

 

LMB is a private, late-stage specialty pharmaceutical company focused on the development and commercialization of critical care products with a concentration on anti-infective drugs. LMB is developing Mino-Lok™, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections that is entering phase 3 trials. Recently, the FDA granted a Qualified Infectious Disease Product designation for the antibiotic lock solution, Mino-Lok™. Receiving QIDP designation means that Mino-Lok™ is now eligible for additional FDA incentives in the approval and marketing pathway, including Fast Track designation and Priority Review, and a five-year extension of market exclusivity.

 

About MD Anderson

 
The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. The institution's sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 45 comprehensive cancer centers designated by the National Cancer Institute ("NCI"). MD Anderson is ranked number1 for cancer care in U.S. News & World Report's "Best Hospital's" survey. It has ranked as one of the nation's top two hospitals since the survey began in 1990, and has ranked first for 11 of the past 14 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

 

 
2
 

 

Safe Harbor

 

This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions.

 

Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

 

For additional information, please contact:

 

Robert Haag
Managing Director
IRTH Communications
CTXR@irthcommunications.com

 

866-976-4784

 

 

3